The diagnosis of extrapulmonary tuberculosis (EPTB): scanning protocols and innovative methods for image quality improvement of FDG PET/CT imaging by Abdul Razak, H
The Diagnosis of Extrapulmonary 
Tuberculosis (EPTB): Scanning 
Protocols and Innovative Methods 
for Image Quality Improvement of 
FDG PET/CT Imaging 
 
A thesis submitted in fulfilment of the requirements for the degree of 
Doctor of Philosophy 
 
 
Submitted by 
Hairil Rashmizal Abdul Razak  
B. Sc (Hons) 
 
 
 
 
School of Medical Sciences 
College of Science, Engineering and Technology 
RMIT University 
August 2011 
 
 ii 
DECLARATION 
I certify that except where due acknowledgement has been made, the work is that of the 
author alone; the work has not been submitted previously, in whole or in part, to qualify 
for any other academic award; the content of the thesis is the result of work which has 
been carried out since the official commencement date of the approved research 
program; any editorial work, paid or unpaid, carried out by a third party is 
acknowledged; and, ethics procedures and guidelines have been followed. 
 
 
 
Hairil Rashmizal Abdul Razak 
4th of August 2011 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iii 
ACKNOWLEDGEMENTS 
First and foremost, I would like to address my sincere thanks to my primary supervisor, 
A/Prof Moshi Geso, who had given me the necessary freedom in bringing forward my 
own idea in my PhD studies, as well as for all the advice, help, supervision, support, and 
trust throughout my PhD journey. Also, I would like to acknowledge my co-supervisor 
Prof Abdul Jalil Nordin from the Nuclear Imaging Centre, Faculty of Medicine and 
Health Sciences, University Putra Malaysia, for being a good mentor especially in 
helping up with the important clinical issues during my PhD studies. 
  
I would also like to acknowledge our collaborators; A/Prof Claudio Rossetti and his 
team from the Advanced Technology Department, Division of Nuclear Medicine at 
Ospedale Niguarda Ca’ Granda, Milan, Italy, and Dr. Luigi Bertolazzi and his team 
from the Nuclear Medicine Department at Ospedale Santa Corona, Pietra Ligure, Italy, 
for providing us with the FDG PET/CT imaging data of the twelve EPTB patients.  
 
My sincere thanks go to Dr Noraini Abdul Rahim, Consultant Radiologist at Diagnostic 
Imaging Department, Serdang Hospital, Selangor, Malaysia, for her assistance in the 
recruitment of the patients during the clinical trial of this research.  
 
A special vote of thanks is due to Bruce Van Every and Ruth Martin from the Nuclear 
Medicine Department of Alfred Hospital, and Trevor Ackerly from the William 
Buckland Radiotherapy Centre, Alfred Hospital, for so graciously providing facilities 
and assistance in PET/CT imaging and the irradiation works.   
 
 iv 
I would also like to thanks Dr Adrian Schembri and Dr Anthony Bedford from the 
School of Mathematical and Geospatial Sciences, RMIT University for their assistance 
in the statistical analyses. Special thanks too to the University Technology MARA and 
the Ministry of Higher Education Malaysia for providing me with a scholarship 
throughout my PhD studies. I also want to acknowledge the financial support given by 
the School of Medical Sciences, RMIT University.  
 
I wish to thank all my colleagues from the Medical Radiation Physics and Biology 
Research Group; Dr Pradip Dep, Dr Price Jackson, Dr Wan Nordiana Rahman, Nathan 
Annabell and Mamdooh Alqathami. 
   
My special thanks must go to Damian D’Souza and Kristi Milley, PhD students at the 
School of Medical Sciences, RMIT University for their assistance in proofreading this 
thesis. 
 
Finally, I dedicate this thesis to my beloved wife; Wan Ismawati Ismail, parents, 
brothers and sisters for their prayers, support, encouragement and love. 
 
 
 
 
 
 
 
 v 
CONTENTS 
 
Declaration ……………………………………………………………………….......... ii 
Acknowledgements …………………………………………………………..….……. iii 
Contents ……………………………………………………………………..….……… v 
List of figures ……………………………………………………………….………….. x 
List of tables ………………………………………………………………………….. xx 
Abbreviations and acronyms ………………………………………………….......... xxiii 
Summary …………………………………………………………..…………………… 1 
 
1. INTRODUCTION ……………………………………………………………. 5 
1.1. Problem statement ……………………………………………………... 6 
1.2. Hypotheses and aims of the research ………………………………….. 8 
1.3. Thesis outline …………………………………………………………. 10 
 
2. LITERATURE REVIEW ……………………………………………………. 13 
2.1. Positron Emission Tomography (PET) ……………………………….. 14 
2.1.1. PET detectors …………………………………………………. 18 
2.1.2. Attenuation correction of PET ………………………………... 25 
2.2. Multi-slice CT scanner ……………………………………………….. 30 
2.3. Positron Emission Tomography/Computed Tomography (PET/CT) … 36 
2.3.1. PET/CT detectors …………………………………………….. 40 
2.3.2. Attenuation correction of PET/CT …………………………… 40 
2.4. Fluorodeoxyglucose (FDG) ………………………………………….. 42 
2.5. Standardised Uptake Value (SUV) …………………………………... 47 
2.6. Common PET/CT image artifacts and the potential solutions ……….. 48 
2.7. Tuberculosis …………………………………………………………... 50  
2.7.1. Tuberculosis in Malaysia ……………………………………... 52 
2.7.2. Pathogenesis of tuberculosis in human ……………………….. 53 
2.7.3. Diagnosis of tuberculosis ……………………………………... 57 
2.7.3.1. Clinical diagnosis …………………………………….. 57 
2.7.3.2. Bacteriological investigations ………………………… 58 
 vi 
2.7.3.3. Radiological examinations …………………………… 61 
2.7.3.4. Other diagnostic techniques ………………………….. 63 
2.7.4. Treatment of tuberculosis …………………………………….. 63 
 
SECTION A: CLINICAL IMAGING STUDY ……………………………………. 66 
3. SECTION A1: BACKGROUND AND THE SCANNING METHODS …… 68  
3.1. Background …………………………………………………………… 69 
3.1.1. Malaysian patients ……………………………………………. 72 
3.1.2. Italian patients ………………………………………………… 73 
3.2. FDG PET/CT imaging ………………………………………………... 74 
3.2.1. Malaysian patients ……………………………………………. 74 
3.2.1.1. Patient preparation ………………………………….… 74 
3.2.1.2. FDG PET/CT scanning protocols …………………….. 79 
3.2.1.3. Image analysis and interpretation …………………….. 85 
3.2.2. Italian patients ………………………………………………… 88 
3.2.2.1. Patient preparation …….……………………………… 88 
3.2.2.2. FDG PET/CT scanning protocols …………………….. 89 
3.2.2.3. Image analysis and interpretation …………………….. 89 
3.2.3. Follow-up FDG PET/CT scan ………………………………... 90 
3.3. Statistical analysis …………………………………………………….. 92 
 
4. SECTION A2: RESULTS AND DISCUSSION …………………………….. 94 
4.1. Results ………………………………………………………………... 95 
4.1.1. Malaysian patients ……………………………………………. 95 
4.1.1.1. Whole body FDG PET/CT imaging ………………….. 95 
4.1.1.2. Dual time point imaging of FDG PET/CT scan .…..... 109 
4.1.2. Italian patients ……………………………………………….. 117 
4.1.2.1. Comparison between the SUVmax values of EPTB 
lesions in Malaysian and Italian patients ……………. 117 
4.1.3. Follow-up FDG PET/CT scan ………………………………. 119 
 vii
4.1.3.1. Comparison between the SUVmax values of EPTB 
lesions in the follow-up and initial diagnostic FDG 
PET/CT scans ……………………………………….. 119 
4.2. Discussion …………………………………………………………… 125 
4.2.1. FDG uptake in EPTB lesions ………………………………... 125 
4.2.2. Effects of iodine contrast media on SUVmax values of PET/CT 
images ……………………………………………………….. 127 
4.2.3. Dual time point imaging (DTPI) of FDG PET/CT scan in EPTB 
patients ………………………………………………………. 128  
4.2.4. FDG PET/CT imaging in assessing therapeutic responses of 
EPTB patients ……………………………………………….. 130 
4.2.5. Technical factors that can improve the quality of FDG PET/CT 
images ……………………………………………………….. 131 
 
5. SECTION B: PHANTOM STUDY ………………………………………. 138 
5.1. Introduction …………………………………………………………. 140 
5.2. Materials and methods ………………………………………………. 142 
5.2.1. PET/CT imaging acquisition ………………………………... 142 
5.2.2. FDG PET/CT scans of the phantom ………………………… 142 
5.2.2.1. Phase 1: Simulation of an enhanced liver …………… 143 
5.2.2.2. Phase 2: PET/CT imaging of the simulated liver …… 144 
5.2.2.3. Phase 3: PET/CT imaging of the simulated liver and 
spinal lesion …………………………………………. 145 
5.2.2.4. Phase 4: PET/CT imaging of the simulated liver, spinal 
lesion and blood vessels …………………………….. 147 
5.2.3. Image analysis ………………………………………………. 149 
5.3. Results ………………………………………………………………. 152 
5.4. Discussion …………………………………………………………… 156 
5.5. Conclusion …………………………………………………………... 158 
 
6. SECTION C: DOSIMETRIC STUDY …………………………………... 159 
6.1. A theoretical and historical overview of PET/CT dosimetry ……….. 161 
 viii
6.1.1. PET radiation dose …………………………………………... 164 
6.1.1.1. ICRP Publications …………………………………… 164 
6.1.2. CT radiation dose ……………………………………………. 167 
6.1.2.1. Computed Tomography Dose Index (CTDI), Dose Length 
Product (DLP) and the effective dose ……………….. 168 
6.2. FDG PET/CT dose estimation of Malaysian patients ………………. 173 
6.2.1. Calculation results and analyses …………………………….. 175 
6.2.2. Discussion …………………………………………………… 180 
6.2.3. Conclusion …………………………………………………... 182 
6.3. The dosimetric experiments to partially validate the clinical data ….. 182 
6.3.1. FDG PET/CT irradiation ……………………………………. 183 
6.3.2. The dose response curves …………………………………… 185 
6.3.2.1. The x-ray dose response curves ……………………... 185 
6.3.2.2. The gamma radiation dose response curves ………… 188 
6.3.3. The dosimetric results and analyses ………………………… 190 
6.3.3.1. FDG PET/CT irradiation ……………………………. 191 
6.3.3.2. The dose response curves …………………………… 194 
6.3.4.  Discussion …………………………………………………... 202 
6.3.5. Conclusion …………………………………………………... 203 
6.4. Recommendations for reducing the FDG PET/CT radiation dose ….. 203 
6.4.1. FDG PET scan ………………………………………………. 203 
6.4.2. CT scan ……………………………………………………… 205 
 
7. CONCLUSIONS AND FUTURE DIRECTIONS …………………………. 208 
7.1. Conclusions …………………………………………………………. 209 
7.2. Future directions ……………………………………………………. 212 
 
APPENDICES ………………………………………………………………………. 213 
Appendix 1: Human ethics approval from University Putra Malaysia (UPM) ……... 214 
Appendix 2: Human ethics approval from Ministry of Health Malaysia …………… 215 
Appendix 3: Patient’s information sheet ……………………………………………. 216 
Appendix 4: Informed consent form ………………………………………………... 222 
 ix 
Appendix 5: Brown fat case report ………………………………………………….. 227 
Appendix 6: Estimating the PET effective dose of the seven Malaysian patients ….. 230 
Appendix 7: Estimating the CT effective dose of the seven Malaysian patients ….... 234 
Appendix 8: Published papers ………………………………………………………. 237 
 
REFERENCES ……………………………………………………………………… 239 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 x 
LIST OF FIGURES 
 
CHAPTER 2 
Figure 2.1: Positron- electron annihilation reaction ………………………………….. 16 
Figure 2.2: Three different types of coincidences detected in a PET imaging system. (a) 
True coincidence from a single positron-electron annihilation process is captured by a 
pair of PET detector systems. (b) Random coincidence; two photons from different 
positron-electron annihilation processes are detected within the coincidence time 
window, which appears to form a true coincidence event. (c)  Scatter coincidence; one 
of the photons has undergone Compton scattering (star shape) prior to being detected by 
the PET detectors ……………………………………………………………………... 20 
Figure 2.3: Illustration of Compton scattering reaction. Part of the energy from incident 
photon is transferred to an atomic electron. After this interaction, the incident photon 
undergoes a change in direction and the electron is ejected from the atom. The deflected 
photon and the ejected electron are known as scattered photon and recoil electron, 
respectively. This effect dominates in human tissue at energies above approximately 
100 keV and less than ~ 2 MeV ………………………………………………………. 21 
Figure 2.4: Schematic diagram of a photo-multiplier tube; consists of a vacuum 
enclosure with a thin photo-cathode layer at the entrance window. When the emitted 
visible light hits the photo-cathode, it will eject a photo-electron. This photo-electron is 
then accelerated to a nearby electrode called dynode. The increase in kinetic energy 
acquired by this process will produce a number of electrons at the next dynode, and so 
on, causing large amplification of the signal at the anode ……………………………. 24 
Figure 2.5: Schematic representation of a block detector for PET system. It consists of 8 
x 8 scintillator crystals and bonds to four photomultiplier tubes (PMTs) ……………. 25 
Figure 2.6: Detectors A and B record a pair of photons from an annihilation reaction 
that is located at ‘a’ depth from detector A and ‘b’ depth from detector B. For each 
annihilation reaction, the probability of detecting both photons is the product of the 
individual photon detection probabilities. Thus, the number of annihilation photons 
recorded by both detectors (A and B) is depth independent, and the total attenuation is 
only determined by the total thickness of the medium, D and the linear attenuation 
coefficient of the medium, μ (as in the Equation 2.5) ………………………………... 28 
 xi 
Figure 2.7: The basic principle of a helical/spiral CT scan. The table/patient is translated 
at a constant speed while the volume data are acquired. The x-ray tube and detector 
system are continuously rotated in a helical/spiral shape. The images could be 
reconstructed at any point along the longitudinal axis; z-axis ………………………... 31 
Figure 2.8: Schematic diagrams of a) a single-slice CT system with one detector row, 
and b) a four-slice CT system with four detector rows ………………………………. 32 
Figure 2.9: A rotating envelope x-ray tube. The anode plate constitutes an outer wall of 
the x-ray tube and it is in direct contact with the cooling oil in the tube housing (blue 
arrow). In addition, rotating envelope tubes have no moving parts and no bearing in the 
vacuum ………………………………………………………………………………... 33   
Figure 2.10: Schematic illustration of a dual-source CT (DSCT) system using two x-ray 
tubes (A and B) and two corresponding detectors offset by 90o ……………………... 34 
Figure 2.11: Summary of the technology developments in CT scanning system ……. 35 
Figure 2.12: Schematic representation of the first PET/CT scanner, where PET 
components were mounted on the rear of a common rotating support. Both CT and PET 
scans were acquired and reconstructed on separate consoles, but the image fusion 
display was only installed in PET console …………………………………………… 38 
Figure 2.13: Biograph 6 PET/CT imaging system from Siemens Healthcare Solutions. 
The PET imaging system consists of a multi LSO detector ring system, whereas the CT 
scanner is the SOMATOM Emotion 6; that enables for an acquisition of 6 slices per one 
revolution ………………………………………………………………………...…… 39 
Figure 2.14: The simple bi-linear scaling algorithms that are typically used to convert 
the CT number (Hounsfield Unit; HU) to the linear attenuation value (μ) of 511 keV 
PET energy level. The graph shows the μ value as a function of the corresponding HU. 
An optimal threshold of about 100 HU (dashed green line) is applied for classifying all 
the biologic tissues of the CT images into two different compositions of either the air-
water mixture or the water-bone mixture …………………………………………..… 42 
Figure 2.15: A comparison of the chemical structure of a) glucose (C6H12O6) and b) 
Fluorodeoxyglucose; FDG (C6H11FO5), in which the hydroxyl group (OH) at the C-2 
position is being replaced by 18F molecule …………………………………………… 44 
Figure 2.16:  Illustration for early metabolic pathway of glucose and FDG …………. 44 
 xii
Figure 2.17: Decay scheme diagram for radioactive 18F to its stable material; 18O, which 
decays by both electron capture; EC, and positron emission; β+ ………………...…… 45 
Figure 2.18: Illustration for the biochemical pathway of FDG in the living cell …..… 46 
Figure 2.19: Case notification rates per 100 000 population, for all forms of TB cases in 
the countries and areas in the Western Pacific Region (WPR) and the neighbouring 
countries and areas ……………………………………………………………………. 51 
Figure 2.20: Tuberculosis profile for Malaysia. The notified cases were recorded from 
1995 to 2007 ………………………………………………………………………….. 53 
Figure 2.21: Schematic diagram for the pathogenesis of human tuberculosis ……….. 56 
Figure 2.22: Flow chart of 24 weeks or 6 months anti-tuberculous treatment in an adult 
patient ……………………………………………………………………………….... 65 
 
CHAPTER 3 
Figure 3.1: Preparation on the FDG is conducted in the hot lab, which has been 
equipped with the radioactivity meter. The amount of FDG radioactivity for the whole 
body PET/CT imaging is estimated based on patient’s body weight ………………… 76 
Figure 3.2: A litre of plain water is given to act as negative oral contrast media during 
the preparation process. This method will help for better bowel distention during the 
image interpretation procedure ……………………………………………………….. 77 
Figure 3.3: Intravenous injection of FDG is performed in the preparation room. 
Immediately after this injection, an infusion of using 100 mL normal saline is given for 
maximising the injected amount of FDG or minimising the amount of FDG left in the 
tube …………………………………………………………………………………… 78 
Figure 3.4: Position of the patient during the PET/CT image acquisitions with 
immobilisation supports under the head and knee joint. Both arms are positioned above 
the head and two strapping belts are used to minimise patient’s movement. Note that 
two lasers are used for aiding the patient positioning …………………..……………. 82   
Figure 3.5: Intravenous bolus injection of 100 mL iodine contrast media (Omnipaque 
350) is given just before performing the contrast-enhanced CT (CECT) scan. This 
injection utilises the same route as for the FDG injection. After the injection the arm is 
repositioned at above of the head …………………………………………………….. 83 
 xiii
Figure 3.6: Schematic illustration for FDG PET/CT scans of Malaysian patients. (a – f) 
are the methods involved during the initial whole body PET/CT scan, whereas (g and h) 
are for the delayed PET/CT scan …………………………………….……………….. 84 
 
CHAPTER 4 
Figure 4.1: The aspiration of the pus collection from the right anterior chest wall region 
of patient 8 of the Malaysian patients, which has been performed under ultrasound 
guided and aseptic techniques ………...……………………………………………… 98 
Figure 4.2: The mean SUVmax1 value for each of EPTB and non-EPTB patients. There 
is an overlapping distribution of this value between both patients ……………..…… 101 
Figure 4.3: The mean SUVmax1 values of EPTB and non-EPTB lesions. There is no 
significant difference between these two mean values, where an independent samples t-
test results with P = 0.07 ……………………………..………………………..……. 101 
Figure 4.4: The receiver operating characteristic (ROC) curve on the diagnostic 
performance (sensitivity and specificity) of the SUVmax1 value in differentiating 
between EPTB and non-EPTB lesions. This analysis yields an area under curve of 0.398 
(blue line) ………...………………………………………………………………….. 102 
Figure 4.5: The mean HU values that have been obtained from the CT images of four 
normal organs (heart, liver, spleen and urinary bladder) before and after the intravenous 
injection of iodine-based contrast media. The two-tailed paired samples t-tests result 
with significant differences with P values of less than 0.05 (*) for all organs, except the 
urinary bladder (P = 0.54) ……………………………...…………………………… 105 
Figure 4.6: The mean SUVmax values that have been obtained from both 
PET/unenhanced CT and PET/CECT fusion images of four normal organs (heart, liver, 
spleen and urinary bladder). None of the changes in the SUVmax values of any of these 
organs are found to be statistically significant (P values > 0.05) …………………… 106 
Figure 4.7: FDG PET/CT image acquisitions of patient 4 of the Malaysian patients. (a) 
Maximum Intensity Projection (MIP) image. (b) PET/unenhanced CT and (c) 
PET/CECT fusion images, which demonstrate the differences in HU and SUVmax 
values of his heart (yellow arrows). It has been clearly shown that the utilisation of 
iodine-based contrast media will cause enormous change in HU value (from 26 to 123), 
whereas the SUVmax value is increased minimally (from 1.30 to 1.38) ………..….. 107 
 xiv
Figure 4.8: The mean differences in the SUVmax values of EPTB and non-EPTB 
Malaysian patients, obtained from PET/CT fusion images of 22 EPTB and 8 non-EPTB 
lesions during the image acquisition of using DTPI technique. The two-tailed paired 
samples t-tests result with significant differences with P values of less than 0.05 (*) for 
both groups of patients. However, the changing pattern in non-EPTB patients is smaller 
in amplitude than of EPTB patients …………….…………………………………… 112 
Figure 4.9: FDG PET/CECT image acquisitions of patient 1 of Malaysian patients 
showing an avid FDG activity at her right infraclavicular lymph node (blue arrows). (a) 
PET image of early scan. (b) Contrast-enhanced CT (CECT) image of early scan with 
peripheral enhancement of the right infraclavicular node. (c) PET/CECT fusion image 
which demonstrated a volume of interest (VOI) at the right infraclavicular node; 
SUVmax value was 8.3 (yellow arrow). (d) Delayed PET image at almost the same 
level as in (a). (e) Delayed CT image at almost the same level as in (b). (f) PET/CT 
fusion image showed higher SUVmax value; 11.6 (yellow arrow). The percentage 
difference between these two SUVmax values (%∆SUVmax) was about 40% ….…. 113 
Figure 4.10: FDG PET/CECT image acquisitions of patient 11 of Malaysian patients 
showing an avid FDG activity at the tibial plateau of his left knee joint (blue arrows). 
(a) PET image of early scan. (b) Contrast-enhanced CT (CECT) image using bone 
window setting of early scan. (c) PET/CECT fusion image which demonstrated a 
volume of interest (VOI) at the left tibial plateau; SUVmax value was 5.6 (yellow 
arrow). (d) Delayed PET image at almost the same level as in (a). (e) Delayed CT image 
also using bone window setting at almost the same level as in (b). (f) PET/CT fusion 
image showed higher SUVmax value; 5.8 (yellow arrow). The percentage difference 
between these two SUVmax values (%∆SUVmax) was only about 4% ………...….. 114 
Figure 4.11: The mean difference in the percentage change of SUVmax value 
(%∆SUVmax) of EPTB and non-EPTB patients. An independent samples t-test shows 
an insignificant difference with P = 0.06 …………..……………………………….. 115 
Figure 4.12: The receiver operating characteristic (ROC) curves that compare the 
diagnostic performance (sensitivity and specificity) of the SUVmax1, SUVmax2 and 
%∆SUVmax values in differentiating between EPTB and non-EPTB lesions. This 
analysis yields that the use of %∆SUVmax value (blue line) is superior to the other two 
values, with an area under curve of 0.804 ……………...…………………………… 116 
 xv 
Figure 4.13: Bar charts show the mean SUVmax1 values of EPTB lesions in both 
Malaysian and Italian patients. There is an insignificant difference between these two 
mean values, as the independent samples t-test results with P = 0.404 …………….. 118 
Figure 4.14: PET/CT images during the diagnosis process of patient 3 of Malaysian 
patients show an avid FDG activity at her left submandibular lymph node (blue arrows). 
(a) Axial PET image of early scan. (b) Axial Contrast-enhanced CT (CECT) image of 
early scan. (c) Axial PET/CECT fusion image which demonstrated a volume of interest 
(VOI) at the left submandibular lymph node with 9.7 in SUVmax value. (d) Axial 
delayed PET image at almost the same level as in (a). (e) Axial delayed CT image at 
almost the same level as in (b). (f) Axial PET/CT fusion image showed higher SUVmax 
value; 11.2. The percentage difference between these two SUVmax values 
(%∆SUVmax) was about 16% ………………………………………………...……. 121 
Figure 4.15: Follow-up PET/CT images of patient 3 of Malaysian patients at almost the 
same level as in Fig. 4.14, show no more avid FDG activity at her left submandibular 
lymph node. (a) Axial PET image of early scan. (b) Axial Contrast-enhanced CT 
(CECT) image of early scan. (c) Axial PET/CECT fusion image. (d) Axial delayed PET 
image at almost the same level as in (a). (e) Axial delayed CT image at almost the same 
level as in (b). (f) Axial PET/CT fusion image at almost the same level as in (c). These 
findings have been classified as complete remission of the disease. Note that the 
bilateral symmetrical FDG avid areas are found to be caused by the physiological brown 
fats uptakes ……………………………………………………………………….…. 122 
Figure 4.16: PET/CT images during the diagnosis process of patient 4 of Malaysian 
patients show an avid FDG activity at his right hip joint (blue arrows). (a) Axial PET 
image of early scan. (b) Axial Contrast-enhanced CT (CECT) image of early scan. (c) 
Axial PET/CECT fusion image which demonstrated a volume of interest (VOI) at the 
right hip joint with SUVmax value of 8.3. (d) Axial delayed PET image at almost the 
same level as in (a). (e) Axial delayed CT image at almost the same level as in (b). (f) 
Axial PET/CT fusion image showed higher SUVmax value; 8.9. The percentage 
difference between these two SUVmax values (%∆SUVmax) was about 7% …...…. 123 
 
 
 xvi
Figure 4.17: Follow-up PET/CT images of patient 4 of Malaysian patients show less 
avidity of FDG uptake at his right hip joint (blue arrows), as compared with the 
previous images in Fig. 4.16.  (a) Axial PET image of early scan. (b) Axial Contrast-
enhanced CT (CECT) image of early scan. (c) Axial PET/CECT fusion image with 
SUVmax value of 4.1 at the right hip joint. (d) Axial delayed PET image at almost the 
same level as in (a). (e) Axial delayed CT image at almost the same level as in (b). (f) 
Axial PET/CT fusion image showed higher SUVmax value; 4.7. The percentage 
difference between these two SUVmax values (%∆SUVmax) was about 15%, which 
corresponds to an active lesion. However, this less avidity of FDG uptake of the lesion 
is classified as a partial treatment response …………………………………………. 124 
Figure 4.18: PET/CECT fusion image of patient 8 of Malaysian patients shows the 
respiratory motion artefact, which can be seen as the fuzzy reddishness outline. The 
green box represents a volume of interest (VOI) at the right subscapular soft tissue 
space with SUVmax value of 11.7 ………………………………………..………… 133 
Figure 4.19: Anterior Maximum Intensity Projection (MIP) image from one of Italian 
patients (patient 8) shows both hands position (by the sides) during her PET/CT 
imaging. Small blue box demonstrates an avid FDG activity at her right hip joint with 
SUVmax value of 4.9 ……………………………………………………………….. 134 
Figure 4.20: The axial PET (a & d), Contrast-enhanced CT (b & e) and fused 
PET/CECT (c & f) images from patient 2 of Malaysian patients. The upper row (a-c) 
images represent the PET/CT images during the initial diagnostic scan, whilst the lower 
row (d-f) images are during the follow-up scan. The white thin arrows demonstrate the 
fuzzy streaking lines, which occurs due to the humerus bones of the upper limbs. 
However, this patient is not large enough to produce truncation artifact at the rim region 
of CT Field of View (FOV) …………………………………………………………. 135 
Figure 4.21: Axial PET/CT fusion images from patient 8 of Italian patients show 
streaking artifact, which has been caused by metallic hip prosthetic implant at her right 
hip joint. (a) PET/CT fusion image at an abdomen window CT setting; width: 400 and 
level: 40, demonstrates a remarkable streaking artifact. (b) Less streaking artifact is seen 
when the PET image has been fused with bone window setting of CT image; width: 
2000 and level: 350. The SUVmax values of both VOIs from these two images are 
same; 4.9 ……..……………………………………………………………………… 136 
 xvii
CHAPTER 5 
Figure 5.1: The set-up for the anthropomorphic phantom, which has been filled with 
saline bag 2 and four additional saline bags. The blue arrow shows saline bag 2 
which has been injected with 15mL of iodine contrast media, so that the CT number of 
the bag is over 100 HU and it can be used to simulate iodine contrast enhancement in a 
normal liver ………………………………………………………………………….. 144 
Figure 5.2: The set-up of the phase 2 phantom imaging study. The phantom is first 
imaged with saline bag 1 in place to obtain PET/CT2a (saline bag 1 contains radioactive 
FDG but no iodine contrast media). Then, the phantom is re-imaged with saline bag 2; 
replacing saline bag 1, to obtain PET/CT2b (saline bag 2 contains the same radioactivity 
of FDG as in saline bag 1, but also contains the typical clinically observed iodine 
contrast uptake for a normal liver) ………………………..………………………… 145 
Figure 5.3: The blue arrow indicates tube 1, showing the positioning into which it has 
been placed within the vertebral foramen to simulate an FDG avid spinal lesion. This 
setting is only a gross approximation to spinal tuberculosis. Spinal TB typically grows 
within the vertebral body, and not in position of the spinal cord …………………… 146 
Figure 5.4: The set-up for PET/CT imaging of the phase 4 case (f). The blue arrow 
shows the position of tube 1 in the vertebral foramen, containing 1.7 MBq of FDG to 
simulate spinal tuberculosis. The yellow arrow shows the position of tube 3 stuck to the 
side of dried vertebrae, containing a higher concentration of iodine contrast media (19.0 
mg/mL) to simulate the effect of a blood vessel with high contrast uptake. Saline bag 2 
(not discernable) is also present to simulate a liver with FDG and iodine contrast 
uptakes …………………………………………...………………………………….. 149 
Figure 5.5: An example of the image analysis on axial PET/CT fusion image. (a) PET 
image without attenuation correction shows the moderate activity of saline bag 2 (blue 
arrow). (b) CT image shows the contrast-enhancement of saline bag 2 with the average 
HUmax of 105 (yellow arrow). (c) Attenuation corrected PET/CT image shows the ROI 
of saline bag 2 with SUVmax and SUVmean values of 2.4 and 1.8, respectively (white 
arrow) ……………………………………………………………………...………… 151 
 
 
 
 xviii
CHAPTER 6 
Figure 6.1: The mean differences in the effective doses of unenhanced CT, CECT, 
delayed CT and PET scans for the seven Malaysian patients. One-way repeated 
measures ANOVA results with a significant difference among the four stand-alone 
imaging conditions (Wilks’ Lambda (Λ) = 0.024, F (3, 4) = 54.047, P = 0.001, η2 = 
0.976). In addition, post-host Bonferroni test has shown significant differences at P < 
0.05 for all six possible pairwise comparisons, except for the pair between unenhanced 
CT and delayed CT scans (P = 1.00) ………………………...……………………… 177 
Figure 6.2: The mean difference in the effective doses of the two integrated scanning 
acquisitions (PET + unenhanced CT + CECT and PET + unenhanced CT + CECT + 
delayed CT) for the seven Malaysian patients. A two-tailed paired samples t-test results 
with a high significant difference with P value of less than 0.001 ………………….. 179 
Figure 6.3: The set-up for FDG PET/CT irradiation of the anthropomorphic phantom, 
where three dosimetry methods (Gafchromic XRCT and XRQA films, and PRESAGE) 
have been utilised ……………………………………...……………………………. 184  
Figure 6.4: The set-up for CT irradiation of gafchromic XRCT and XRQA films with 
the CT scanner of PET/CT imaging system ……………………………...…………. 186 
Figure 6.5: The set-up for gafchromic XRCT films irradiations with the SXRT machine, 
where the source to film distance is kept at approximately 87 cm. All irradiations are 
performed at 150 kVp x-ray energy with a 15 cm diameter collimator ……......…… 187 
Figure 6.6: The set-up for gafchromic XRCT films irradiations with Technetium-99m; 
Tc-99m (gamma energy of 140.5 keV). The irradiations have been performed for 30, 60 
and 90 min …………………………………………...……………………………… 189 
Figure 6.7: The set-up for gafchromic XRCT films irradiations with Flourine-18; F-18, 
solution (gamma energy of 511 keV). The irradiations have been performed for 30, 60 
and 90 min ………………………………………………………….……………….. 190 
Figure 6.8: Gafchromic XRQA and XRCT films at 24 hours after irradiation to the CT 
component of PET/CT imaging. The mean net gray values of both films are 8.16 and 
12.04, respectively ……………………………..……………………………………. 192 
Figure 6.9: Gafchromic XRQA and XRCT films at 24 hours after irradiation to 1 GBq 
radioactivity of FDG and the CT component of PET/CT imaging. The mean net gray 
values of both films are 155.18 and 159.93, respectively ………………...………… 193 
 xix
Figure 6.10: Gafchromic XRCT films at 24 hours after CT irradiations with various 
exposure factors (kVp and mAs) …………………………….……………………… 194 
Figure 6.11: Gafchromic XRQA films at 24 hours after CT irradiations with various 
exposure factors (kVp and mAs) ……………………………………………………. 195 
Figure 6.12: Dose response curves of gafchromic XRCT and XRQA films at 100 kVp 
CT energy. Both curves fit with second order polynomial trend lines. This result shows 
that XRCT film has a slightly higher sensitivity in detecting the absorbed radiation dose 
than XRQA film …………………………………………………………………….. 196 
Figure 6.13: Gafchromic XRCT films at 24 hours after the irradiations with SXRT 
machine at 150 kVp energy level. A noticeable colour change can be seen at 20.0 mGy 
dose ……………………………………………………………..…………………… 197 
Figure 6.14: The dose response curve of XRCT film with the irradiations of SXRT 
machine at 150 kVp energy level. The curve fits with second order polynomial trend 
line ……………………………...…………………………………………………… 198 
Figure 6.15: Gafchromic XRCT films at 24 hours after the irradiations with 15 GBq 
radioactivity of Tc-99m (140.5 keV). A noticeable colour change can be seen at 60 min 
irradiation time ……………………………………………………………………… 199 
Figure 6.16: Gafchromic XRCT films at 24 hours after the irradiations with 1.9 GBq 
radioactivity of FDG (511 keV). Of these three different irradiation times, none of the 
films are found to have a visible colour change ……….……………………………. 200 
Figure 6.17: The dose response curve of XRCT film at Tc-99m gamma energy level 
(140.5 keV). The curve fits with second order polynomial trend line ……...……….. 201 
Figure 6.18: The dose response curve of XRCT film at F-18 gamma energy the level 
(511 keV). The curve fits with second order polynomial trend line ………………… 201 
Figure 6.19: Example of the unenhanced CT (a, c & e) and CECT (b, d & f) images 
from patients 1, 5 and 2 of the Malaysian patients. The mAs value of 30 seems more 
appropriate to be used during unenhanced CT, as compared to 50 mAs (a & e vs. c). In 
CECT scans, although the mAs has been reduced by half (from 100 to 50 mAs), there is 
no different in the image quality of both images (b & d), where the later image can still 
demonstrate a good organs enhancement (d). However, if the mAs is further reduced to 
30, the image quality has been extensively decreased; by less evident of organs 
enhancement and greater noise content (f) ………………………………………….. 207 
 xx 
LIST OF TABLES 
 
CHAPTER 2 
Table 2.1: Physical properties of commonly used scintillators in PET imaging ……... 19  
Table 2.2: A comparison of advantages and disadvantages between software and 
hardware based image fusion techniques …………………………………………….. 36 
Table 2.3: Common positron emitters for PET and/or PET/CT imaging …………….. 43 
Table 2.4: Clinical signs and symptoms of EPTB ………………………….………… 58 
Table 2.5: Summary of the radiological examinations for several types of EPTB …... 62 
 
CHAPTER 3 
Table 3.1: Chronological application of DTPI technique during FDG PET and FDG 
PET/CT scans in distinguishing malignant from benign lesions ……………………... 71 
Table 3.2: Chronological application of DTPI technique during FDG PET and FDG 
PET/CT scans in assessing the activity status of a lesion ……………….……………. 71 
Table 3.3: Demographic data and clinical indications of all Malaysian patients …….. 73 
Table 3.4: Demographic data and date of the FDG PET/CT acquisition of Italian 
patients ……………………………………………………...………………………… 74 
Table 3.5: The blood glucose level, the injected amount of FDG radioactivity and the 
scanning time of both PET/CT image acquisitions (initial whole body and delayed 
scans) for all sixteen Malaysian patients ……………………..………………………. 85    
Table 3.6: The blood glucose level, the injected amount of FDG radioactivity and the 
scanning time of both PET/CT image acquisitions (initial whole body and delayed 
scans) for the first six Malaysian patients who underwent the follow-up FDG PET/CT 
scan …………...……………………………………………………………………..... 91                  
 
CHAPTER 4 
Table 4.1: The FDG PET/CT imaging findings and the final diagnosis of all sixteen 
Malaysian patients ………………………………...………………………………….. 99 
 xxi
Table 4.2: The differences in HU and SUVmax values of four normal organs, caused by 
an intravenous injection of iodine-based contrast media during the CT scan of FDG 
PET/CT imaging for nine confirmed EPTB patients ………………...……………… 104 
Table 4.3: The diagnostic investigation results of all Malaysian patients ………...… 108 
Table 4.4: The diagnostic performance of FDG PET/CT and other conventional imaging 
modalities in detecting the EPTB lesions of all sixteen Malaysian patients …….….. 108 
Table 4.5: The SUVmax values for each of the detected lesions from DTPI of FDG 
PET/CT imaging in the eleven of Malaysian patients ……...……………………….. 111 
Table 4.6: The SUVmax1 values of all detected EPTB lesions from the twelve Italian 
patients ………...…………………………………………………………………….. 117 
Table 4.7: Comparison between the initial diagnostic and follow-up FDG PET/CT 
findings of the first six Malaysian EPTB patients ………………………..…………. 120 
 
CHAPTER 5 
Table 5.1: PET/CT scans of phase 3 phantom study ………………………...……… 146 
Table 5.2: PET/CT scans of phase 4 phantom study ……………...………………… 148 
Table 5.3: The results of the statistical analyses of phase 3 PET/CT imaging …..…. 154 
Table 5.4: The results of the statistical analyses of phase 4 PET/CT imaging …...… 155 
 
CHAPTER 6 
Table 6.1: Tissue weighting factors (WT) from ICRP Publications 26, 60 and 103 … 163 
Table 6.2: The dose coefficient values of various organs and the effective dose 
coefficient value for FDG from ICRP Publications 53, 80 and 106 ……………...…. 166  
Table 6.3: The k coefficient values for adult and paediatric patients of various ages for 
various anatomical scanning regions …………………………..……………………. 171 
Table 6.4: The recommendations for patient dose reduction during CT scan ………. 173 
Table 6.5: The dosimetric data and administered radioactivity of FDG for all sixteen 
Malaysian patients ………………………………...………………………………… 174 
Table 6.6: The effective doses of the stand-alone and the integrating PET/CT scans for 
the seven Malaysian patients ……………………………………...………………… 176 
 xxii
Table 6.7: The exposure factors (kVp and mAs) of all sixteen CT irradiations that have 
been carried out for constructing and plotting the dose response curves of gafchromic 
XRCT and XRQA films at various CT energies (80 kVp – 140 kVp) ……………… 186 
Table 6.8: The CTDIvol of all sixteen CT irradiations …………………...………….. 195 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xxiii
ABBREVIATIONS AND ACRONYMS 
 
Abbreviation Meaning 
2-D Two-dimensional 
3-D Three-dimensional 
AEC Automatic Exposure Control 
AFB Acid Fast Bacilli 
BaF2 Barium fluoride 
BGO Bismuth germinate 
BMI Body Mass Index 
CECT Contrast Enhanced CT 
CMI Cell Mediated Immunity 
CSF Cerebrospinal Fluid 
CT Computed Tomography 
CTDI Computed Tomography Dose Index 
CXR Chest X-ray 
DLP Dose Length Product 
DOTS Directly Observed Treatment Short-course 
DSCT Dual Source CT 
DTH Delayed Type Hypersensitivity 
EC Electron Capture 
EPTB Extrapulmonary Tuberculosis 
FDG Fluorodeoxyglucose 
FOV Field of View 
FPR False Positive Rate 
GSO Gadolinium oxyorthosilicate doped with cerium 
HIV Human Immunodeficiency Virus 
HRCT High Resolution CT 
HU Hounsfield Unit 
ICRP International Commission on Radiological Protection 
LOR Line of Response 
 xxiv
LSO Lutetium oxyorthosilicate doped with cerium 
MDCT Multi Detector CT 
MIP Maximum Intensity Projection 
MRI Magnetic Resonance Imaging 
NaI(Tl) Sodium iodide doped with thalium 
OSEM Ordered Subset Expectation Maximisation 
PCR Polymerase Chain Reaction 
PET Positron Emission Tomography 
PET/CT Positron Emission Tomography/Computed Tomography 
PMT Photo Multiplier Tube 
PPD Purified Protein Derivative 
PTB Pulmonary Tuberculosis 
RAMLA Row Action Maximum Likelihood Algorithm 
ROC Receiver Operating Characteristic 
ROI Region of Interest 
SNR Signal Noise Ratio 
SPECT Single Photon Emission Tomography 
SPECT/CT Single Photon Emission Tomography/Computed Tomography 
SUV Standardised Uptake Value 
SUVmax Maximum Standardised Uptake Value 
SUVmean Mean Standardised Uptake Value 
SXRT Superficial X-ray Radiotherapy 
TB Tuberculosis 
Tc-99m Technetium-99m 
TOF Time of Flight 
TU Tuberculin Unit 
VOI Volume of Interest 
WHO World Health Organisation 
WPR Western Pacific Region 
YSO Yttrium oxyorthosilicate doped with cerium 
 
 
 1
SUMMARY 
Positron emission tomography/computed tomography (PET/CT) is a hybrid imaging 
system that integrates the functional imaging modality known as PET with multi-slice 
CT scanning. PET scan can provide detailed information about functional abnormality, 
particularly when it is associated with the metabolic activity of a disease, but the 
anatomical data (size, shape and location) is usually inadequate. In contrast, multi-slice 
CT scan offers high spatial resolution anatomical imaging. Thus, by combining these 
two imaging modalities into one scanner, the acquisition of both functional and 
anatomical data can be obtained in a single imaging session, and any functional 
abnormalities can also be accurately localised.  
 Fluorodeoxyglucose (FDG) is the most widely and routinely used 
radiopharmaceutical for PET/CT imaging. Numerous studies have demonstrated that 
FDG PET/CT offers synergistic clinical advantages during the initial staging, re-staging 
and therapeutic response assessment of a wide variety of cancers, as compared to other 
conventional imaging modalities including a dedicated PET scanner. In addition, the use 
of FDG PET/CT imaging has expanded into the diagnostic evaluation and treatment 
follow-up of the infectious disease of tuberculosis (TB). However, there is still a lack of 
evidence concerning the utilisation of this imaging technique in the detection of 
extrapulmonary tuberculosis (EPTB) lesions. Therefore, this gap is the primary 
motivating theme of this thesis.  
 The major aim of this research is to determine the feasibility of the application 
of FDG PET/CT for detecting EPTB lesions. A clinical study was prospectively 
conducted on a series of sixteen Malaysian patients who were either highly suspected or 
confirmed with EPTB infectious disease. FDG PET/CT scans were performed during 
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the diagnostic processes of all patients. Of these sixteen patients, nine were positively 
diagnosed with EPTB through the histopathological findings of the sample 
sputum/aspirate/tissue and/or clinical/radiological assessments during their periodical 
follow-up visits, whilst the rest were categorised as non-EPTB patients. All detected 
extrapulmonary lesions were visually and semiquantitatively (by measuring the 
maximum standardised uptake value; SUVmax) analysed and evaluated, and no 
significant difference was observed between the SUVmax values of EPTB and non-
EPTB lesions (7.0 ± 2.3 vs. 8.8 ± 4.6, P=0.07). This may indicate that the SUVmax 
value cannot be used to differentiate between EPTB and non-EPTB lesions. 
Nevertheless, when comparing the imaging findings of FDG PET/CT scans with the 
other conventional imaging modalities, this hybrid imaging system has shown a 
relatively higher in the imaging diagnosis of EPTB patients. Therefore, FDG PET/CT is 
a reliable and practical imaging modality, and can feasibly be used to detect EPTB 
lesions.  
 Dual time point imaging (DTPI) of FDG PET/CT scan has been found to be a 
practical imaging method that could enhance the differentiation between malignant and 
inflammatory/infectious lesions by assessing the SUVmax values of the lesions at two 
different imaging times. This special imaging technique had been successfully carried 
out during the FDG PET/CT scans in thirteen of our patients. However, due to a slight 
variation in the scanning protocols, the proper PET/CT image analyses could only be 
performed on eleven patients. Two sets of the SUVmax values were obtained for each 
patient: SUVmax1 and SUVmax2 values were from initial and delayed images. All 
EPTB lesions exhibited a statistically significant increasing pattern in their SUVmax 
values of both imaging time points (6.8 ± 2.5 vs. 7.9 ± 3.2, P=0.001). The SUVmax 
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values of non-EPTB lesions were also increased, but the change was less significant and 
smaller in amplitude as compared with those of EPTB lesions (6.2 ± 2.6 vs. 6.5 ± 2.8, 
P=0.044). In addition, when comparing the percentage difference of the SUVmax values 
(%∆SUVmax) from both types of lesions (EPTB and non-EPTB), the result showed that 
there was no statistically significant difference (P=0.06). This might indicate that DTPI 
technique was not a useful method in distinguishing between EPTB and non-EPTB 
lesions, thus, the initial whole body FDG PET/CT imaging may be sufficient for 
differentiating the EPTB from other infectious diseases. 
 Another interesting aspect of FDG PET/CT imaging is the application of non-
ionic iodine-based contrast media during its CT image acquisition. Many clinical 
studies have postulated that iodine-based contrast media can be used in FDG PET/CT 
imaging without affecting the diagnostic interpretation, but this data was only well 
documented for cancer patients. Thus, this research also aimed to verify this effect on 
all EPTB patients. This clinical study was conducted by measuring the SUVmax values 
of five different tissues (heart, liver, spleen, urinary bladder and EPTB lesion) from two 
different sets of PET/CT fusion images (PET/contrast-enhanced CT and 
PET/unenhanced CT). None of the changes in the SUVmax values of any of the tissues 
were found to be statistically significant. Based on this study, it is accepted that iodine-
based contrast media could potentially be used in FDG PET/CT imaging of EPTB 
patients, without producing any significant effects on the SUVmax values. To 
strengthen this conclusion, an experimental phantom study has also been executed to 
isolate the expected effect in the absence of the variability inputs prevalent in a clinical 
study. This phantom study was specially designed to closely mimic the in vivo FDG 
PET/CT imaging, by inserting saline bags and bony structures, as well as two test tubes 
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that contained two different concentrations of iodine-based contrast media. The results 
showed that iodine-based contrast media can be safely applied during the CT scan of 
PET/CT imaging, without affecting the diagnostic accuracy of this integrated imaging 
modality.  
 A radiation dose arising from FDG PET/CT imaging plays an important role as 
it could provide a rational framework for the justification and optimisation of this 
imaging scan, and because of that, this research has determined the dosimetric 
component of FDG PET/CT imaging. The FDG PET/CT radiation dose is estimated 
through the calculations of the effective dose from each scan (FDG PET and CT), by 
using the administered radioactivity of FDG and CTDIvol data. These two effective 
doses are then summed in order to calculate the FDG PET/CT effective dose. The 
results of this dosimetric study exhibit that the largest fraction of the radiation dose 
comes from the CT portion of the FDG PET/CT imaging, which contributes to more 
than 60% of the entire FDG PET/CT effective dose. Cumulatively, this data 
demonstrates that our mean PET/CT effective dose is still in accordance with the 
previously reported values, even if the additional delayed CT scan has been performed. 
 In conclusion, it has been shown that FDG PET/CT is a useful imaging tool for 
detecting EPTB lesions, although our results suggest that the DTPI technique is 
ineffective in distinguishing between EPTB and non-EPTB lesions. In addition, iodine 
contrast media could potentially be applied during FDG PET/CT imaging of EPTB 
patients, while maintaining a considerably low effective dose value. These observations, 
taken together, provide the beginnings of a suitable body of evidence upon which a 
clinician can make a diagnostic decision on whether use of FDG PET/CT is indicated 
for the detection of EPTB lesions. 
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CHAPTER 1 
 
INTRODUCTION  
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1.1. Problem statement 
Whole body scanning using fluorodeoxyglucose (FDG) on an integrated PET/CT 
imaging modality has been routinely used in the diagnosis and staging of a wide variety 
of cancers [1-3]. In addition, FDG PET/CT scan is proven to be an important imaging 
tool for detecting inflammatory and infectious lesions [4]. The rationale for the high 
accumulation of FDG in these inflammatory/infectious lesions is mainly due to the 
elevated glycolytic activity of the activated inflammatory cells such as neutrophils and 
macrophages [5]. In an inflammatory/infectious tissue, it has been shown that these two 
cell types utilise large amount of glucose as the main energy source for their chemotaxis 
and phagocytosis processes [6]. Hence, this could elucidate the capability of FDG 
PET/CT imaging in depicting inflammation/infection diseases. 
  Tuberculosis (TB) is a systemic infectious disease caused by Mycobacterium 
tuberculosis [7]. It is one of the most common causes for false positive findings on FDG 
PET/CT imaging in the diagnosis of malignant tumours [8, 9]. The reason for this 
occurrence is due to the essential role of macrophages; particularly of alveolar 
macrophages, as these cells are the first line of defence in combating the 
Mycobacterium tuberculosis infection in humans [10]. In addition, a previous study has 
demonstrated that the macrophages could have higher FDG uptake than the viable 
malignant cells although they are located in the same sample of tissue [11]. Therefore, 
the high accumulation of FDG in tuberculous lesions is expected and could augment the 
effectiveness of FDG as a suitable tracer for infection imaging using an integrated 
PET/CT imaging system.  
 TB can spread to virtually any tissue or organ in the human body [12]. While 
pulmonary tuberculosis (PTB) is the most common presentation, extrapulmonary 
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tuberculosis (EPTB) is also significantly important clinical problem [13]. EPTB occurs 
due to dissemination via the lymphohaematogenous route during the early stage of the 
pulmonary infection [14, 15]. The symptoms of this disease are usually non-specific 
[15] and vary depending on the affected sites or tissues [16]. For this reason, the 
diagnosis procedure of EPTB is typically complicated [8], and to establish a 
definite/confirmed diagnosis of EPTB, it may require invasive and expensive 
serological/radiological investigations [17]. In addition, prompt and accurate diagnoses 
of EPTB are the key elements for an effective treatment [16], but they are often delayed 
primarily due to the difficulty in isolating the small number of Mycobacterium 
tuberculosis present in the affected tissues [13]. Therefore, it is of high clinical 
importance to predetermine and detect the EPTB lesions using non-invasive techniques 
in highly suspected patients, in order to avoid unnecessary invasive and 
sophisticated/expensive procedures. 
 In standard clinical practice, a chest radiograph is the primary imaging technique 
for the detection of both PTB and EPTB lesions [18]. However, due to its limited 
sensitivity and specificity, other imaging modality like computed tomography (CT) has 
been found to be more helpful especially in localising and determining these two lesions 
[12, 16, 18]. Similarly, the usefulness of FDG PET/CT imaging in detecting EPTB 
lesions has been highlighted in a few recent studies [7, 19, 20]. However, these 
observations are mostly derived from the findings of the patients who have also 
concomitantly presented with an underlying malignancy [19] and/or 
immunosuppression diseases such as human immunodeficiency virus; HIV [20], and 
active PTB infection disease [7]. Thus, there are insufficient evidence-based reports in 
the current literature which exclusively describe the utilisation of FDG PET/CT imaging 
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in a series of either confirmed or highly suspected EPTB patients. Hence, this leads to 
the requirement for conducting a prospective study that aims at definitively detecting 
and characterising the EPTB lesions using FDG PET/CT imaging. This novel approach 
should be undertaken as an effort to shorten the diagnostic procedure of EPTB infection 
disease, which then may provide a better prognosis for patients with this disease.   
 The utilisation of dual time point imaging (DTPI) technique during FDG 
PET/CT imaging has been proposed as a method of choice in distinguishing between 
malignancy and inflammations/infections [21-23]. Again, there is scarce data on the 
application of this special imaging technique for differentiating EPTB lesions from 
malignant and/or other inflammatory/infectious lesions [7]. On the other hand, several 
studies have shown that by performing the CT component of FDG PET/CT imaging as 
for the diagnostic scanning protocol; contrast-enhanced CT (CECT) scan, it could result 
to higher diagnostic values of this integrated imaging system [24-27]. However, there 
are no studies in the literature that particularly employ this type of scanning protocol for 
FDG PET/CT imaging of EPTB patients. Thus, it would be valuable to conduct a study 
that could properly address and document both of these issues.   
 
1.2. Hypotheses and aims of the research 
The purpose of the research presented in this thesis is to test the following hypotheses: 
? Hypothesis 1 
EPTB lesions exhibit high intensity uptake of FDG, which can clearly be 
depicted on PET and PET/CT fusion images. 
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? Hypothesis 2 
The utilisation of the dual time point imaging (DTPI) technique during FDG 
PET/CT scan can increase the diagnostic value of this integrated imaging 
modality in detecting EPTB lesions. 
? Hypothesis 3 
The application of iodine-based contrast media during the CT scan of FDG 
PET/CT imaging will not cause any significant image artifacts on PET/CT 
fusion images. 
? Hypothesis 4 
The effective radiation dose of EPTB patient who has undergone FDG PET/CT 
imaging is considerably low as compared with the previously reported values. 
 
The specific aims of all designed studies in this research are: 
1. To evaluate the role of FDG PET/CT imaging in the detection of the EPTB 
lesions. 
2. To define the mean value of FDG uptake in a series of patients who are either 
highly suspected or confirmed for EPTB infection disease using the 
semiquantitative measurement (Maximum Standardised Uptake Value; 
SUVmax).  
3. To investigate the usefulness of DTPI technique of FDG PET/CT scan in 
depicting EPTB lesions, and distinguishing this type of lesion from other 
inflammatory/infectious lesions. 
4. To identify the potential value of FDG PET/CT imaging for assessing the 
therapeutic response of EPTB patients. 
 10
5. To determine the effects of iodine-based contrast media on PET/CT fusion 
images through the clinical imaging findings and the experimental results of the 
phantom study.       
6. To estimate the PET/CT effective dose for a series of patients who have 
undergone the scanning using the established calculation methods and the 
published data. 
 
1.3. Thesis outline 
This thesis is divided into 3 different sections, according to the conducted studies:  
1. Section A: Clinical imaging study 
2. Section B: Phantom study 
3. Section C: Dosimetric study 
 
In addition, here are the brief descriptions on the remainder chapters of this thesis: 
? Chapter 2 reviews the operating principle for PET, CT and PET/CT scanners, 
and briefly explains about FDG, SUV and common PET/CT image artifacts. 
Furthermore, the current issue regarding tuberculosis disease in Malaysia 
together with the essential information on the pathogenesis, diagnosis and 
treatment of tuberculosis are presented in this chapter.     
? Chapter 3 details the FDG PET/CT scanning protocols that have been used 
during the imaging session of all our patients, including the utilisation of dual 
time point imaging (DTPI) technique and an intravenous injection of iodine-
based contrast media during the CT scan of FDG PET/CT imaging. 
Fundamentally, two different types of data are obtained in this clinical study; 
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the prospective data of sixteen Malaysian patients and twelve Italian patients 
for the retrospective data. In addition, out of all Malaysian patients, six of them 
have undergone a repeat FDG PET/CT imaging with an interval of six months 
from the initial scan and upon the completion of 24 weeks of anti-tuberculous 
drugs treatment.  
? Chapter 4 describes and discusses the results of FDG PET/CT scans from both 
Malaysian and Italian patients. Based on the image analysis and interpretation, 
all EPTB lesions demonstrate high accumulation of FDG with the maximum 
standardised uptake value (SUVmax) as high as 20.8. This imaging finding 
clearly indicates that FDG PET/CT imaging could offer a diagnostic potential 
in detecting EPTB lesions. On the other hand, the utilisation of DTPI technique 
may not be a useful method in distinguishing between EPTB and non-EPTB 
lesions. Thus, for diagnostic purposes, initial whole body FDG PET/CT scan 
seems to be sufficient for depicting and differentiating EPTB from other 
infection diseases. Furthermore, this study has found that iodine-based contrast 
media can be safely applied during the CT scan of FDG PET/CT imaging, in 
which it will not cause any significant changes on the SUVmax values of 
PET/CT fusion images. In the last section of this chapter, a few technical 
recommendations that have been believed to improve the quality of PET/CT 
fusion images are also addressed.  
? Chapter 5 quantifies the amount of changes in the standardised uptake values 
(SUVs) of PET/CT fusion images caused by the utilisation of iodine-based 
contrast media during the CT scan of FDG PET/CT imaging. This 
experimental study had been conducted using an anthropomorphic phantom, in 
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which the set-up was aimed to replicate the true in vivo imaging situation. The 
results of this phantom study showed that none of the changes in the SUVs 
were found to be statistically significant. Therefore, this finding supports and 
augments the results from our clinical imaging study, as described in the 
previous chapter; Chapter 4.  
? Chapter 6 estimates the total PET/CT effective dose by slightly modifying the 
established calculation methods and published data. The experimental attempts 
for measuring the PET/CT effective dose using a sensitive type gafchromic 
film are also explained in this chapter. 
? Chapter 7 summarises all the findings of this research work. From these 
findings, then the conclusion remarks have been drawn. Two future studies that 
can be developed from this research are also suggested in the last section of 
this final chapter.       
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LITERATURE 
REVIEW  
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Radiological imaging plays an essential role in the disease management: diagnosing, 
treatment monitoring and follow-up assessment. Conventional imaging modalities like 
general radiography, computed tomography (CT) scan, magnetic resonance imaging 
(MRI) and ultrasonoraphy can be categorized as morphological imaging modalities; 
they have the capability of identifying the anatomical patterns and provide basic 
information regarding location, size and shape of the lesion.  
Nuclear medicine, a branch of radiological imaging, also plays an important role 
in the detection of the lesions. It could act as a complement to morphological imaging 
by integrating biology and in vivo imaging data in order to acquire the 
pathophysiological information of a disease. Generally, nuclear medicine images are 
quite ‘noisy’ and the spatial resolution is low compared to radiographs, CT and/or MRI 
images. Several imaging modalities are commonly used in a nuclear medicine 
department like gamma camera, single photon emission tomography (SPECT), positron 
emission tomography (PET) and the latest are the hybrid imaging scanners; PET/CT 
and SPECT/CT. However, in this chapter, the main focus is only for PET, CT and 
PET/CT scanners; as these three modalities are fundamentally related with this research, 
which will be further discussed in the following sections. 
 
2.1. Positron Emission Tomography (PET)  
The first PET scanner was commercially introduced in 1980, but only after a decade it 
was established as an important imaging modality and widely used in the oncology field 
[3]. PET is a dedicated imaging modality that could map the radiopharmaceutical 
distribution and quantify the cellular metabolic activities by measuring the intensity of 
the accumulated radiopharmaceutical in a particular region of the human body [28]. The 
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operating principle is based on the detection of the coincident photons that have 
originated from the annihilation process between the emitted positrons and the electrons 
of the surrounding tissues [29].   
Positron emitters are produced using a circular particle accelerator, known as a 
cyclotron. The stable (non-radioactive) isotope is bombarded with protons, which then 
will create an unstable isotope with an excess of protons in its nucleus [28]. Thus, in re-
achieving of its stability stage, a proton (p) will be converted into a neutron (n) through 
the nuclear transmutation process [3]. This results in the emission of a positron (β+); a 
positively charged electron emitted from nuclei that have an excess of protons, and a 
neutrino (ν); a particle that has a very small mass and zero charge [30, 31].    
 
                              
              
After being emitted from the nucleus, the positron loses kinetic energy by 
interactions with the surrounding matter. When nearly all of its kinetic energy has been 
lost, then positron will combine with an electron, forming a metastable intermediate 
species called positronium; it is a non-nuclear, hydrogen like element composed of the 
positron and electron that spin around their combined centre of mass. This positronium 
will quickly undergo an annihilation process, thus creating two photons of 511 keV 
gamma rays; the energy of the gamma rays is equivalent to the rest mass of the electron 
and positron. These two gamma rays are emitted in diametrically opposite directions 
(180o) to each other for conserving the momentum, which is close to zero before the 
occasion of an annihilation process [30, 31] (refer to Fig. 2.1).  
(2.1) 
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Figure 2.1: Positron- electron annihilation reaction (β+; positron, e-; electron, and γ; 
gamma ray).  
 
 
 The emission of these two gamma rays are simultaneously captured in a single 
coincident event by PET detector system, within a very short period of time; a few 
nanoseconds, this is called coincidence time window [3]. Therefore, by surrounding the 
patient with a ring detector system, the pairs of coincident photons can be detected. The 
origin of the emission of these coincident photons is assumed to lie within the line 
joining the two points at which the photons hit the detector; this joined line is called the 
line-of-response (LOR). The projection data from the integral activity of sets of LORs 
will be reconstructed to generate an image of the distribution of positron emitter within 
the object [31]. However, in general, there are three different categories of coincident 
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events involved in PET imaging [30], in which each of these coincidences could affect 
the production of PET images in a different way  (refer to Fig. 2.2):  
1. True coincidences  
True coincidences (Fig. 2.2a) are emissions from single annihilation points that 
enter the PET detector without undergoing any significant interactions within 
the imaging field-of-view (FOV).  
2. Random coincidences 
Random coincidences (Fig. 2.2b) occur due to the accidental detection of two 
unrelated single events within the coincidence time window. These coincidences 
only add to the image background that may result in reducing the image 
contrast. 
3. Scatter coincidences 
Scatter coincidences (Fig. 2.2c) are true coincidence events from single 
annihilation points, however one or both of the photons undergo Compton 
scattering reaction (Fig. 2.3) within the imaging FOV before entering the PET 
detector. These coincidences can lead to mispositioning of LOR, which may 
incorrectly represent the true activity distribution within the FOV and worsen 
the image contrast.    
 
Apart from the true coincidences, all others will result in incorrect spatial information 
[31]. Thus, several techniques that utilise sophisticated correction models and complex 
electronic systems have been developed and designed to remove these unwanted 
coincidences [3, 31].  
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2.1.1. PET detectors 
As mentioned earlier, the coincident events are captured by PET detectors. These 
detectors are dedicatedly engineered to operate with the high energy photons; 511 keV, 
and because it is designed in a ring shape system, it has a capability to acquire a 
tomographic image without requiring the rotation of the detectors [32]. In general, 
radiation detectors can be divided into three groups: gas chambers, semiconductor 
detectors, and scintillation detectors. However, in PET imaging, the scintillation 
detectors are the most common and successful method, mainly due to the following four 
paramount properties [30]: 
1. Stopping power for 511 keV photons 
The stopping power of a scintillator is characterised by the average distance 
travelled by the photon before it deposits its energy within the scintillator 
crystal. This means that a scintillator with a short attenuation length will provide 
a high efficiency in stopping the 511 keV photons. Additionally, the attenuation 
length of a scintillator depends upon its density (ρ) and the effective atomic 
number (Zeff).  
2. Signal decay time 
A short signal decay time of a scintillator is important for individually 
processing each detected pulse at high counting rates. This property can also 
help in reducing the number of random coincidence events.    
3. Light output 
A high light output of a scintillator facilitates for attaining good spatial and 
energy resolutions.   
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4. Intrinsic energy resolution 
The intrinsic energy resolution of a scintillator arises due to inhomogeneties in 
the crystal growth process as well as non-uniform light output for the 
interactions within it. Combination of this property with the light output plays a 
role in determining the energy resolution of a scintillator. A good energy 
resolution is necessitated to an efficient rejection of scatter coincidences. 
 
 Several scintillator cystals are commonly used in PET imaging like sodium 
iodide doped with thalium: NaI(Tl), bismuth germanate: BGO, lutetium oxyorthosilicate 
doped with cerium: LSO, yttrium oxyorthosilicate doped with cerium: YSO, gadolinium 
oxyorthosilicate doped with cerium: GSO, and barium fluoride: BaF2 [30]. Some of 
these scintillators physical properties are listed in Table 2.1.  
 
Table 2.1: Physical properties of commonly used scintillators in PET imaging [30]. 
Property NaI(Tl) BGO LSO YSO GSO BaF2 
Density (g/cm3) 3.67 7.13 7.4 4.53 6.71 4.89 
Effective atomic number (Zeff) 50.6 74.2 65.5 34.2 58.6 52.2 
Attenuation length (cm) 2.88 1.05 1.16 2.58 1.43 2.2 
Decay time (ns) 230 300 40 70 60 0.6 
Light output (photons/keV) 38 6 29 46 10 2 
Light output; relative to NaI(Tl) 
(%) 100 15 75 118 25 5 
Wavelength, λ (nm) 410 480 420 420 440 220 
Intrinsic energy resolution (%) 5.8 3.1 9.1 7.5 4.6 4.3 
Energy resolution (%) 6.6 10.2 10 12.5 8.5 11.4 
Index of refraction 1.85 2.15 1.82 1.8 1.91 1.56 
Linear attenuation coefficient, μ 
(cm-1); measured at 511 keV 0.3411 0.9496 0.8658 0.3875 0.6978 0.4545 
Mass attenuation coefficient, μ/ρ 
(cm2/g); measured at 511 keV 0.0948 0.1332 0.117 0.853 0.104 0.0929 
NaI(Tl): sodium iodide doped with thalium, BGO: bismuth germanate, LSO: lutetium 
oxyorthosilicate doped with cerium, YSO: yttrium oxyorthosilicate doped with cerium, GSO: 
gadolinium oxyorthosilicate doped with cerium, and BaF2: barium fluoride. 
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Figure 2.2: Three different types of coincidences detected in a PET imaging system. (a) 
True coincidence from a single positron-electron annihilation process is captured by a pair 
of PET detector systems. (b) Random coincidence; two photons from different positron-
electron annihilation processes are detected within the coincidence time window, which 
appears to form a true coincidence event. (c)  Scatter coincidence; one of the photons has 
undergone Compton scattering (star shape) prior to being detected by the PET detectors. 
The dashed line represents the line-of-response (LOR).   
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Figure 2.3: Illustration of Compton scattering reaction. Part of the energy from incident 
photon is transferred to an atomic electron. After this interaction, the incident photon 
undergoes a change in direction and the electron is ejected from the atom. The deflected 
photon and the ejected electron are known as scattered photon and recoil electron, 
respectively. This effect dominates in human tissue at energies above approximately 100 
keV and less than ~ 2 MeV [30].     
 
 
 The first PET scanners were developed with various geometric configurations of 
NaI(Tl) crystals; a common scintillator material for the standard nuclear medicine 
gamma cameras. NaI(Tl) provides a high light output, which leads to good energy and 
spatial resolutions. This crystal has low stopping power mainly due to its low density 
[30]. Thus, NaI(Tl) is not quite suitable to be used as a scintillator for PET [3]. In the 
late 1970s, a denser scintillator known as bismuth germanate (BGO) with greater 
stopping power than NaI(Tl) had been considered as a prospective material for PET 
detectors [3]. Its excellent stopping power contributes to an enhanced sensitivity of PET 
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scanners, by increasing the ability of the scanner to detect the coincident photons 
emitted within its imaging FOV [30]. This crystal was established as the material of 
choice and has been the most widely used scintillator in PET detector system for more 
than 25 years [3, 29].  
 The introduction of new and faster scintillators such as LSO and GSO has been 
found to improve the performance of PET scanners in the clinical imaging; both of 
these scintillators have shorter decay times than BGO by a factor of 6 to 7 [3]. In 
addition, LSO appears to be an ideal scintillator crystal with a combination of the high 
light output and the high stopping power. For the last type of scintillator crystal; in this 
case is BaF2, it has an extremely short decay time: 0.6 ns (refer Table 2.1). Thus, this 
special feature makes it ideal to be used as a detector material in time-of-flight (TOF) 
PET scanner; a newer generation of PET scan that is able to estimate the location of the 
annihilation point within an object [30].  
 The operating principle of PET imaging is primarily based on coincidence 
detection, which starts when an incoming photon hits its scintillation detector. This 
process results in the emission of visible light or often refers as luminescence reaction. 
The emitted visible light is then detected by a photo-detector. The photo-detectors that 
are commonly utilised in PET detector system can be divided into two categories: the 
photo-multiplier tubes (PMTs) and the semiconductor based photodiodes. However, the 
most reliable technique to measure and detect the emitted visible light photons from the 
scintillation detectors is using the PMTs. Basic construction of a PMT is shown in Fig. 
2.4, which consists of a vacuum enclosure with a thin photo-cathode layer at the 
entrance window [30].   
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 A signal detection mechanism begins once the emitted visible light hits the 
photo-cathode, where the light photon will deposit its energy into the photo-cathode and 
trigger for an ejection of a photo-electron by the photo-cathode. In the presence of an 
electrical field, the photo-electron is accelerated to a nearby electrode called the dynode. 
This acceleration increases the energy of the photo-electron, and results in the emission 
of multiple secondary electrons. These acceleration and emission processes continue 
through several dynodes in increasing electrical potentials, and this leads to a gain of 
photo-electrons of more than a million at the anode side  (refer to Fig. 2.4). This high 
gain generates a very good signal-to-noise ratio (SNR) which can easily be measured by 
an external circuit. Hence, this is the primary reason for the widespread success and 
applicability of the PMTs in scintillation detectors system [30].  
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Figure 2.4: Schematic diagram of a photo-multiplier tube; consists of a vacuum enclosure 
with a thin photo-cathode layer at the entrance window. When the emitted visible light 
hits the photo-cathode, it will eject a photo-electron. This photo-electron is then 
accelerated to a nearby electrode called dynode. The increase in kinetic energy acquired 
by this process will produce a number of electrons at the next dynode, and so on, causing 
large amplification of the signal at the anode. 
 
 
 25
 Nowadays, most dedicated PET scanners employ an array of block detectors for 
identifying coincident events. Each of these block detectors typically consists of an 
array of scintillator crystals (between 8 x 8 and 13 x 13 distinct crystal elements) and 
bonds to four PMTs [31] (Fig. 2.5). This special design allows for improved spatial 
resolution of PET system and reduced dead time of the scintillator detector [30].     
 
 
Figure 2.5: Schematic representation of a block detector for PET system. It consists of 8 x 
8 scintillator crystals and bonds to four photomultiplier tubes (PMTs).   
 
 
2.1.2. Attenuation correction of PET 
For nuclear medicine, the term attenuation usually refers to a decrease in the energy 
intensity of a photon, as it passes through a medium/matter either by absorption or 
scatter reactions [32]. Accordingly, as highlighted before at the PET energy level, the 
dominant interaction between photon and human tissue belongs to Compton scattering 
[30]. This means that in PET imaging system, most of the emitted annihilation photons 
are actually being attenuated in tissue, rather than directly entering the scintillation 
detectors [29].  
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 The attenuation of the emitted annihilation photons follows the low of 
exponential absorption [3], outlined in the following equation: 
   
     Ix = Ioe-μx                                                   (2.2) 
where, I represents the photon beam intensity, the subscriptions of ‘0’ and ‘x’ refer 
respectively to the unattenuated beam intensity and the intensity measured through a 
thickness of medium of thickness x, and μ refers to the linear attenuation coefficient of 
the medium. The linear attenuation coefficient (μ) is a measure of the probability that a 
photon will be attenuated by a unit length of the medium, and it has a unit of cm-1 [30]. 
However, when an annihilation reaction occurs at a depth of ‘a’ from one detector (refer 
to Fig. 2.6), in a medium of total thickness of D, the number of photons recorded by 
detector A; Na, would be as of the equation below:  
 
     Na = Noe-μa                                          (2.3) 
where No represents the number of emitted photons, and μ is the linear attenuation 
coefficient of the medium (assumed to be a constant). Based on the above equation, it 
can clearly be seen that the number of detected photons changes with the depth of 
‘a’[31]. On the other hand, for the opposite detector; detector B, the recorded number of 
photons is equal to: 
  
     Nb = Noe-μ(D-a)                                       (2.4) 
where the depth of b = D − a. Thus, as in PET imaging system, the number of 
annihilation photons (N) that can be detected by the two opposed detectors would be: 
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    N = (Noe-μa) · (Noe-μ(D-a))                                  
        = No (e-μa · e-μ(D-a)) 
        = Noe-μ[a+ (D-a)] 
        = Noe-μD          (2.5)  
Based on the above equation, it shows that the detected number of annihilation photons 
depends upon the linear attenuation coefficient of the medium, μ, and the total thickness 
of the medium/object, D [31]. In addition, this value is independent of the depth [3] or 
the location of the annihilation reaction within the medium/object [30, 31].  
 For a dedicated PET imaging system, the attenuation can be corrected by 
performing a transmission scan using an external source of 511 keV photons such as 
Germanium-68 (68Ge), in either a ring or rod shape [31]. During the transmission scan, 
usually three 68Ge sources are used to rotate around the patient, to fully cover the axial 
extent of PET scanner [3]. With this transmission data, an attenuation map of the patient 
can be derived from the ratio between the known (true) and measured (attenuated) 
intensity of the external sources [29]. This patient-specific attenuation map is then used 
to correct the emission data [31], and it happens before the PET image reconstruction 
[3]. In spite of the fact that transmission scan is essential for PET imaging, this scan is 
also a time consuming technique [33], which may represent about 40% or more of the 
total duration of PET imaging [3]. Thus, the application of transmission scan during 
PET imaging results in a long total acquisition time, ranging between 50 – 70 min [34].   
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Figure 2.6: Detectors A and B record a pair of photons from an annihilation reaction that 
is located at ‘a’ depth from detector A and ‘b’ depth from detector B. For each 
annihilation reaction, the probability of detecting both photons is the product of the 
individual photon detection probabilities. Thus, the number of annihilation photons 
recorded by both detectors (A and B) is depth independent, and the total attenuation is 
only determined by the total thickness of the medium, D and the linear attenuation 
coefficient of the medium, μ (as in the Equation 2.5).      
 
 
 In general, PET imaging consists of two different scans, which are the 
transmission and the emission scans. Each of these scans generates a set of images that 
correspond to its scanning; the transmission and the emission images. Usually, the PET 
image acquisition commences with the transmission emission scan then followed by the 
emission scan [3]. As mentioned earlier, the emission data are corrected for attenuation 
using the transmission data prior to the PET image reconstruction. This enables the PET 
scanner to create a new set of images, the so called attenuation corrected images [31], 
which have been found to demonstrate less evident of image artifacts [3]. However, 
PET images can occasionally also be reconstructed without the attenuation correction 
due to two reasons: to identify the presence of the motion artifact and to determine the 
additional anatomical information that is available in the uncorrected image [33]. 
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Therefore, it can be considered that the imaging information provided by these two 
scans are complementary to one another [33].   
 Although PET imaging can successfully provide the functional information of 
various diseases, several limitations of this imaging technique have been identified. 
These include: 
? The attenuation map from the transmission is usually noisy and sensitive to the 
emission activity in the injected patient [33]. 
? A long acquisition time may limit the throughput capability of the PET scanner 
[35]. 
? The spatial resolution of PET images is generally poor compared with 
radiographs, CT or MRI images [35].   
? The cost of all PET instruments and facilities is relatively high as compared to 
other conventional imaging modalities [31, 35]. 
? The cost of each PET imaging is also high, which mainly depends on the cost of 
radiopharmaceuticals used [35]. 
? Patient may suffer to an internal whole body exposure with a non-uniform 
distribution [35, 36]. 
? The radiation dose largely depends on the amount of injected radioactivity [35]. 
 
However, with the evolution in technology, most of these limitations have been 
resolved. For example, the introduction of a new PET imaging system that is capable of 
acquiring the imaging data in either a two-dimensional (2-D) or three dimensional (3-D) 
mode [3]. The acquisition of PET images in a 3-D mode can increase the sensitivity of 
the scanner at least by a factor of 6 [3]. Thus, this new imaging technique may decrease 
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the total acquisition time and/or allow for reducing the amount of injected radioactivity 
to the patient [35]. In addition, the performance characteristics of PET scanner have 
shown a dramatic improvement from the introduction of new and faster scintillator 
crystals, and the advances in computer and electronic systems [3, 35].       
 
2.2. Multi-slice CT scanner 
The technology of CT scanners is more rapidly developed when compared with 
dedicated PET imaging systems [3]. The first CT scanner was commercially introduced 
in 1972 [3, 37]. About two decades later, the era of the helical/spiral CT scanner 
emerged [37], in which the images/projections are acquired continuously while the 
patient/table is translated at a constant speed [38] (Fig. 2.7). This type of scanning offers 
three main advantages: 1) complete organ coverage in a single breath hold, 2) uniform 
sampling density as a result from the translation of patient/table at a constant speed and 
3) the ability of producing overlapped images without overlapped scans [38] also 
known as volume data acquisition [37]. Interestingly, by utilising these overlapped 
images or volume data, the scanner can reconstruct the images in 3-D [37, 38]. Thus, 
this helical/spiral scanning has also paved the way for the development of 3-D image 
processing techniques, which have become a vital component in newer generations of 
the CT scanners [37].  
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Figure 2.7: The basic principle of a helical/spiral CT scan. The table/patient is translated 
at a constant speed while the volume data are acquired. The x-ray tube and detector 
system are continuously rotated in a helical/spiral shape. The images could be 
reconstructed at any point along the longitudinal axis; z-axis.   
 
 
 In 1998, a four-slice CT system was invented, the technology of which solved 
two major problems with single-slice helical/spiral CT scanner: 1) insufficient volume 
coverage within a single breath hold, and 2) missing spatial resolution in the 
longitudinal axis due to wide collimation [37]. The four-slice CT system can acquire 
larger volume coverage in shorter scanning times with an improvement in the 
longitudinal resolution. In this new CT system, four rows of detector have been used 
instead of a single detector row as its predecessor (Fig. 2.8), and hence, it can also be 
named as a multi-detector CT; MDCT, scanner.  
 Currently, the detectors for modern CT systems are made from radiation-
sensitive solid state materials. These detectors convert the attenuated x-rays into visible 
lights, which then will be detected by silicon photodiodes. Similar to the PMTs in PET 
imaging system, the photodiodes convert visible lights into electrical currents, and these 
electrical currents are amplified and converted into digital signals. In addition, the x-ray 
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tube for MDCT scanner requires larger heat storage capacity of the anode plate. This 
characteristic can be achieved either by using the thick graphite layers attached to the 
backside of the anode plate or the rotating envelope x-ray tube. In a rotating envelope 
tube, the anode plate constitutes an outer wall of the x-ray tube, and thus, it has direct 
contact with the cooling oil in the tube housing which allows for very efficient heat 
dissipation [37]. An example of a rotating envelope x-ray tube is shown in Fig. 2.9.     
 
Figure 2.8: Schematic diagrams of a) a single-slice CT system with one detector row, and 
b) a four-slice CT system with four detector rows.   
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Figure 2.9: A rotating envelope x-ray tube. The anode plate constitutes an outer wall of the 
x-ray tube and it is in direct contact with the cooling oil in the tube housing (blue arrow). 
This design allows for efficient heat dissipation via thermal conduction. In addition, 
rotating envelope tubes have no moving parts and no bearing in the vacuum [37].  
 
  
 With the development of MDCT system, the technology in CT imaging has 
tremendously changed. In 2007, a scanner with the capability of acquiring 320 slices 
during one tube rotation was introduced. However, prior to this, the first dual-source CT 
(DSCT) system was developed in 2005. This DSCT system has two x-ray tubes and two 
corresponding detectors, or in other words it has two acquisition systems that are 
mounted onto the rotating gantry with an angular offset of 90o, as shown in Fig. 2.10. In 
DSCT, both x-ray tubes can either be operated simultaneously or at different kV 
settings. The later technique allows for dual energy acquisitions which may provide 
additional functional information to the morphological information, based on the 
differences in x-ray attenuation coefficients [37]. In addition, the timeline of the 
technological advancements in CT scanning systems is summarised in Fig. 2.11.        
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Figure 2.10: Schematic illustration of a dual-source CT (DSCT) system using two x-ray 
tubes (A and B) and two corresponding detectors offset by 90o [37]. 
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Figure 2.11: Summary of the technology developments in CT scanning system. 
 
 
In 1972:  
The first CT scanner was commercially introduced 
In the early 1990s: 
The introduction of a helical/spiral CT system 
In 1998: 
 The introduction of a 4-slice CT scanner 
In 2000: 
 The introduction of an 8-slice CT scanner 
In 2004: 
 The introduction of a 64-slice CT scanner 
In 2005: 
 The introduction of a dual-source CT (DSCT) 
system 
In late 2007: 
 Toshiba and Philips had introduced a single-source 
CT system that could acquire 256 and 320 slices 
during one tube rotation, respectively  
In 2002: 
 The introduction of a 16-slice CT scanner 
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2.3. Positron Emission Tomography/Computed Tomography (PET/CT) 
In the imaging diagnosis of a disease, CT images are primarily used for detecting 
anatomical or morphological changes, whereas PET imaging provides functional or 
metabolic information that is associated with the disease. The utilisation of both 
anatomical and functional information may facilitate for more accurate lesion detection 
and differentiating between normal and abnormal tissues. Thus, this issue demands the 
integration of these two images into a single display system, regardless of either using 
software or hardware fusion techniques.  
 The first attempt of integrating the images from different modalities began in the 
1980s [39]. It started with the fusion of the metabolic emission images from PET to the 
much higher resolution anatomic images from either MRI or CT scans by using a 
software based image fusion technique. At that time, this technique was successful for 
the brain, whereas for the other parts of the body, it was seemed to be complicated 
mainly due to the synchronisation problems [39-41]. The drawbacks for this software 
based image fusion technique are addressed in Table 2.2.   
 
Table 2.2: A comparison of advantages and disadvantages between software and 
hardware based image fusion techniques [39]. 
Software fusion Hardware fusion 
Image retrieval from different archives Image available from one device 
Repeated patient positioning Single patient positioning 
Different scanner bed profiles One bed for both scans 
Uncontrolled internal organ movement 
between scans 
Consecutive scans with little internal organ 
movement in between scans 
Disease progression in time between scans Scans acquired close in time 
Limited registration accuracy Improved registration accuracy 
Less convenient for patient (two scans) Single, integrated exam 
Labour-intensive registration algorithms No further image alignment required 
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 To resolve the problems associated with the software fusion technique (refer to 
Table 2.2), a combination of CT and PET systems in one scanner was proposed. This 
approach is referred to the hardware based image fusion technique [3]. The 
development of the first integrated PET/CT prototype was initiated in 1992 and took 
about six years until the prototype became fully operational allowing for clinical trials 
of more than 300 cancer patients. These studies emphasised of the following advantages 
[3]: 
? an accurate localisation of functional abnormalities,  
? a clear differentiation between the normal uptake and the pathological uptake,  
? a minimisation on the effects of both external and internal patient movements, 
and 
? a significant reduction in scanning time and an increase in patient throughput 
from the utilisation the CT based PET attenuation correction factors.  
 
  The first integrated PET/CT imaging modality was commercially made available 
to be used for clinical imaging in early 2001 [2, 39]. In this first PET/CT scanner, CT 
and PET scans were acquired and reconstructed on separate consoles, while the image 
fusion display system was only installed on the PET console [3, 39] (Fig. 2.12). 
However, with the advances in technology, all PET/CT imaging systems can now be 
operated and displayed from a single console, and five major vendors offer this 
integrated imaging system: a) Philips Healthcare Systems, b) Siemens Healthcare 
Solutions, c) General Electrics (GE) Healthcare, d) Toshiba Medical Systems, and e) 
Hitachi Medical Systems. Indeed, over 5000 PET/CT imaging systems have been 
installed worldwide [3, 29].  
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Figure 2.12: Schematic representation of the first PET/CT scanner, where PET 
components were mounted on the rear of a common rotating support. Both CT and PET 
scans were acquired and reconstructed on separate consoles, but the image fusion display 
was only installed in PET console [39]. 
 
 
 Currently, PET/CT imaging modality consists of the combination between a 
whole-body dedicated PET system and a standard multi-slice CT scanner, which have 
been incorporated into a single gantry [29] (Fig. 2.13). Usually, the CT scanner is 
mounted in front of the gantry, then followed by the PET imaging system [42]. This 
design allows for the acquisition of functional PET and morphological CT images in a 
single imaging session without positional change of the patient, and with very minimal 
delay in time between those two scans [43]. These two sets of images can be 
intrinsically co-registered using an automated PET/CT image registration technique, 
which offers several advantages such as convenience and fast method, observer 
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independence, and well tolerate with all respiratory phases either during CT or PET 
scan [44]. Thus, PET/CT fusion images can result in more accurate anatomical 
localisation of both normal tissues and pathologic lesions [45].  
 
 
Figure 2.13: Biograph 6 PET/CT imaging system from Siemens Healthcare Solutions, 
which incorporates PET and CT scanners into a single gantry setting. The PET imaging 
system consists of a multi LSO detector ring system, whereas the CT scanner is the 
SOMATOM Emotion 6; that enables for an acquisition of 6 slices per one revolution. 
Image courtesy from Prince Court Medical Centre, Kuala Lumpur, Malaysia. 
 
 
 The most recent development in PET/CT imaging is the incorporation of a PET 
system with a MDCT scanner of up to 128 detector rows [29, 46]. This new 
PET/MDCT integration has improved the capability of the imaging system, in which it 
can potentially be used in the standard acquisition protocols for imaging of the heart 
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[47]. However, instead of functioning as an integrated imaging modality, PET/CT 
scanner can also be operated as two different modalities, either a dedicated PET system 
or a CT scanner [45].  
 
2.3.1. PET/CT detectors 
The scintillator materials for PET/CT detector are basically the same as in a dedicated 
PET imaging system. The first PET/CT prototype utilised the BGO detector, however, 
presently most of PET/CT detectors are made of LSO [29]. The LSO material has fast 
timing properties with a high light output and good stopping power for 511 keV gamma 
ray photons [48] (refer to Table 2.1).  
 
2.3.2. Attenuation correction of PET/CT 
Unlike a dedicated PET scanner, in PET/CT imaging system, the information on the 
attenuation correction of the PET emission data can be derived by using CT data [43, 
49], in which it may eliminate the need for a separate and lengthy PET transmission 
scan [39]. With this CT-based attenuation correction technique, the overall whole body 
PET/CT scanning time can substantially be reduced by about 30% – 40% [3, 42]. In 
addition, this data provides essentially noiseless attenuation correction factors as 
compared to those from PET transmission scan [3, 39]. Therefore, this novel approach 
has been found to increase the throughput capability of a PET/CT scanner with less 
patient discomfort [42].  
 As highlighted in section 2.1.2, the attenuation correction of PET emission data 
depends upon the linear attenuation coefficient value of the medium; μ, and the total 
thickness of the medium; D [31]. Of these two factors, only the linear attenuation 
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coefficient values can be effectively determined from the CT images, and these values 
are energy dependent [3, 30]. To calculate the PET attenuation correction factors, CT 
numbers (represent in Hounsfield Units; HU) that are acquired at a mean photon energy 
of 70 keV (the mean energy of the polychromatic x-ray beam produced by CT scan) 
must be converted and scaled to the linear attenuation coefficient values of 511 keV 
PET energy level [3, 39]. This process can be done by applying the scaling algorithms 
to the HU data of the CT images, in which the algorithms use a bi-linear function to 
transform the HU data to the linear attenuation coefficient values above and below a 
threshold with different factors [43, 49]. Accordingly, all biological tissues on the CT 
images are classified into two different compositions of either the air-water mixture or 
the water-bone mixture, with an optimal threshold is found to be at around 100 HU [3] 
(refer to Fig. 2.14). These bi-linear scaling algorithms have been widely used and 
accepted in the clinical PET/CT imaging [49].  
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Figure 2.14: The simple bi-linear scaling algorithms that are typically used to convert the 
CT number (Hounsfield Unit; HU) to the linear attenuation value (μ) of 511 keV PET 
energy level. The graph shows the μ value as a function of the corresponding HU. An 
optimal threshold of about 100 HU (dashed green line) is applied for classifying all the 
biologic tissues of the CT images into two different compositions of either the air-water 
mixture or the water-bone mixture. Based on these scaling and conversion methods, the 
PET attenuation correction factors are calculated by using CT numbers [3].  
 
 
2.4. Fluorodeoxyglucose (FDG) 
Carbon, nitrogen, oxygen and hydrogen represent the fundamental elements of 
biological molecules. The first three elements have isotopes that decay by positron 
emission, however, hydrogen can generally be replaced with another similar element, 
known as Fluorine-18 (18F) [28]. The routinely used positron emitters for PET and/or 
PET/CT imaging are listed in Table 2.3. 
 
 43
Table 2.3: Common positron emitters for PET and/or PET/CT imaging [32]. 
Radioisotope Atomic number 
(protons) 
Number of nucleons 
(protons + neutrons) 
Approximate half-life 
(min) 
Carbon-11 6 11 20 
Nitrogen-13 7 13 10 
Oxygen-15 8 15 2 
Fluorine-18 9 18 110 
 
 
Today, a number of positron-labelled radiopharmaceuticals are commercially 
available, and can either be applied in clinical or research studies. However, the most 
widely used one is 18F-2-fluoro-2-deoxy-D-glucose, also known as Fluorodeoxyglucose 
(FDG). This radiopharmaceutical has been utilised for more than 90% of all PET 
oncological imaging [29], which mainly due to the longer half-life of 18F compared to 
the others (refer to Table 2.3). Thus, FDG offers a capability to be transported to 
satellite PET or PET/CT imaging centres, especially for those without on-site cyclotron 
facility.  
 Fundamentally, FDG is an analogue of glucose, with a chemical formula of 
C6H11FO5 [32]. However, the hydroxyl (OH) group at the Carbon-2 (C-2) position is 
missing and has been replaced by a Fluorine-18 (18F) molecule [50] (refer to Fig. 2.15). 
Like glucose, FDG enters the living cell via glucose transporters which are located on 
the cell membrane. Once FDG has reached the cytoplasm of the cell, it undergoes the 
glycolysis process, and is phosphorylated to FDG-6-phosphate by the hexokinase 
enzyme. However, FDG-6-phosphate cannot be further metabolised by the glucose-6-
phosphate isomerise enzyme, mainly due to the absence of an oxygen atom at the C-2 
position. FDG-6-phosphate is also not a suitable substrate for the glucose-6-phosphatase 
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enzyme; an enzyme that is responsible for converting FDG-6-phosphate to FDG. As a 
consequence, FDG-6-phosphate is trapped in the cytoplasm [32, 50] (refer to Fig. 2.16).  
 
 
Figure 2.15: A comparison of the chemical structure of a) glucose (C6H12O6) and b) 
Fluorodeoxyglucose; FDG (C6H11FO5), in which the hydroxyl group (OH) at the C-2 
position is being replaced by 18F molecule [51].  
 
 
Figure 2.16:  Schematic illustration for early metabolic pathway of glucose and FDG [32]. 
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The radioactive Fluorine-18 (18F) molecule will decay to its stable molecule, 
known as Oxygen-18 (18O) [28] (Fig. 2.17). As in FDG-6-phosphate, 18F atom at the C-
2 position carries a negative charge; 18F-. This unstable negative ion decays to a new 
stable negative ion of Oxygen-18 (18O-). Then, 18O- ion combines with a hydronium ion 
(H+) from its aqueous environment, and creates a new substrate which is called glucose-
6-phosphate labelled with a harmless non-radioactive "heavy oxygen" [52]. This new 
substrate can undergo a normal glycolysis process in the same way as the ordinary 
glucose, which finally produces non-radioactive end-products [52] (Fig. 2.18).  
 
 
 
 
Figure 2.17: Decay scheme diagram for radioactive 18F to its stable material; 18O, which 
decays by both electron capture; EC, and positron emission; β+ (t½; half-life).  
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Figure 2.18: Schematic illustration for the biochemical pathway of FDG in the living cell. 
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2.5. Standardised Uptake Value (SUV) 
Although visual assessment of PET and PET/CT fusion images is often sufficient for 
image analysis and interpretation, the quantitative image analysis using the standardised 
uptake value (SUV) is also commonly used to augment the finding by measuring the 
degree of FDG uptake on the area of the suspected lesion. SUV is a semiquantitative 
measurement that normalises the measured radioactivity concentration in a tissue to the 
body weight and total injected radioactivity [53], and a unitless ratio [32]; as in 
Equation 2.6.  
 
    Measured radioactivity concentration in a lesion (kBq/mL)              (2.6) 
       Total injected radioactivity (kBq) / Body weight (g) 
 
The concentration of radioactivity is assumed to be uniformly distributed 
throughout the body [54]. Therefore, this value can be easily determined by marking the 
region of interest (ROI) at the desired area of the PET and PET/CT fusion images. SUV 
has also been known as an index of glucose metabolism which represents the amount of 
FDG uptake in a given ROI in relation to the average uptake throughout the body [55]. 
Indeed, this semiquantitative method is widely used to assess the metabolic activity in a 
lesion.  
SUV value of more than 2.5 to 3.8 is frequently used as a cut-off value for 
differentiating between malignant and inflammatory/infectious lesions on PET and 
PET/CT fusion images [1-3]. This technique has been the preferred method for 
quantitative PET and PET/CT imaging as it is reproducible, practical and time-saving 
[56, 57]. Nevertheless, the clinical cut-off value for SUV based evaluation of PET and 
PET/CT fusion images is still a matter of debate, mainly due to the problems in defining 
SUV = 
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the normal values and threshold levels between the two main groups of lesions 
(malignant and inflammatory/infectious) [29]. In addition, several factors like the 
patient’s serum glucose levels, insulin levels, the scanning time (time interval between 
FDG injection and image acquisition) and partial volume effects in PET imaging can 
significantly affect the accuracy of SUV [55, 58-61]. However, in the recent clinical 
study, it has been reported that the image analysis using SUV may result in more 
reliable diagnosis as compared to the visual assessment [62]. 
 
2.6. Common PET/CT image artifacts and the potential solutions 
As mentioned earlier in section 2.3, PET/CT imaging system offers several advantages 
over a dedicated PET scanner. However, this integrated imaging modality still has some 
drawbacks especially in respect to the image artifacts. Improved knowledge and 
awareness of PET/CT image artifacts could play an important role towards producing 
more accurate image analysis and interpretation. This may in turn aid the nuclear 
medicine physicians and/or the nuclear medicine technologists in performing the scan in 
the best conditions possible, and thus, avoiding the repetition of the scan. PET/CT 
image artifacts mainly arise from the application of CT images for calculating the PET 
attenuation correction factors [42]. Accordingly, all these artifacts are categorised into 
four different groups, depending on their causes [42]: a) metallic implants, b) 
respiratory motion, c) contrast media, and d) truncation. 
 Metallic implants such as dental fillings, hip prosthetics and/or chemotherapy 
ports can generate streaking artifacts on CT images, which then results in the high PET 
attenuation coefficient values. This kind of artifacts will lead to an overestimation of the 
PET tracer uptake, and it may potentially cause false positive PET/CT findings. In order 
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to overcome this problem, an interpretation using non-attenuated PET images has been 
recommended [63, 64]. Furthermore, by asking the patient to remove all metallic 
objects before commencing the imaging scan, and documenting the location of 
nonremovable metallic objects, these approaches may help in identifying the source of 
the artifacts [42].  
 Respiratory motion artifact occurs due to the inconsistency of chest position 
during the PET and CT image acquisitions [42]. This misregistration artifact (also 
known as curvilinear cold area) is usually seen at the base of the lung [65]. This issue 
can be addressed sufficiently by reviewing the CT images for any anatomical 
abnormality, and a proper breathing instruction may also possibly reduce the occurrence 
of this image artifact [42].   
 Similar to the metallic implants, the application of contrast media (administered 
either through intravenous injection or oral) during the CT scan of PET/CT imaging can 
cause an artifact on PET images, in which it may result in false positive findings [66, 
67]. However, instead of utilising the non-corrected PET images during the image 
interpretation, the proper patient’s schedule can also help in reducing the occurrence of 
this artifact; by allowing the time gap (up to several days) particularly for those patients 
who have recently undergone the contrast-enhanced CT (CECT) scan [42].  
 For the truncation artifact, it is more frequently seen in large patients or when 
the scanning is performed with patient’s arms down [68]. This artifact occurs due to the 
difference in the size of the field of view (FOV) between the CT and PET scanners: 50 
cm vs. 70 cm [42, 68]. Truncation artifact may also cause an overestimation of the SUV 
value [68]. As a solution to this hitch, therefore patient needs to be carefully positioned 
at the centre of the PET/CT FOV with the arms at above of the head [42].    
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2.7. Tuberculosis 
Apart from being routinely used in the imaging diagnosis of various malignancies, FDG 
PET/CT scan has also been found to be a valuable imaging technique for detecting 
many inflammation/infection diseases [4]. As highlighted in Chapter 1, the main focus 
of this thesis is to identify the potential role of FDG PET/CT imaging in the detection of 
a special type of tuberculosis infectious disease; extrapulmonary tuberculosis (EPTB). 
Thus, the current issues and practice pertaining to tuberculosis need to be addressed.   
 Tuberculosis (TB) remains one of the deadliest diseases in the world [69]. It is 
an airborne infectious disease, which caused by Mycobacterium tuberculosis infection. 
Even though the cause of TB was first identified by Robert Koch over than one century 
ago [70], it remains to be a major cause of morbidity and mortality, particularly in 
developing countries [18, 70]. In the most recent annual TB report published by World 
Health Organisation (WHO), Regional Office for the Western Pacific, there were an 
estimated about 3.5 million prevalent cases of TB in the Western Pacific Region 
(WPR), which consist of more than 1.9 million new TB cases [71]. In addition, the 
following four countries were respectively ranked from first to fourth for all incident 
cases: 1) China, 2) Philippines, 3) Vietnam, and 4) Cambodia. These four countries 
accounted for 93% of the total estimated incidence in the WPR. Indeed, the highest 
mortality rate was notified in Cambodia (89 cases per 100 000 population), while the 
lowest were in Australia and New Zealand (1 case per 100 0000 population) (refer to 
Fig. 2.19).   
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Figure 2.19: Case notification rates per 100 000 population, for all forms of TB cases in the countries and areas in the Western Pacific Region 
(WPR) and the neighbouring countries and areas [71].
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2.7.1. Tuberculosis in Malaysia 
TB also plays a major role in a developing country like Malaysia. It is an endemic 
disease [72] and can be considered as one of the most deadly infectious diseases in this 
country [73]; with a steady increasing pattern in the annual notified new TB cases [74]. 
As an intermediate TB burden country [75], in 2007, a total of 16 918 cases were 
notified with an estimated incidence rate per 100 000 population of about 103 [71]. The 
state with the highest disease burden was Sabah (3433 cases), followed by Selangor 
(2484 cases) and Sarawak (1705 cases), respectively [73]. In terms of gender, males 
outnumbered females with more than double in percentage (67.9% vs. 32.1%), and 
about 56.6% cases were in the patients with an age range of 25 – 54 years old [73]. 
 TB is able to spread to any organ system in the body [12], thus it can be 
categorised into two different types, depending on the site of the lesion: (a) pulmonary, 
and (b) extrapulmonary; the term ‘extra’ describes the isolated occurrence of TB at the 
other body sites, excluding the lung. Extrapulmonary tuberculosis (EPTB) occurs in 5 – 
20% of all TB cases [12, 76]. Generally, patients with EPTB are often presented with 
non-specific symptoms such as fever, anorexia, weight loss, malaise (discomfort) and 
fatigue, but these symptoms can also vary accordingly to the affected site [16].  
 In 2007, a total of 2107 new EPTB cases were recorded, which corresponded to 
about 13% from all notified TB cases [71] (refer to Fig. 2.20). The most common 
forms/sites of EPTB in Malaysian patients were reported to be the lymph nodes, bone 
and joint, and miliary TB [74]. In addition, according to the latest Malaysia’s TB 
profile, the incidence of EPTB infectious disease has shown an increasing pattern [77]. 
Thus, this issue implies a significant importance for early detection and accurate 
diagnosis of EPTB.  
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Figure 2.20: Tuberculosis profile for Malaysia. The notified cases were recorded from 
1995 to 2007. DOTS: Directly Observed Treatment Short-course, ss+: smear positive,  
ss-/unk: smear negative/unknown causes [78]. 
 
 
2.7.2. Pathogenesis of tuberculosis in human 
Mycobacterium tuberculosis (also known as tubercle bacillus) is an aerobic pathogen, 
and therefore it is more likely to become established in a tissue with high oxygen 
saturation such as the lung [10]. The tubercle bacilli (plural for tubercle bacillus) enter 
the human body via the respiratory route. The pathogenesis of TB in humans has been 
well documented and explained in the literature [10, 16, 79], and it can be divided into 
five stages [79] (refer to Fig 2.21 for the schematic illustration).  
Stage 1 begins when the bacilli implant into the alveolus of the lung. As the first 
line of defence mechanism, the pulmonary alveolar macrophages will subsequently 
ingest and often destroy the bacilli through the phagocytosis process. However, the 
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bacilli that survive from the initial attack will multiply intracellularly until the 
macrophage ruptures; this is the beginning of stage 2. The dying macrophage will 
release the chemokines, which then attract other alveolar macrophages and 
monocytes/macrophages arriving from the bloodstream. The macrophages from the 
bloodstream are nonactivated and immature. Therefore, these macrophages can only 
ingest the bacilli without destroying them. The bacilli cannot harm the macrophages, 
and thus develop a symbiotic relationship with the macrophages. Over the time, the 
accumulation of macrophages and bacilli produce a microscopic tubercle. 
 Stage 3 is the cessation of the symbiotic stage of bacillary growth with 
subsequent tissue damage via Delayed Type Hypersensitivity (DTH). This mechanism 
kills the infected macrophages by damaging the blood vessels, and ends with the 
formation of a solid caseous centre. This eliminates the favourable intracellular 
environment for bacillary growth, because tubercle bacilli cannot multiply in solid 
caseum. Apart from DTH, there is also another process that acts synergistically in 
controlling the progression of the disease; it is known as Cell Mediated Immunity 
(CMI), which is responsible for the production of the activated macrophages. 
 Both CMI and DTH play an important role in stage 4. During this stage, the 
disease may become clinically apparent, and can be seen on the radiograph. If CMI is 
weak (stage 4a), the bacilli can escape from the edge of caseous centre and again 
multiply intracellularly in nonactivated macrophages, and as usual DTH will kill these 
infected cells. This results in the enlargement of the tubercle and its caseous centre. At 
this stage, the bacilli can be disseminated through the blood and lymphatic system, 
which then produce secondary lesions especially in the hilar lymph nodes, lungs, and 
other organs. On the other hand, if CMI is strongly developed (stage 4b), the escaping 
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bacilli are ingested and destroyed by highly activated macrophages, and finally ends 
with the stabilisation and regression of the lesions.  
 Consequent to stage 4a, stage 5 begins when the solid caseum turns into liquid 
form; known as liquefied caseum. The bacilli may multiply extracellularly and reach 
tremendous numbers. The large numbers of bacilli are toxic to the tissues. It causes 
DTH to erode the nearby bronchial wall and forms a cavity. Then, bacilli in the 
liquefied caseum are discharged into the airways, and may spread to other parts of the 
lung and to the outside environment. These bacilli can also be contagious to members of 
the population. 
In humans, it is believed that extrapulmonary dissemination of TB occurs at 
around two weeks after the initial infection [80]. The normal route for extrapulmonary 
dissemination of TB is first by the draining into the lymph nodes, then into the thoracic 
duct and followed by the blood stream [81]. However, it can also directly enter the 
blood system through the alveolar epithelial barrier or via the sites other than the lung; 
like the upper respiratory system (nasal cavity, pharynx and larynx) or the digestive 
system [81]. The following forms/types of EPTB are classified as severe; meningeal 
tuberculosis, military tuberculosis, pericardial tuberculosis, peritoneal tuberculosis, 
bilateral or extensive pleural effusion, spinal tuberculosis, intestinal tuberculosis, and 
genitourinary tuberculosis, whereas tuberculous lymphadenitis, bone tuberculosis 
(excluding spine), unilateral pleural effusion, peripheral joint tuberculosis, and skin 
tuberculosis are the less severe types of EPTB [82, 83].  
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Figure 2.21: Schematic diagram for the pathogenesis of human tuberculosis [79].  
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2.7.3. Diagnosis of tuberculosis 
Early identification and diagnosis are the main elements for effective control of TB 
[84]. The definitive diagnosis of TB is mainly based on the microscopic demonstration 
of Acid-Fast Bacilli (AFB) and culture isolation and identification of Mycobacterium 
tuberculosis in sputum or other clinical samples [84-86]. This involves a series of 
procedures that employ special reagents and techniques [69], but most of them suffer 
from either lacks of sensitivity and specificity [84, 85], or time consuming [69, 84, 85]. 
To develop clear understanding on the diagnosis process of TB, it can be divided into 
three major components: (1) clinical, (2) bacteriological, and (3) radiological. 
 
2.7.3.1. Clinical diagnosis 
The clinical diagnosis of TB is based on the clinical signs and symptoms. A person is 
suspected to have pulmonary TB, if he/she presents with either one or the combination 
of the following classical signs and symptoms [82]: 
? Persistent of cough for more than two weeks 
? Cough with sputum which occasionally contains blood; haemoptysis 
? Low-grade fever 
? Loss of weight and loss of appetite 
? Difficulty in breathing; dyspnoea 
? Night sweats 
? Chest pain 
? Hoarseness or loss of voice  
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These symptoms are however non-specific [86], and in fact, patients with active 
pulmonary infections may also be asymptomatic [18]. The haematological signs such as 
an elevated peripheral blood leukocyte count and a mild anaemia can also be correlated 
with TB [86]. On the other hand, the signs and symptoms for EPTB are also found to be 
non-specific [15] and vary according to the affected sites or tissues [16]. Therefore, in 
2005, an effort in listing all signs and symptoms of EPTB was made by Golden and 
Vikram [87], as in Table 2.4.  
 
Table 2.4: Clinical signs and symptoms of EPTB [87]. 
Signs and symptoms of EPTB 
1. Ascites with lymphocyte predominance and negative bacterial 
cultures 
2. Chronic lymphadenopathy (most common cervical node) 
3. Cerebrospinal Fluid (CSF) lymphocytosis with elevated protein 
and low glucose 
4. Differential diagnosis of Crohn's disease and amebiasis 
5. Exudative pleural effusion with lymphocyte predominance and 
pleural thickening 
6. Human Immunodeficiency Virus (HIV) infection 
7. Monoarticular joint inflammation with negative bacterial cultures 
8. Persistent sterile pyuria with or without haematuria 
9. Tuberculosis-endemic country of origin 
10. Unexplained pericardial effusion, constrictive pericarditis or 
pericardial calcification 
11. Vertebral osteomyelitis involving the thoracic spine 
 
 
2.7.3.2. Bacteriological investigations 
Bacteriological or laboratory investigations for TB comprise many types of microscopic 
tests, and the most widely used and available method is the tuberculin skin test (also 
known as Mantoux test) [69]. It is based on the fact that infection with Mycobacterium 
tuberculosis produces a Delayed Type Hypersensitivity (DTH) reaction to certain 
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antigenic components of the organism that are contained in extracts of culture filtrates  
called ‘tuberculins’ [69]. This test is usually carried out by injecting 0.1 mL of the 
standard 5 tuberculin unit dose of purified protein derivative (5-TU PPD) into the dorsal 
surface of the forearm [69]. However in Malaysia, the standard dose for tuberculin skin 
test is only 2-TU [82]. The test is read 72 hours after injection, and the interpretation of 
the result is based on the diameter of induration, which can be divided into 3 categories: 
1. Diameter of less than 10 mm (<10 mm) is considered to be a negative result, but 
this does not exclude a diagnosis of TB. 
2. Diameter of 10 mm or more (≥10 mm) is classified as positive result.  
3. Diameter of 15 mm or more (≥15 mm) may indicate recent infection.  
 
In a patient who has a sputum-producing cough, the main diagnostic procedure 
consists of direct sputum smears for acid fast bacilli (AFB) [82, 86] and culture 
examination of three sputum specimens collected on different days [69, 82, 86]. The 
sputum smear is the easiest and quickest method, which provides the physician with a 
preliminary confirmation of TB [69]. There are two commonly used methods for AFB 
staining [69, 86]: 
1. The carbolfuchsin method (include Ziehl-Neelson and Kinyoun methods), which 
will be used in combination with light microscope [86]. 
2. A fluorochrome procedure using auramine-rhodamine dye in combination with 
fluorescent microscope [86]. 
 
On the other hand, the culvitation of mycobacteria from the sputum and other 
clinical specimens requires a longer time; up to 8 weeks [69, 82], primarily because of 
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the slow growth rate of tubercle bacilli [18, 86]. As TB may occur in almost any site in 
the body (especially for EPTB and disseminated/ miliary TB cases); therefore many 
kinds of clinical specimens can be collected and sent for laboratory examinations like 
gastric aspirate, urine, cerebrospinal fluid, pleural fluid, peritoneal fluid, pericardial 
fluid, other biopsy specimens or resected tissue and cold abscess pus [12, 69]. Gastric 
aspiration may be necessary in particular for children and those patients who cannot 
produce sputum even though has been induced with aerosol inhalation [69]. Urine 
smears and culture examinations are usually negative, but it is mandatory in patients 
who are suspected with genitourinary tuberculosis [12].  
When non-invasive techniques have not provided a definite diagnosis, invasive 
procedures such as percutaneous needle biopsy or aspiration, transbronchial biopsy, 
bone marrow biopsy, lung biopsy and liver biopsy should be conducted to procure 
tissue and/or other body fluids (including the pus aspirated from cold abscess) for 
culture investigation and histological evaluation [12, 69]. Automated culture system 
such as BACTEC (Becton Dickinson Microbiology Systems, Sparks, MD) represents a 
major improvement in the technology of mycobacterial identification [69, 86]. It allows 
the detection of Mycobacterium tuberculosis growth within 2 weeks [82, 86].  
Polymerase Chain Reaction (PCR) is one of the nucleic acid amplification 
techniques, which aims for a rapid detection and identification of Mycobacterium 
tuberculosis  from various clinical specimens, without the need for the culture 
examination [86, 88]. In fact, many studies show that PCR yields a higher sensitivity 
when compared to other laboratory examinations [85, 88, 89]. Consequently, PCR could 
be considered as an important microbiological test in the diagnosis of TB, particularly 
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for EPTB [12]. This test could also allow quick implementation of anti-tuberculous 
drugs treatment. 
 
2.7.3.3. Radiological examinations 
The radiological imaging for detecting TB usually consists of a multi-modality 
approach, from general radiographic to sectional and/or functional imaging modalities. 
Chest radiographs play a major role in the screening, diagnosis and monitoring the 
treatment response of patients with TB [18]. The pattern of disease on chest radiographs 
can be described either as primary TB or post-primary TB [18, 90]. Primary TB pattern 
represents the infection resulting from recent contact with Mycobacterium tuberculosis, 
whereas for post-primary TB pattern, it results from reactivation of a dormant focus 
within the lungs [90]. 
In primary TB, there are few signs that can clearly be seen on a chest radiograph 
such as pleural effusion (usually unilateral), parenchymal consodilation, and hilar or 
mediastinal lymphadenopathy [18, 90]. However, all of these imaging features are better 
depicted on CT images, which is more sensitive than chest radiograph [18, 90]. The 
parenchymal consodilation is most commonly dense and homogenous on CT images 
[18]. In addition, contrast-enhanced CT (CECT) images may demonstrate the enlarged 
lymph nodes with a typical central low attenuation (which represents caseous necrotic 
centre) and peripheral rim enhancement (which represents the vascular rim of the 
granulomatous inflammatory tissue) [18, 90, 91]. This pattern is strongly suggestive for 
TB [90].   
 For post-primary TB (also called as reactivation TB), the most common 
radiographic characteristic is focal or patchy heterogenous consodilation involving the 
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apical and/or posterior segments of the upper lobes, and/ or superior segment of the 
lower lobes [86]. Cavitation is the radiologic hallmark for the reactivated TB patients 
[18, 90]. Furthermore, the presence of endobronchial spread is also common in post-
primary TB, and it appears as centrilobular small nodules with branching linear and 
nodular opacities (tree-in-bud sign) on CT images [92]. Both cavitation and tree-in-bud 
sign are the reliable indications for the active process of TB infection [18, 93]. The 
utilisation of PET scan can also help in detecting the tuberculous nodules [94, 95].  
 Similarly, for the imaging diagnosis of EPTB patients, the radiological 
investigations are mainly based on the sites of the involvement like lymph nodes, 
pleural cavity, abdomen, bone and joint, and central nervous system. All the imaging 
studies that relate to a particular EPTB infectious disease are highlighted and 
summarised in Table 2.5.  
 
Table 2.5: Summary of the radiological examinations for several types of EPTB. 
Types of EPTB Radiological examinations 
Tuberculous lymphadenitis Chest radiograph [16, 87] and CECT [12] 
Pleural tuberculosis Chest radiograph [12, 16, 87] and chest CT scan [87]
Abdominal tuberculosis:  
 a) gastrointestinal tuberculosis Barium studies like small bowel barium meal and 
barium enema [96], and abdominal CT scan [87, 96] 
 b) peritoneal tuberculosis Ultrasonography of the abdomen [16, 96] and 
abdominal CT scan [16] 
 c) genitourinary tuberculosis Chest and abdomen radiographs [16], intravenous 
pyelography [12], percutaneous nephrogram [12] 
and abdominal CT scan [16, 87] 
Bone and joint tuberculosis:  
 a) spinal tuberculosis Spine radiograph [16, 87], CT and MRI scans of the 
spine [12, 16, 87] 
 b) articular tuberculosis Joint radiograph [87] 
Central nervous system tuberculosis CECT scan of the head [12, 16, 87] and gadolinium 
enhanced MRI scan of the brain [12] 
Miliary tuberculosis Chest radiograph [12, 87], chest CT scan [12, 87] 
and HRCT scan of the chest [12] 
MRI; Magnetic Resonance Imaging, CECT; Contrast-enhanced Computed Tomography, 
HRCT; High Resolution Computed Tomography. 
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2.7.3.4. Other diagnostic techniques 
Few other diagnostic techniques are also clinically important, and they may help in the 
diagnosis of EPTB infectious disease such as echocardiography for pericardial 
tuberculosis [12] and colonoscopy for gastrointestinal tuberculosis [96]. In addition, 
recent study has found that optical imaging using fluorescent proteins can demonstrate 
the extrapulmonary spread of tuberculosis in a living animal [81], therefore it has been 
believed that this new technique could serve some potential benefits for human study in 
the near future. 
 
2.7.4. Treatment of tuberculosis 
TB can be completely curable through short-course chemotherapy. Directly observed 
treatment short-course (DOTS) is highly efficient and cost-effective, and it has been 
accepted as an international recommendation strategy for controlling TB infectious 
disease, regardless of either for PTB or EPTB [83]. According to the latest TB report 
from WHO, Malaysia had been reported to have a 100% DOTS coverage, and the 
overall treatment success rate for the WPR was about 92%, which was beyond the target 
of 85% [71]. Basically, the treatment of TB has five different aims, which are as the 
following [83]:   
1. To cure the TB patient. 
2. To prevent death form active TB or its late effects. 
3. To prevent relapse of TB. 
4. To decrease transmission of TB to others. 
5. To prevent the development of acquired drug resistance.  
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Five drugs are considered as the essential first-line drugs for anti-tuberculous 
treatment: isoniazid (H), rifampicin (R), pyrazinamide (Z), streptomycin (S), and 
ethambutol (E) [86]. In Malaysia, the treatment for a new PTB/EPTB patient consists of 
a six months regimen , which can be divided into two different phases: (1) 2 months of 
intensive phase and (2) 4 months of continuation phase [74, 82]. During the intensive 
phase, patient will be prescribed with daily doses of S or E, H, R and Z, and followed 
by biweekly doses of H and R, or S, H and R for the continuation phase [15, 74, 82]. 
However, this continuation phase may be further extended particularly for severe forms 
of EPTB and immunocompromised patient. The patient management for the 6 months 
or 24 weeks period of the anti-tuberculous drugs treatment is summarised in Figure 
2.22.  
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FBC; Full Blood Count, RFT; Renal Function Test, RBS; Random Blood Sugar, HIV; Human 
Immunodeficiency Virus, AFB; Acid-Fast Bacilli, S; streptomycin, H; isoniazid, R; rifampicin, 
Z; pyrazinamide (Z), E; ethambutol and CXR; chest x-ray. 
 
Figure 2.22: Flow chart of 24 weeks or 6 months anti-tuberculous treatment in an adult 
patient [15, 82].  
Visit 1 
(Week 0) 
Baseline investigations 
FBC, RFT, RBS, HIV test, sputum AFB 
direct smear, sputum culture and sensitivity 
test for Mycobacterium tuberculosis
Initiation of anti-tuberculous treatment  
8 weeks of intensive phase 
Daily doses SHRZ or EHRZ 
(Total of 56 doses) 
16 weeks of continuation phase 
Biweekly doses SHR or HR 
(Total of 32 doses)
16 weeks of continuation phase 
Biweekly doses SHR or HR 
(Total of 32 doses)
Treatment completion for 6 months 
regimen 
First follow-up  
(3 months from the treatment completion) 
Visit 2 
(Week 8) 
Visit 3 
(Week 16) 
Visit 4 
(Week 24) 
Visit 5 
(Week 36) 
Visit 6 
(Week 60) 
Visit 7 
(Week 96) 
Second follow-up  
(9 months from the treatment completion) 
Third follow-up  
(18 months from the treatment completion) 
Sputum culture and 
sensitivity test, sputum 
AFB direct smear, CXR 
Sputum AFB direct 
smear and CXR
Sputum AFB direct 
smear and CXR 
Sputum AFB direct 
smear and CXR 
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SECTION A 
 
CLINICAL IMAGING 
STUDY 
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This section A (Clinical imaging study) is divided into two parts: 
1. Section A1: Background and the scanning methods. 
2. Section A2: Results and discussion. 
 
Each of these two parts is described in a separate chapter; Chapter 3 for section A1 and 
Chapter 4 for section A2, respectively. 
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CHAPTER 3 
SECTION A1: 
 
BACKGROUND AND 
THE SCANNING 
METHODS 
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This clinical trial is an important study of this research thesis. This chapter describes 
and details the FDG PET/CT scanning protocols of sixteen Malaysian patients, who 
were prospectively recruited for the trial. In addition, the retrospective data of FDG 
PET/CT imaging for twelve Italian patients who had a confirmed diagnosis of EPTB 
were acquired. The findings of these two datasets were analysed and compared. Overall, 
this chapter only covers the methodological aspects of all FDG PET/CT scans.   
 
3.1. Background 
As stated above, there are two datasets from two different patient populations involved 
in this clinical imaging study:  
1. Prospective data of Malaysian patients. 
2. Retrospective data of Italian patients. 
 
For both populations, FDG PET/CT imaging was performed during the diagnosis 
procedure of the disease. First, details of the patient’s preparation, scanning protocols of 
FDG PET/CT imaging and the image interpretation for Malaysian patients are explained 
and followed by those of Italian patients. However, due to complicated circumstances*, 
only few Malaysian patients had undergone repeat FDG PET/CT scan with an interval 
of about six months from their initial diagnostic PET/CT scan. This repeated scan is 
termed as follow-up FDG PET/CT scan, and it will be further described in section 3.2.3.    
                                                
* This phrase is mainly used to indicate that of all recruited Malaysian patients, some of them 
were categorised as defaulted and few patients refused to undergo repeat FDG PET/CT scan 
because of clinically well progressing with the given treatment. In addition, one patient died 
during the diagnosis process.   
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 Numerous studies have demonstrated that the application of a special imaging 
technique known as dual time point imaging (DTPI) during both FDG PET and FDG 
PET/CT scans could enhance the differentiation between benign (including 
inflammatory and infectious) and malignant lesions [21-23, 97-105]. This DTPI 
technique means the image acquisitions are performed twice; initial and delayed scans, 
with a certain interval between the two scans. Furthermore, this technique was found to 
be useful for evaluating the activity status of a lesion in malignant and infectious 
diseases [106-112]. Based on these two advantages, it has been hypothesised that the 
use of DTPI technique during FDG PET/CT scan could increase the diagnostic values 
of this hybrid imaging modality in detecting and determining the lesions of the 
prospective Malaysian patients. The technical data primarily on the interval between 
each of the scans for all the referred studies are listed and summarised in Tables 3.1 and 
3.2.  
 Aside from DTPI technique, the utilisation of an intravenous iodine-based 
contrast media during the CT scan of PET/CT imaging may offer some potential 
benefits, by providing more diagnostic information that is closely related with the 
enhancement of a lesion [113]. Indeed, CT (CECT) images have been found to increase 
the sensitivity and accuracy of detecting and characterising the lesions [114]. On the 
other hand, few reports state that when CECT data is used for calculating the PET 
attenuation correction factors, it will lead to the overestimated values [115-117], which 
then may cause false positive findings [66, 67]. However, the changes in the SUVs of 
PET and PET/CT fusion images were found to be clinically insignificant [5, 113, 118-
122]. Therefore, this CECT scan has also been carried out during FDG PET/CT imaging 
of all recruited Malaysian patients.   
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Table 3.1: Chronological application of DTPI technique during FDG PET and FDG 
PET/CT scans in distinguishing malignant from benign lesions. 
Author Year  Initial scan acquisition (after injection of FDG) 
Delayed scan acquisition 
(after injection of FDG) 
Imaging 
modality 
Hustinx, et al. 
[97] 1999 
70 min 
(range,  47 – 112 min) 
98 min 
( range, 77 – 142 min) PET scanner 
Nakamoto, et al. 
[98] 2000 60 min 120 min PET scanner 
Kubota, et al. 
[99] 2001 60 min 120 min PET scanner 
Zhuang, et al. 
[100] 2001 48 – 63 min 89 – 128 min PET scanner 
Matthies, et al. 
[101] 2002 
69 min 
(range, 55 – 110 min) 
122 min 
(range, 100 – 163 min) PET scanner 
Demura, et al. 
[102] 2003 60 min 180 min PET scanner 
Kumar, et al. 
[103] 2005 63 min 101 min PET scanner 
Xiu, et al. [104] 2007 58 min (range, 50 – 110 min) 
114 min 
(range, 99 – 163 min) PET scanner 
Lan, et al. [23] 2008 45 – 55 min 150 – 180 min PET/CT scanner 
Alkhawaldeh, et 
al. [105] 2008 60 min 
100 min 
(range, 90 – 110 min) PET scanner 
Suga, et al. [21] 2009 60 min (range, 56 – 65 min) 
120 min 
(range, 110 – 131 min) 
PET/CT 
scanner 
Suga, et al. [22] 2009 60 min (range, 56 – 65 min) 
120 min 
(range, 110 – 131 min) 
PET/CT 
scanner 
 
Table 3.2: Chronological application of DTPI technique during FDG PET and FDG 
PET/CT scans in assessing the activity status of a lesion. 
Author Year  Initial scan acquisition (after injection of FDG) 
Delayed scan acquisition 
(after injection of FDG) 
Imaging 
modality 
Higashi, et al. 
[106] 2002 60 min 120 min PET scanner 
Nishiyama, et al. 
[107] 2006 62 min 146 min PET scanner 
Mavi, et al. [108] 2006 63 min (range, 46 – 112 min) 
104 min 
(range, 81 – 156 min) PET scanner 
Kim, et al. [109] 2008 60 min (range, 53 – 71 min) 
120 min 
(range, 109 – 131 min) 
PET/CT 
scanner 
Nishiyama, et al. 
[110] 2008 60 min 120 min PET scanner 
Zytoon, et al. 
[111] 2008 55 – 60 min 110 – 120 min 
PET/CT 
scanner 
Zytoon, et al. 
[112] 2009 55 – 60 min 100 – 120 min 
PET/CT 
scanner 
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3.1.1. Malaysian patients 
This prospective clinical trial was conducted from July 2008 to March 2009. A total of 
sixteen patients (nine men and seven women) who were highly suspected for 
extrapulmonary tuberculosis (EPTB) infection; based on the clinical signs of EPTB [87] 
or family history of TB and/or previously diagnosed with EPTB, were enrolled and 
evaluated (refer to Table 3.3). Their mean ± SD for age, height and weight were 35 ± 16 
years (range 15 – 60 years), 161 ± 7 cm (range 148 – 173 cm) and 61 ± 13.8 kg (range 
30.8 – 93.5 kg), respectively. All patients were from the teaching hospital of University 
Putra Malaysia, whom presented with a variety of non-specific clinical signs and 
symptoms like malaise (discomfort), low grade fever, lassitude (fatigue), weight loss 
and body ache. All of them underwent extensive clinical, radiological and 
histopathological investigations. However, none were on anti-tuberculosis drugs 
treatment at the time of FDG PET/CT scanning.   
This research was approved by the ethics committee for human research at 
University Putra Malaysia and Ministry of Health Malaysia (Appendices 1 and 2). 
Details of the imaging protocol were explained by the physician in charge, and a written 
informed consent was obtained from all patients (Appendices 3 and 4).  
As the gold standard of this study, the laboratory/microscopic findings 
(including the biopsy results) are required to attain a definitive diagnosis. If these 
findings are found to be inconclusive for TB, radiological and/or clinical assessment of 
the given treatment during the periodic follow-up visits could also play a major role in 
making the final diagnosis. The exclusion criteria are claustrophobia, severe obesity and 
linguistic/communication problems. 
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Table 3.3: Demographic data and clinical indications of all Malaysian patients. 
Patient 
no. Gender Age 
Weight 
(kg) 
Height 
(cm) Clinical indications 
1 Female 26 93.5 159 Right neck and mediastinal nodes enlargement 
2 Male 49 72 164 Backache 
3 Female 22 60.5 148 Left submandibular lymphadenopathy 
4 Male 53 58 172.5 Right hip pain 
5 Female 31 56.4 160 Backache 
6 Male 17 44 162 Anorexia 
7 Male 28 60 158 Severe headache and poor general health condition 
8 Female 19 55 154 
History of tuberculous 
lymphadenitis and right anterior 
chest wall swelling 
9 Female 24 30.8 153.5 Poor general health condition and anorexia 
10 Female 29 77.8 161 Right neck pain and swollen, and low grade fever 
11 Female 25 54 153 Left lateral neck swollen 
12 Male 15 60.4 173 Heel pain and swollen with fluid collection 
13 Male 51 68.4 164.5 Left knee joint pain 
14 Male 59 60 170 Backache 
15 Male 60 60 160 Severe backache 
16 Male 55 65 163 Severe backache 
 
 
3.1.2. Italian patients 
The retrospective data of twelve confirmed EPTB patients, who underwent FDG 
PET/CT imaging between June 2007 and February 2008, were reviewed and evaluated 
(refer to Table 3.4). These data were from the Nuclear Medicine and PET/CT Centre of 
Ospedale Niguarda Ca’ Granda, Milan, Italy and the Nuclear Medicine Department of 
Ospedale Santa Corona, Pietra Ligure, Italy. However, only FDG PET/CT imaging data 
were obtained for these patients, with no other details in their clinical information, 
mainly due to limited accessibility and a high patient privacy and confidentiality. 
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Table 3.4: Demographic data and date of the FDG PET/CT acquisition of Italian patients. 
Patient no. Gender Age Date of scanning 
1 Male 74 June 7, 2007
2 Female 55 December 13, 2007 
3 Female 39 February 20, 2008 
4 Male 67 August 22, 2007 
5 Female 59 July 31, 2007 
6 Male 45 September 19, 2007 
7 Female 54 January 16, 2008 
8 Female 70 September 11, 2007 
9 Male 76 August 29, 2007 
10 Male 45 July 18, 2007 
11 Female 80 July 25, 2007 
12 Male 56 January 23, 2008 
   
 
3.2. FDG PET/CT imaging 
The image acquisition for FDG PET/CT scan usually includes the preparations of the 
patient, the scanning protocols and the image analysis and interpretation. Thus, in this 
section, each of these matters will be described in detail, particularly for Malaysian 
patients. However, for the twelve Italian patients, the information is only extracted from 
the FDG PET/CT imaging data that have been obtained during the image analysis and 
interpretation processes.    
 
3.2.1. Malaysian patients 
3.2.1.1. Patient preparation 
All PET/CT examinations were conducted using the imaging facilities at two private 
hospitals: Prince Court Medical Centre, Kuala Lumpur, Malaysia and Beacon 
International Specialist Centre, Selangor, Malaysia.  
Patients were required to be fasting overnight or at least 8h prior to the scanning 
day; however oral hydration with plain water was allowed. During the scanning day, the 
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blood glucose level was firstly checked and it should not exceed the normal range (>7.2 
mmol/L; Table 3.5); as the high blood glucose level could affect the semiquantitative 
measurements of FDG PET and FDG PET/CT images [123]. Subsequently, patients 
were asked to change into a hospital gown in the preparation room and all their personal 
belongings were safely kept in a locker.  
Based on patient’s body weight, the amount of FDG radioactivity to be used was 
calculated and the preparation of FDG had been conducted in the hot lab (Fig. 3.1). 
Then, 1 L of negative oral CT contrast media (plain water) was given to those patients 
who were clinically fit, just before commencing the FDG injection (Fig. 3.2). The 
injected amount of FDG radioactivity for each patient was about 364 ± 97 mega 
Becquerel; MBq, (mean ± SD, ranging from 145 – 592 MBq; Table 3.5) which had been 
administered intravenously (Fig. 3.3). To maximise the injected amount of FDG, an 
infusion of 100 mL normal saline was applied immediately after the FDG injection. 
Patients were also administered intravenously with 20 mg of furosemide (Lasix); to 
accelerate renal excretion of FDG, and 20 mg of butylscopolamine (Buscopan); to 
reduce abdominal muscles spasm.  
Subsequently, patients were asked to rest comfortably for about 55 ± 14 min 
(mean ± SD, ranging from 30 – 86 min; Table 3.5) in the preparation room. During this 
uptake period, patients were instructed to restrict their movements including talking; to 
minimise the potential of false positive FDG uptake in the muscles. Finally, just before 
entering the PET/CT scanning room, patients were asked to empty their bladder, as the 
scanning session may consume quite longer time and for maintaining their 
comfortability. 
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Figure 3.1: Preparation on the FDG is conducted in the hot lab, which has been equipped 
with the radioactivity meter. The amount of FDG radioactivity for the whole body 
PET/CT imaging is estimated based on patient’s body weight.  
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Figure 3.2: A litre of plain water is given to act as negative oral contrast media during the 
preparation process. This method will help for better bowel distention during the image 
interpretation procedure [27, 124].  
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Figure 3.3: Intravenous injection of FDG is performed in the preparation room. 
Immediately after this injection, an infusion of using 100 mL normal saline is given for 
maximising the injected amount of FDG or minimising the amount of FDG left in the tube.  
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3.2.1.2. FDG PET/CT scanning protocols 
In general, the scanning protocols of PET/CT imaging in this study are divided into two 
separate scans: 
1. Whole body FDG PET/CT imaging 
2. Dual time point imaging (DTPI) of FDG PET/CT scan 
 
As mentioned in Chapter 1, there are no previous studies that have specifically utilised 
the DTPI technique during FDG PET/CT imaging of EPTB patients. In addition, the 
application of intravenous iodine-based contrast media on the CT component of FDG 
PET/CT scan for EPTB patients has not been well documented in the literature. Thus, 
almost all FDG PET/CT scans of this clinical imaging study were conducted using the 
DTPI technique and the intravenous injection of iodine-based contrast media. 
 
3.2.1.2.1. Whole body FDG PET/CT scan 
All FDG PET/CT scans were acquired using an integrated Biograph PET/CT system 
(Siemens Healthcare Solutions) which consists of lutetium oxyorthosilicate (LSO) 
crystal detectors (as of the Fig. 2.13 in Chapter 2). Patient was laid supine on the 
PET/CT table with both arms positioned above head. To acquire a precise anatomic 
correlation between PET and CT images, the scanning was performed with the arms in 
the same position for both PET and CT scans. For minimising technical errors and 
avoiding the occurrence of misregistration and truncation artifacts [42], the patient’s 
body was carefully positioned using the guidance from longitudinal and horizontal laser 
beams. The patient was gently fixed to the scanning table by using two strapping belts 
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placed at the thigh and forearm regions. Immobilisation supports had also been given 
under patient’s head and knee joint (Fig. 3.4).  
The PET/CT imaging commenced with a standard CT topogram (110 kV); to 
define the scanning range (from base of skull to mid-thigh region). The scanning was 
performed in the cranio-caudal direction. The unenhanced CT scan (also called as low 
dose CT protocol) was first carried out using the following parameters: 30 mAs, 130 
kV, 5 mm slice thickness, 4 mm collimation and 12 mm table feed per rotation. Then, 
an intravenous bolus injection of 100 mL iohexol (Omnipaque 350 mgI/mL, GE 
Healthcare) was administered to the patient as a contrast enhancing agent, and the 
contrast-enhanced CT (CECT) scan was immediately started using the same parameters 
as in unenhanced CT, but with higher tube current; 100 mAs (diagnostic dose CT 
protocol), for reducing the effects of the increased in tissue density due to the 
application of iodine contrast media [125] (Fig. 3.5). Upon completion of the CECT 
scan, straightaway, a whole body PET emission scan was performed using a three-
dimensional (3-D) acquisition mode with the scanning time of 3 minutes per bed 
position; 6 to 10 bed positions were required depending on patient’s height. All these 
image acquisitions took about 25 – 35 min to be completed.   
 
3.2.1.2.2. Dual time point imaging of FDG PET/CT scan 
After the acquisition of a whole body PET/CT scan, the patient was again asked to rest 
in the preparation room, in order to be made ready for the delayed PET/CT imaging 
(Fig. 3.6g). This special imaging technique is called dual time point imaging (DTPI) or 
known as double phase PET/CT. During this period of time, the initial whole body 
PET/CT images were reviewed and evaluated to confirm the limited regional coverage 
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(only for the regions where the lesions were detected) for the delayed scan, with 1 to 8 
bed positions. Basically, this scanning method is similar to the previous two studies by 
Suga, et al. [21, 22], which it may result in reducing the radiation dose to the patient and 
increase the throughput capability of the scanner. A delayed PET/CT scan (Fig. 3.6h) 
was performed after about 136 ± 14 min (mean ± SD, ranging from 120 – 163 min; 
Table 3.5) from the FDG injection time, by utilising the same PET scanning parameters 
(3-D acquisition mode with the scanning time of 3 min per bed position) and low dose 
CT protocol as in the initial whole body PET/CT imaging. To avoid the occurrence of 
the image artifacts due to high concentration of contrast agent [67], therefore, no 
additional iodine-based contrast media was used during the CT scan of this delayed 
PET/CT imaging. In addition, the 2 hours delayed scanning time (from the FDG 
injection) was reported to be well tolerant among the fasted patients [22], and thus, it 
had been employed in this study.    
 
During all the image acquisitions (initial whole body and delayed scans), patients were 
asked to breathe normally, or in other words no special breathing technique was applied 
in this study. The total scanning acquisition time for each of the patients was about an 
hour for both initial whole body and delayed scans. After completing these PET/CT 
scans, all patients had been served with light meal before they were sent back to the 
hospital.  
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Figure 3.4: Position of the patient during the PET/CT image acquisitions with 
immobilisation supports under the head and knee joint. Both arms are positioned above 
the head and two strapping belts are used to minimise patient’s movement. Note that two 
lasers are used for aiding the patient positioning.  
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Figure 3.5: Intravenous bolus injection of 100 mL iodine contrast media (Omnipaque 350) 
is given just before performing the contrast-enhanced CT (CECT) scan. This injection 
utilises the same route as for the FDG injection. After the injection the arm is repositioned 
at above of the head. 
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Figure 3.6: Schematic illustration for FDG PET/CT scans of Malaysian patients. (a – f) are 
the methods involved during the initial whole body PET/CT scan, whereas (g and h) are 
for the delayed PET/CT scan.  
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Table 3.5: The blood glucose level, the injected amount of FDG radioactivity and the 
scanning time of both PET/CT image acquisitions (initial whole body and delayed scans) 
for all sixteen Malaysian patients.                           
       
Patient 
no. 
Blood glucose 
levels 
(mmol/L) 
Injected FDG 
radioactivity 
(MBq) 
Initial whole body scan; 
after the FDG injection 
time (min) 
Delayed scan; after 
the FDG injection 
time (min) 
1 7.0 592 30 138 
2 4.0 419 41 126 
3 4.8 277 57 120 
4 5.3 322 73 132 
5 7.0 337 58 128 
6 4.7 145 75 131 
7 6.4 382 61 – 
8 4.6 361 55 120 
9 5.1 383 42 158 
10 7.1 500 64 141 
11 4.3 368 46 121 
12 4.7 375 49 152 
13 4.4 346 86 163 
14 1.4 272 46 133 
15 3.8 354 51 – 
16 5.3 383 47 – 
MBq, megabecquerel; –, not done. 
 
 
3.2.1.3. Image analysis and interpretation 
For each of the scanning protocols, the image analysis and interpretation are slightly 
differed. Thus, this section is divided into two subsections: 
1. Whole body FDG PET/CT imaging 
2. DTPI of FDG PET/CT scan 
 
3.2.1.3.1. Whole body FDG PET/CT scan 
As usual, CT images are reconstructed in a 512 x 512 matrix, while PET images are in a 
matrix of 128 x 128 [42]. Thus, to fuse both of these images, the matrix of CT data need 
to be resized and matched PET data matrixes, which can either be done on the same 
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imaging acquisition system or using a different medical imaging workstation, depending 
on the manufacturer [42]. However, in this study, this process was made on the 
workstation. Attenuation-corrected PET images were reconstructed iteratively using a in 
standard protocol with an attenuation-weighted ordered subset expectation 
maximisation (OSEM) algorithm [126]. Both CT datasets (unenhanced CT and CECT) 
were utilised for attenuation correction of the whole body PET/CT images, creating two 
sets of PET/CT fusion images (PET/unenhanced CT and PET/CECT), based on the 
same set of PET emission data. All images were displayed in axial, coronal and sagittal 
planes along with maximum intensity projection (MIP) image. MIP image is a common 
3-D image used for visualising FDG distribution throughout the body [32].  
The image analyses were visually and semiquantitatively interpreted by an 
experienced radiologist. In the visual assessment of PET/CT images, the intensity of 
FDG uptake in the lesion was scored using a 4-point grading system: normal 
background uptake (grade 1), mild uptake as in liver or spleen (grade 2), higher uptake 
than liver or spleen (grade 3) and very high uptake with equal or more than 
brain/bladder uptake (grade 4). Grade 3 and/or 4 was considered to represent 
significantly high FDG uptake.  
In the semiquantitative PET/CT image analysis, by utilising all the three 
imaging planes (axial, coronal and sagittal) of PET/CT fusion images, a volume of 
interest (VOI) with 3-D isocontours set at the 40% threshold line of the maximum 
standardised uptake value (SUV) [127, 128] was carefully drawn around the site of the 
suspected lesion that demonstrated a high FDG uptake. The maximum pixel value in the 
VOI was defined as maximum standardised uptake value (SUVmax), and it can be 
calculated by using the following equation [129-131]:  
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                                           Maximum pixel value in VOI (MBq/mL)                          (3.1) 
    [Injected radioactivity (MBq) / Body weight (g)] 
 
 In this study, SUVmax value was employed mainly due to its higher 
reproducibility [132]. In addition, this semiquantitative value had been found to be less 
affected by the size and the location in the VOI during the image analysis procedure 
[32, 131]. A lesion was highly suspected and considered when it had exceeded the 
standard cut-off value of 2.5; SUVmax > 2.5 [133]. The SUVmax values of all detected 
lesions were recorded and labelled as SUVmax1a and/or SUVmax1b (the superscripts of 
‘a’ and ‘b’ were respectively for PET/unenhanced CT and PET/CECT fusion images).  
With regard to evaluating the effects of applying an intravenous iodine-based 
contrast media during the CT scan of FDG PET/CT imaging, a separate image analysis 
was performed. The changes in the Hounsfield unit; HU and the SUVmax values of four 
normal organs/tissues (heart, liver, spleen and urinary bladder) were measured. These 
organs/tissues were chosen based on the variations of the contrast media concentrations 
at the time of the CT image acquisition, and in fact, they were sited apart from the 
detected lesions. In order to quantify the maximum changes caused by the application 
intravenous iodine-based contrast media, the axial CT, fused PET/unenhanced CT and 
fused PET/CECT images of those four normal organs were analysed by manually 
identifying a single pixel that has the highest value in both HU and the SUVmax. For 
maintaining the consistency of the analysis, this single pixel was originally drawn on 
PET/CECT fusion images and then copied to PET/unenhanced CT fusion images. 
However, in some cases, the pixel was repositioned based on the anatomical structures, 
mainly to resolve the differences that had been caused by the movements of the patient.  
 
SUVmax =  
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3.2.1.3.2. Dual time point imaging of FDG PET/CT 
The image analysis and interpretation of the delayed PET/CT scan were almost similar 
to the above section; initial whole body PET/CT imaging. For creating the PET/CT 
fusion images, as no CECT scan had been performed during this delayed imaging, 
therefore only unenhanced CT dataset was used. From these fusion images, the 
SUVmax values of the detected lesions were again measured by using the same VOI 
technique; as for the initial whole body images, and labelled as SUVmax2. As a result, 
the percentage difference between these two SUVmax values (%∆SUVmax) was 
calculated based on the following equation [7, 21-23, 109, 111].  
 
    (SUVmax2 − SUVmax1)                     (3.2) 
      SUVmax1 
 
In the application of the above equation, both SUVmax1a and SUVmax1b values of the 
detected lesions were used. In addition, for comparing the imaging findings of the initial 
whole body and the delayed PET/CT scans, these two images were displayed 
simultaneously on the workstation. 
 
3.2.2. Italian patients 
3.2.2.1. Patient preparation 
The preparation procedures in this group of patients were the same as for Malaysian 
patients, with a fasting period of at least 8h prior to the scanning day and normal blood 
glucose level. The injected amount of FDG radioactivity was based on patient’s body 
weight and PET/CT image acquisitions commenced at about 1h after the injection 
(minimum resting time was no less than 45 min). However, as mentioned earlier 
%∆SUVmax =  × 100%  
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(section 3.1.2), more detailed information were not available due to limited accessibility 
and a high patient privacy and confidentiality. 
 
3.2.2.2. FDG PET/CT scanning protocols 
The scanning protocols for these twelve patients were mainly derived from the FDG 
PET/CT imaging data that had been visualised on the workstation. PET/CT scans were 
conducted by using the same imaging system as for Malaysian patients; Biograph 
PET/CT (Siemens Healthcare Solutions). Therefore, all images of both Malaysian and 
Italian patients are well-founded to be compared. 
PET/CT scanning commenced with a standard CT topogram, covering the area 
from the base of the skull to the mid-thigh region. However, during this image 
acquisition procedure only low dose unenhanced CT scan (low dose CT protocol) was 
performed, by using the following parameters: 110 kV, 30 mAs and 5 mm slice 
thickness. Then, PET emission scan was conducted in a three-dimensional (3-D) 
acquisition mode at the scanning time of 5 min per bed position. Patient was positioned 
supine with both arms rested straight and placed close to the body.  
 
3.2.2.3. Image analysis and interpretation 
All PET/CT images were reconstructed on the workstation with the similar principles as 
in the initial whole body FDG PET/CT scan of Malaysian patients, but only the low 
dose unenhanced CT dataset was used for anatomical localisation and calculation of 
PET attenuation correction factors. Again, all images were displayed in axial, coronal 
and sagittal planes along with maximum intensity projection (MIP) image. 
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 To avoid the occurrence of ambiguity and bias, this image analysis was visually 
and semiquantitatively interpreted by the same personnel using the same methods. As 
no delayed PET/CT scans had been performed, therefore, only the SUVmax values of 
the initial whole body images were measured and recorded (SUVmax1). 
 
3.2.3. Follow-up FDG PET/CT scan 
As specifically mentioned in section 3.1, the prospective data were from Malaysian 
patients. To assess the therapeutic responses for this group of patients, therefore, the 
follow-up PET/CT scan needs to be performed. However, only small number of patients 
had undergone this type of scanning, with an interval of about six months from their 
initial diagnostic PET/CT scan. Again, all PET/CT examinations were conducted at 
Prince Court Medical Centre, Kuala Lumpur, Malaysia and/or Beacon International 
Specialist Centre, Selangor, Malaysia.  
 This study was carried out from February 2009 to December 2009, and it 
consisted of six consecutive patients a male-to-female ratio of 1:1. The mean ± SD age, 
height and weight of these six patients were 33 ± 15 years, 161 ± 8 cm and 64 ± 19 kg, 
respectively. The patient preparation procedures were the same as described earlier, 
with the mean injected amount of FDG radioactivity was about 383 ± 136 MBq 
(ranging from 254 – 612 MBq). The whole body PET/CT imaging commenced at about 
50 ± 17 min after the FDG injection with 6 – 7 bed positions, and followed by 1 – 3 bed 
positions for the delayed PET/CT scan at about 130 ± 14 min after the FDG injection 
time (refer to Table 3.6); by using the same scanning protocols as in the initial 
diagnostic PET/CT scan.  
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 PET/CT fusion images were reconstructed with the same principles as described 
in the previous section, by utilising both unenhanced CT and CECT datasets for the 
initial whole body PET/CT images, while unenhanced delayed CT dataset was used for 
the delayed PET/CT images. Indeed, the image analysis and interpretation had also been 
performed by the same radiologist.   
 
Table 3.6: The blood glucose level, the injected amount of FDG radioactivity and the 
scanning time of both PET/CT image acquisitions (initial whole body and delayed scans) 
for the first six Malaysian patients who underwent the follow-up FDG PET/CT scan. The 
patient number of this table is the same as in the Tables 3.3 and 3.5. 
       
Patient 
no. 
Blood glucose 
levels 
(mmol/L) 
Injected FDG 
radioactivity 
(MBq) 
Initial whole body scan; 
after the FDG injection 
time (min) 
Delayed scan; after 
the FDG injection 
time (min) 
1 4.0 612 42 120 
2 5.5 277 79 152 
3 4.1 400 35 120 
4 4.7 453 36 121 
5 7.1 254 60 124 
6 5.8 299 45 142 
MBq, megabecquerel. 
 
 
Exclusively to the sixteen Malaysian patients, all of them underwent extensive 
laboratory/microscopic investigations. The sample of the tissue and/or aspirate was 
taken under the guided procedures of either using CT scan or ultrasound. The final 
diagnosis of all these patients was based on the laboratory findings and/or 
clinical/radiological assessments during their periodic follow-up visits.  
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3.3. Statistical analysis 
The data extracted from the images obtained in these studies were expressed as mean ± 
standard deviation (SD). The difference in SUVmax values of all detected lesions from 
the initial whole body to the delayed FDG PET/CT scans was determined using a two-
tailed paired samples t-test. This statistical test was also used to analyse the changes in 
SUVmax values caused by the application of an intravenous iodine-based contrast 
media during the CT scan of FDG PET/CT imaging. On the other hand, an independent 
samples t-test was carried out to determine the significance difference of two groups of 
patients like between Malaysian and Italian patients. All results were evaluated using a 
5% error level and a difference was considered to be statistically significant when P < 
0.05.  
 In order to assess the diagnostic quality or performance of all recorded and 
calculated data, the receiver operating characteristic (ROC) curve was used. An ROC 
curve is a plot of test sensitivity (plotted on the y axis) versus its false positive rate 
(FPR) or 1 − specificity (plotted on the x axis) [134, 135]. It is an effective method of 
evaluating the accuracy of a diagnostic test, and indeed, it has been widely used in 
radiology [135]. Sensitivity and specificity are defined as the number of true positive 
decisions divided by the number of actually positive cases and the number of true 
negative decisions divided by the number of actually negative cases, respectively [135]. 
One of the most popular measures of the ROC curve is an area under curve; it is a 
measure of the overall performance of a diagnostic test that can take on values between 
0.0 and 1.0 [134, 135]. The closer an area under curve is to 1.0, the better the overall 
diagnostic performance of the test [135]. A test with an area under curve of 1.0 is 
considered as a perfectly accurate test [134, 135], and a practical lower limit for an area 
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under curve of a diagnostic test is 0.5 [135]. In addition, ROC curves can be used to 
compare the overall diagnostic performance of different tests by comparing their area 
under curve values [135]. From ROC curve, an optimum cut-off threshold value for all 
recorded and calculated data of this clinical imaging study could also be identified.  
 
All the statistical analyses and ROC curves were performed using the Statistical 
Package for Social Sciences (SPSS) program for Windows version 18.0. 
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CHAPTER 4 
SECTION A2: 
 
RESULTS AND 
DISCUSSION 
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This chapter presents the results obtained from the clinical imaging study and 
accompanied with the discussion. The major focus of this study is to develop an 
optimum FDG PET/CT scanning protocol for detecting the EPTB lesions.  
 
4.1. Results 
4.1.1. Malaysian patients 
As mentioned in Chapter 3, all sixteen Malaysian patients underwent the initial whole 
body FDG PET/CT imaging, while DTPI technique was only performed in thirteen 
patients. Therefore, the results are classified according to the imaging procedure: 
1. Whole body FDG PET/CT imaging 
2. DTPI of FDG PET/CT scan 
 
4.1.1.1. Whole body FDG PET/CT imaging 
No adverse effects were noticed during and/or after the imaging acquisitions of all 
patients. However, only one patient had an underlying medical condition that 
contraindicated to the administration of iodine-based contrast media; patient 14 was 
previously diagnosed with end-stage renal failure. Thus, for this particular patient, the 
whole body FDG PET/CT scan was performed without utilising the iodine-based 
contrast media. The FDG PET/CT imaging findings; along with the SUVmax1 values 
(SUVmax1a and SUVmax1b) of all detected lesions, the final diagnosis and the 
diagnostic method of all patients are listed in Table 4.1.  
Of these sixteen patients, nine patients (five women and four men) were 
positively diagnosed with EPTB infectious disease, while the other seven patients were 
categorised as non-EPTB patients. The final diagnosis was mainly based on the 
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microscopic/histopathological findings of the sample sputum/aspirate/tissue (Fig. 4.1) 
and/or clinical/radiological assessment during the periodical follow up visits. Although 
there was no histological confirmation of Mycobacterium tuberculosis for the patients 2 
and 5, due to increasing pattern of TB incidence in Malaysia and the high index of 
suspicion by the physicians, they were treated with anti-tuberculous (anti-TB) drugs. 
With no adverse reactions during the treatment period and significant progress in their 
general health conditions, therefore these two patients had been classified as EPTB 
patients. All EPTB patients were being prescribed with the standard regimen of anti-TB 
drugs treatment (2 months with daily doses of SHRZ or EHRZ, and biweekly doses of 
SHR or HR for the next 4 months). However, depending on the treatment responses 
(clinically, pathologically and/or radiologically), the physician would then decide either 
to continue or stop the treatment. Therefore, some of EPTB patients were under anti-
tuberculous drugs for about 9 months, and even up to 12 months.  
In contrast, all non-EPTB patients showed positive response after about a month 
or more with antibiotics treatment (excluding patient 12, who had surgical removal of 
the lesion, and patient 13, who had steroid therapy), which had been assessed during 
their periodical follow-up visits. Furthermore, only four patients (patients 11, 12, 13 and 
15) were negatively diagnosed for EPTB infectious disease through histopathological 
investigations. Apparently, all FDG avid sites of patient 11 were caused by the 
physiological uptake of brown adipose tissues, rather than the infectious lesions. This 
interesting imaging finding is attached as an appendix for this thesis (Appendix 5), and 
it has also been recently cited by Son’kin and his colleagues in their review article about 
brown adipose tissues [136].  
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A total of 54 extrapulmonary lesions with avid FDG uptake were detected, in 
which 27 lesions were in EPTB patients and the remainder presented in non-EPTB 
patients. All of these detected lesions were in either grade 3 or 4 of the visual image 
analysis, and the SUVmax values of them were higher than the standard cut-off value of 
2.5; SUVmax > 2.5. As shown in Table 4.1, entirely, there were no differences in the 
SUVmax values of all detected lesions from both PET/unenhanced CT and PET/CECT 
fusion images, which indicated that iodine-based contrast media could be used during 
the CT scan of FDG PET/CT imaging. The mean ± SD SUVmax values for EPTB and 
non-EPTB lesions were 7.0 ± 2.3 and 8.8 ± 4.6, respectively. There was an overlap on 
the distribution of these two mean values (Fig. 4.2 and 4.3) and the independent samples 
t-test resulted with an insignificant difference, P = 0.07. However, according to the 
receiver operating characteristic (ROC) curve analysis, when the SUVmax1 value of 5.7 
was used as the cut-off point, the sensitivity and specificity were 51.9% and 40.7%, 
respectively (refer to Fig. 4.4). From a diagnostic imaging point of view, these values 
were quite low, and therefore, it can be concluded that the use of the SUVmax1 value 
alone was impractical for differentiating between EPTB and non-EPTB lesions. 
For ethical reasons, it was impossible to perform biopsy and/or histological 
analysis on each lesion detected by means of this integrated imaging scan. Accordingly, 
the diagnostic quality (sensitivity, specificity and accuracy) of FDG PET/CT imaging in 
detecting the EPTB lesions could not be determined.  
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Figure 4.1: The aspiration of the pus collection from the right anterior chest wall region of 
patient 8 of the Malaysian patients, which has been performed under ultrasound guided 
and aseptic techniques.  
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Table 4.1: The FDG PET/CT imaging findings and the final diagnosis of all sixteen Malaysian patients. 
Patient no. Lesion site SUVmax1a SUVmax1b Final diagnosis Diagnostic method 
EPTB  
1 
1. Right base of the neck node 8.0 8.0 
Tuberculous 
lymphadenitis Aspiration biopsy 
2. Right parathyroid node 8.6 8.6 
3. Right infraclavicular node 8.3 8.3 
4. Right paratracheal 11.7 11.7 
2 T12 and L1 vertebral bodies 7.2 7.2 Tuberculous spondylitis Anti-TB treatment response 
3 Left submandibular node 9.7 9.7 Tuberculous lymphadenitis Aspiration biopsy 
4 Right hip joint 8.3 8.3 Tuberculous synovitis Aspiration biopsy 
5 1. L3-L4 intervetebral disc space 8.5 8.5 Tuberculous spondylitis Anti-TB treatment response 2. Left psoas muscle at level L4 6.7 6.7 
6 
1. Right retrocrural node 6.0 6.0 
Miliary tuberculosis Tissue biopsy 2. Right subhepatic node 3.5 3.5 
3. Peripancreatic node 7.1 7.1 
7 
1. Left psoas muscle 9.5 9.5 
Miliary tuberculosis AFB sputum test 
2. Left inguinal node 7.4 7.4 
3. Left axillary node 7.5 7.5
4. Right paratracheal node 5.5 5.5
5. Right para-aortic node 9.5 9.5 
8 
1. Right supraclavicular fossa 2.8 2.8 Tuberculous 
lymphadenitis PCR 2. Right anterior chest wall 5.8 5.8 3. Right subscapular soft tissue space 11.7 11.7 
9 
1. Right crural node 4.3 4.3 
Miliary tuberculosis AFB sputum test 
2. Left diaphragmatic node 5.3 5.3 
3. Right diaphragmatic node 3.4 3.4 
4. Preaortic node 7.0 7.0 
5. Left renal vein node 5.7 5.7 
6. Left retrosternal node 4.8 4.8 
7. Right carinal node 4.7 4.7 
(Continue on the next page) 
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Patient no. Lesion site SUVmax1a SUVmax1b Final diagnosis Diagnostic method 
Non-EPTB  
10 
1. Right posterior triangle of neck (anterior) 3.5 3.5 
Lymphadenitis Antibiotics treatment response 2. Right posterior triangle of neck (posterior) 3.8 3.8 
3. Right paratracheal node 8.8 8.8
11 
1. Right supraclavicular brown fat 17.6 17.6 
Lymphadenitis Aspiration biopsy + antibiotics treatment response 
2. Left supraclavicular brown fat 18.9 18.9 
3. Mediastinal brown fat 7.0 7.0 
4. Right paravertebral brown fat 13.9 13.9 
5. Left paravertebral brown fat 7.4 7.4 
6. Right perirenal brown fat 10.4 10.4 
7. Left perirenal brown fat 20.8 20.8 
12 Left calcaneum bone area 3.2 3.2 Brodie abscess Tissue culture 
13 
1. Right posterior of 9th rib 9.6 9.6 
Rheumatoid arthritis Aspiration and tissue biopsies 2. Right lateral of 10
th rib 7.0 7.0 
3. Right posterior of 11th rib 8.3 8.3 
4. Tibial plateau of left knee joint 5.6 5.6 
14* L5/S1 intervetebral disc space 4.6 – Infective spondylitis Antibiotic treatment response + MRI
15 
1. Right head of humerus 8.0 8.0 
Lung cancer with distant 
metastases Aspiration biopsy + CT 
2. Right posterior clavicle node 4.9 4.9 
3. Left posterior clavicle node 6.4 6.4 
4. Left scapula area 5.1 5.1 
5. Right adrenal gland 12.6 12.6 
6. Left adrenal gland 7.5 7.5 
7. T11 vertebral body 7.6 7.6 
8. Right pubic bone area 12.2 12.2 
16 
1. Left nasopharyngeal area 9.3 9.3 
Infective spondylitis Antibiotics treatment response 2. T7 vertebral body 8.6 8.6 
3. Left vastas muscle group 5.9 5.9 
EPTB, extrapulmonary tuberculosis; non-EPTB, non-extrapulmonary tuberculosis; T, thoracic vertebrae; L, lumbar vertebrae; S, sacral vertebrae; SUVmax1a, 
maximum standardised uptake value from PET/unenhanced CT fusion image; SUVmax1b, maximum standardised uptake value from PET/CECT fusion image; anti-
TB, anti-tuberculous; PCR, Polimerase Chain Reaction; AFB, Acid Fast Bacilli; MRI, Magnetic Resonance Imaging; CT, Computed Tomography; –, not done. 
* Patient who had been previously diagnosed with end-stage renal failure and no iodine-based contrast media was administered. 
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Figure 4.2: The mean SUVmax1 value for each of EPTB and non-EPTB patients. There is 
an overlapping distribution of this value between both EPTB and non-EPTB patients. 
Error bars represent ± standard deviation. 
 
 
Figure 4.3: The mean SUVmax1 values of EPTB and non-EPTB lesions. There is no 
significant difference between these two mean values, where an independent samples t-test 
results with P = 0.07. Error bars represent ± standard deviation. 
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Figure 4.4: The receiver operating characteristic (ROC) curve on the diagnostic 
performance (sensitivity and specificity) of the SUVmax1 value in differentiating between 
EPTB and non-EPTB lesions. This analysis yields an area under curve of 0.398 (blue line). 
The black line represents the reference line of the ROC curve.   
 
 
4.1.1.1.1. The effects of using iodine-based contrast media on the 
 SUVmax values of EPTB patients 
The CT scans of the initial whole body FDG PET/CT imaging for all nine EPTB 
patients were conducted twice; with and without intravenous injection of iodine-based 
contrast media. Thus, to determine the effects of this contrast media on the SUVmax 
values of PET/CT fusion images, as previously highlighted in Chapter 3, a separate 
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analysis has been performed by measuring the changes in HU and SUVmax values of 
four normal organs (heart, liver, spleen and urinary bladder). The results are tabulated in 
Table 4.2. 
 All four normal organs showed a statistically significant increment in HU, 
except the urinary bladder (P = 0.54) (refer to Fig. 4.5). This result is not unexpected 
because an essential bladder enhancement can usually be seen on CT images when a 60-
second scanning delay is used [137]. Nevertheless, in this study, the acquisition of 
CECT scan was commenced immediately after the intravenous injection of iodine-based 
contrast media.   
 On the contrary, all the changes in the SUVmax values of these four normal 
organs were found to have no statistical significance (P values > 0.05) (refer to Fig. 4.6 
and 4.7). Combining these results with the findings from the changes in the SUVmax 
values of all EPTB lesions (Table 4.1), it suggests that iodine-based contrast media 
could potentially be applied during the CT scan of FDG PET/CT imaging in a group of 
EPTB patients, without producing any significant effects on the SUVmax values 
regardless of either in the lesion or the other normal organs.  
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Table 4.2: The differences in HU and SUVmax values of four normal organs, caused by an intravenous injection of iodine-based contrast 
media during the CT scan of FDG PET/CT imaging for nine confirmed EPTB patients. All data are expressed as mean ± SD. 
Organ HU SUVmax without CM with CM P value Remarks without CM with CM P value Remarks 
Heart 42.44 ± 18.84 128.44 ± 22.96 < 0.05 S 1.79 ± 0.53 1.80 ± 0.53 0.60 NS 
Liver 35.11 ± 18.37 98.78 ± 15.94 < 0.05 S 2.37 ± 0.70 2.37 ± 0.70 1.00 NS 
Spleen 51.11 ± 25.14 96.89 ± 8.33 < 0.05 S 2.00 ± 0.60 2.00 ± 0.59 0.86 NS 
Urinary bladder 11.89 ± 17.36 19.44 ± 30.41 0.54 NS 5.67 ± 3.22 5.66 ± 3.21 0.85 NS 
HU, Hounsfield unit; SUVmax, maximum standardised uptake value; CM, iodine-based contrast media; S, significant; NS; not significant 
 
 
 
 
 
 
 
 105
 
Figure 4.5: The mean HU values that have been obtained from the CT images of four 
normal organs (heart, liver, spleen and urinary bladder) before and after the intravenous 
injection of iodine-based contrast media. The two-tailed paired samples t-tests result with 
significant differences with P values of less than 0.05 (*) for all organs, except the urinary 
bladder (P = 0.54). Error bars represent ± standard deviation. 
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Figure 4.6: The mean SUVmax values that have been obtained from both 
PET/unenhanced CT and PET/CECT fusion images of four normal organs (heart, liver, 
spleen and urinary bladder). None of the changes in the SUVmax values of any of these 
organs are found to be statistically significant (P values > 0.05). Error bars represent ± 
standard deviation. 
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Figure 4.7: FDG PET/CT image acquisitions of patient 4 of the Malaysian patients. (a) 
Maximum intensity projection (MIP) image. (b) PET/unenhanced CT and (c) PET/CECT 
fusion images, which demonstrate the differences in HU and SUVmax values of his heart 
(yellow arrows). It has been clearly shown that the utilisation of iodine-based contrast 
media will cause enormous change in HU value (from 26 to 123), whereas the SUVmax 
value is increased minimally (from 1.30 to 1.38). 
 
 
4.1.1.1.2. Diagnostic performance of FDG PET/CT imaging against 
 the other conventional imaging modalities 
As mentioned earlier, all sixteen Malaysian patients had undergone extensive clinical, 
radiological and histopathological investigations during their diagnosis process of the 
disease and the periodical follow-up visits. Thus, the diagnostic performance of FDG 
PET/CT imaging can be validated against the imaging findings of other conventional 
imaging modalities like general radiography, MRI and CT scans, and ultrasound. Any 
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suspicious sign of having tuberculous infection reported from these scanning (including 
FDG PET/CT imaging) was considered as a positive diagnostic imaging result. The 
microscopic/histopathological findings and the outcome of the treatment response 
(clinically and/or radiologically) during the follow-up visits are used as the 
baseline/standard, and all of these are summarised in Table 4.3. 
 
Table 4.3: The diagnostic investigation results of all Malaysian patients. 
Patient no. PET/CT CM HPE or F/up 
EPTB  
1 + + + 
2 + − + 
3 + + + 
4 + + + 
5 + + + 
6 + + + 
7 + + + 
8 + + + 
9 + + + 
Non-EPTB  
10 + − − 
11 − + − 
12 − − − 
13 − − − 
14 + + − 
15 − − − 
16 + + − 
CM, conventional imaging modalities; HPE, histopathological examination; F/up, 
follow-up; +, positive; −, negative. 
 
 
Table 4.4: The diagnostic performance of FDG PET/CT and other conventional 
imaging modalities in detecting the EPTB lesions of all sixteen Malaysian patients. 
 Sensitivity Specificity Accuracy PPV NPV 
PET/CT 100% 57.1% 81.3% 75% 100% 
CM 88.9% 57.1% 75% 72.7% 80% 
CM, conventional imaging modalities; PPV, positive predictive value; NPV, 
negative predictive value. 
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The sensitivity, specificity, accuracy, positive and negative predictive values for 
PET/CT and other conventional imaging modalities are listed in Table 4.4. Based on 
these results, FDG PET/CT imaging has shown a relatively higher in its diagnostic 
performance as compared to the other conventional imaging modalities.  
 
4.1.1.2. DTPI of FDG PET/CT scan  
The DTPI of FDG PET/CT scans were only performed in thirteen patients, where other 
three patients were clinically unfit and presented with severe backache; patients 7, 15 
and 16 (refer to Tables 3.3 and 3.5 in Chapter 3). Of these, only twelve patients 
underwent two CT examinations, which consisted of unenhanced CT and CECT scans 
during their FDG PET/CT imaging (exclude patient 14 who was previously diagnosed 
with end-stage renal failure, refer to Table 4.1). However, for this analysis, only 11 
patients were included (patient 11 was excluded due to the fact that all her detected 
FDG areas were caused by the physiological brown fats uptakes, refer to Appendix 5). 
All the SUVmax values (SUVmax1; initial whole body scan, and SUVmax2; delayed 
scan) for each of the detected lesions are tabulated in Table 4.5.  
A total of 30 extrapulmonary lesions with avid FDG uptake were detected. All 
lesions showed the SUVmax values of higher than standard cut-off value of 2.5; 
SUVmax > 2.5, during both image acquisitions (excluding only one lesion of patient 8). 
The mean ± SD values for SUVmax1 and SUVmax2 of the 22 EPTB lesions were 6.8 ± 
2.5 and 7.9 ± 3.2, respectively. There was a significant difference between these two 
time points (P = 0.001) (refer to Fig. 4.8). This result indicated that there was a 
significant increment on SUVmax values between the two time points within the 
studied EPTB lesions. The mean %∆SUVmax of the EPTB lesions was about 16%, with 
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the highest value of about 40% had been recorded at the right infraclavicular node of 
patient 1 (Fig. 4.9).  
 In comparison, for the eight non-EPTB lesions, the mean ± SD values of 
SUVmax1 and SUVmax2 were 6.2 ± 2.6 and 6.5 ± 2.8, respectively. There was a 
significant difference between these two time points (P = 0.044) (refer to Fig. 4.8). 
However, the pattern of SUVmax change in these non-EPTB lesions was less apparent 
than those of EPTB lesions, in which the mean %∆SUVmax value was only about 4% 
(Fig. 4.10).  
When comparing the mean of %∆SUVmax values from both types of lesions 
(EPTB vs. non-EPTB), there was an insignificant difference statistically (P = 0.06) 
(refer to Fig. 4.11). This result indicated that the %∆SUVmax value was insufficient to 
be used for differentiating between EPTB and non-EPTB lesions. However, according 
to the ROC curves analyses (Fig. 4.12), when the SUVmax1 value of 5.7 was used as 
the cut-off value, the sensitivity and specificity were 68.2% and 50%. When the 
SUVmax2 value of 5.9 was used as the cut-off value, the sensitivity and specificity 
were 72.7% and 50%. When %∆SUVmax value of 7.6 was used as the cut-off value, the 
sensitivity and specificity were 77.3% and 75%. Based on these results, %∆SUVmax 
value demonstrated the highest diagnostic performance as compared with the other two 
values; SUVmax1 and SUVmax2. 
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Table 4.5: The SUVmax values for each of the detected lesions from DTPI of FDG 
PET/CT imaging in the eleven of Malaysian patients. Note that the patient number is the 
same as in Table 4.1.  
Patient no. Lesion site SUVmax1 SUVmax2 %∆SUVmax 
EPTB  
1 
1. Right base of the neck node 8.0 10.4 30.0 
2. Right parathyroid node 8.6 11.8 37.2 
3. Right infraclavicular node 8.3 11.6 39.8 
4. Right paratracheal 11.7 15.7 34.2 
2 T12 and L1 vertebral bodies 7.2 9.5 31.9 
3 Left submandibular node 9.7 11.2 15.5 
4 Right Hip 8.3 8.9 7.2 
5 1. L3-L4 intervetebral disc space 8.5 10.7 25.9 2. Left psoas muscle at level L4 6.7 8.1 20.9 
6 
1. Right retrocrural node 6.0 6.0 0.0 
2. Right subhepatic node 3.5 4.3 22.9 
3. Peripancreatic node 7.1 8.1 14.1 
8 
1. Right supraclavicular fossa 2.8 2.3 -17.9
2. Right anterior chest wall 5.8 6.8 17.2 
3. Right subscapular soft tissue space 11.7 8.8 -24.8 
9 
1. Right crural node 4.3 4.8 11.6 
2. Left diaphragmatic node 5.3 6.2 17.0 
3. Right diaphragmatic node 3.4 4.0 17.6 
4. Preaortic node 7.0 7.1 1.4 
5. Left renal vein node 5.7 6.7 17.5 
6. Left retrosternal node 4.8 5.3 10.4 
7. Right carinal node 4.7 5.7 21.3 
Non-EPTB     
10 
1. Right posterior triangle of neck (anterior) 3.5 4.0 14.3 
2. Right posterior triangle of neck (posterior) 3.8 4.0 5.3 
3. Right paratracheal node 8.8 9.5 8.0 
12 Left calcaneum bone 3.2 2.9 -9.4 
13 
1. Right posterior of 9th rib 9.6 10.3 7.3 
2. Right lateral of 10th rib 7.0 7.4 5.7 
3. Right posterior of 11th rib 8.3 8.3 0.0 
4. Tibial plateau of left knee joint 5.6 5.8 3.6 
EPTB, extra-pulmonary tuberculosis; non-EPTB, non-extra-pulmonary tuberculosis; T, thoracic vertebrae; 
L, lumbar vertebrae; SUVmax1, maximum standardised uptake values at early imaging; SUVmax2, 
maximum standardised uptake values at delayed imaging; %∆SUVmax, percentage difference of SUVmax 
values. 
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Figure 4.8: The mean differences in the SUVmax values of EPTB and non-EPTB 
Malaysian patients, obtained from PET/CT fusion images of 22 EPTB and 8 non-EPTB 
lesions during the image acquisition of using DTPI technique. The two-tailed paired 
samples t-tests result with significant differences with P values of less than 0.05 (*) for 
both groups of patients. However, the changing pattern in non-EPTB patients is smaller in 
amplitude than of EPTB patients. Error bars represent ± standard deviation.  
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Figure 4.9: FDG PET/CECT image acquisitions of patient 1 of Malaysian patients showing an avid FDG activity at her right infraclavicular 
lymph node (blue arrows). (a) PET image of early scan. (b) Contrast-enhanced CT (CECT) image of early scan with peripheral enhancement 
of the right infraclavicular node. (c) PET/CECT fusion image which demonstrated a volume of interest (VOI) at the right infraclavicular node; 
SUVmax value was 8.3 (yellow arrow). (d) Delayed PET image at almost the same level as in (a). (e) Delayed CT image at almost the same level 
as in (b). (f) PET/CT fusion image showed higher SUVmax value; 11.6 (yellow arrow). The percentage difference between these two SUVmax 
values (%∆SUVmax) was about 40%. 
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Figure 4.10: FDG PET/CECT image acquisitions of patient 11 of Malaysian patients showing an avid FDG activity at the tibial plateau of his 
left knee joint (blue arrows). (a) PET image of early scan. (b) Contrast-enhanced CT (CECT) image using bone window setting of early scan. 
(c) PET/CECT fusion image which demonstrated a volume of interest (VOI) at the left tibial plateau; SUVmax value was 5.6 (yellow arrow). 
(d) Delayed PET image at almost the same level as in (a). (e) Delayed CT image also using bone window setting at almost the same level as in 
(b). (f) PET/CT fusion image showed higher SUVmax value; 5.8 (yellow arrow). The percentage difference between these two SUVmax values 
(%∆SUVmax) was only about 4%. 
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Figure 4.11: The mean difference in %∆SUVmax value of EPTB and non-EPTB patients. 
An independent samples t-test shows no significant difference with P = 0.06. Error bars 
represent ± standard deviation. 
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Figure 4.12: The receiver operating characteristic (ROC) curves that compare the 
diagnostic performance (sensitivity and specificity) of the SUVmax1, SUVmax2 and 
%∆SUVmax values in differentiating between EPTB and non-EPTB lesions. This analysis 
yields that the use of %∆SUVmax value (blue line) is superior to the other two values, with 
an area under curve of 0.804.  
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4.1.2.  Italian patients 
A total of 19 extrapulmonary lesions with avid FDG uptake were detected, in these 
twelve confirmed EPTB patients (as listed in Table 4.6). Again, all the detected lesions 
were in either grade 3 or 4 of the PET/CT visual analysis, with SUVmax > 2.5. The 
mean ± SD of the SUVmax1 value for these EPTB lesions was 7.8 ± 4.0.  
 
Table 4.6: The SUVmax1 values of all detected EPTB lesions from the twelve Italian 
patients. 
Patient no. Lesion site SUVmax1
1 
1. Posterolateral aspect left rib, at the level of T4 13.4 
2. Right pretracheal node, at the level of T4 vertebral body 6.7 
3. Right peribroncheal node 8.6 
2 L2-L3 intervertebral disc 9.8 
3 
1. Right 8th intercostal muscle 7.8 
2. Left sternum 9.3 
3. Left prevertebral area space of lower cervical and thoracic 
spines 8.8 
4 Left hip joint 6.7 
5 Left knee joint 5.0 
6 Left shoulder joint 4.7 
7 
1. L4-L5 intervertebral disc 7.2 
2. Mediastinal node 5.3 
3. Right hilar node 5.8 
8 Right hip joint 4.9 
9 L3-L4 intervertebral disc 10.0 
10 Right hip joint 3.1 
11 Right knee joint 20.8 
12 1. T10 -T11 intervertebral disc 4.8 2. Right carinal 5.0 
T, thoracic vertebrae; L, lumbar vertebrae; SUVmax, maximum standardised uptake value. 
 
 
4.1.2.1. Comparison between the SUVmax values of EPTB lesions in   
  Malaysian and Italian patients 
When comparing between the mean SUVmax1 values of EPTB lesions in both 
Malaysian and Italian patients, an independent samples t-test revealed an insignificant 
statistical difference with a P value equal to 0.404 (refer to in Fig. 4.13). This indicates 
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that an infectious lesion like EPTB could have a high FDG uptake, which then results in 
a high SUVmax value. Thus, FDG PET/CT scan is proven to be an important diagnostic 
imaging procedure in depicting EPTB lesions.    
 
 
Figure 4.13: Bar charts show the mean SUVmax1 values of EPTB lesions in both 
Malaysian and Italian patients. There is no significant difference between these two mean 
values, as the independent samples t-test results with P = 0.404. Error bars represent ± 
standard deviation.  
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4.1.3. Follow-up FDG PET/CT scan 
All six patients were treated with anti-tuberculous drugs for at least six months prior to 
the follow-up scanning acquisition. From the follow-up FDG PET/CT images, twelve 
EPTB lesions were re-evaluated and reviewed (refer to Table 4.7). Of that, eight lesions 
were found to have no more FDG uptake, which then had been classified as complete 
remission and positive treatment response (Fig. 4.14 and 4.15). On the contrary, the 
other four lesions still demonstrated a significantly high FDG uptake (SUVmax > 2.5), 
and categorised as the active EPTB lesions.  
 
4.1.3.1. Comparison between the SUVmax values of EPTB lesions in the 
  follow-up and initial diagnostic FDG PET/CT scans 
When comparing the SUVmax values of the detected EPTB lesions during the follow-
up scan with the initial PET/CT fusion images of the diagnostic process, the four EPTB 
lesions exhibited a substantial reduction in their SUVmax values. However, these 
lesions had demonstrated an increasing pattern in the SUVmax values of the delayed 
PET/CT fusion images (Fig. 4.16 and 4.17). This imaging characteristic was assumed to 
be a sign of an active lesion with a partial treatment response, and therefore the anti-
tuberculous treatment of these particular patients was continued for another three 
months, or in some patients up to six months. These findings show that FDG PET/CT 
imaging can be considered as a valuable imaging modality for detecting and monitoring 
the treatment response of EPTB patients. Furthermore, DTPI may offer some helps to 
the physician in assessing the activity status of EPTB lesion, which then will facilitate 
the treatment management of the patient.    
 120
Table 4.7: Comparison between the initial diagnostic and follow-up FDG PET/CT findings of the first six Malaysian EPTB patients. 
Patient no. Lesion site Initial diagnostic PET/CT Follow-up PET/CT SUVmax1 SUVmax2 %∆SUVmax SUVmax1 SUVmax2 %∆SUVmax
1 
1. Right base of the neck 8.0 10.4 30.0 Complete remission 
2. Right parathyroid 8.6 11.8 37.2 Complete remission
3. Right infraclavicular 8.3 11.6 39.8 4.3 6.7 55.8 
4. Right paratracheal 11.7 15.7 34.2 5.3 8.1 52.8 
2 T12 and L1 vertebral bodies 7.2 9.5 31.9 7.0 9.0 28.6 
3 Left submandibular node 9.7 11.2 15.5 Complete remission 
4 Right hip joint 8.3 8.9 7.2 4.1 4.7 14.6 
5 1. L3-L4 intervetebral disc space 8.5 10.7 25.9 Complete remission 2. Left psoas muscle at level L4 6.7 8.1 20.9 Complete remission 
6 
1. Right retrocrural node 6.0 6.0 0.0 Complete remission 
2. Right subhepatic node 3.5 4.3 22.9 Complete remission
3. Peripancreatic node 7.1 8.1 14.1 Complete remission 
T, thoracic vertebrae; L, lumbar vertebrae; SUVmax1, maximum standardised uptake values at early imaging; SUVmax2, maximum 
standardised uptake values at delayed imaging; %∆SUVmax, percentage difference of SUVmax values. 
 
 
 
 
 
 121
 
Figure 4.14: PET/CT images during the diagnosis process of patient 3 of Malaysian patients show an avid FDG activity at her left 
submandibular lymph node (blue arrows). (a) Axial PET image of early scan. (b) Axial Contrast-enhanced CT (CECT) image of early scan. (c) 
Axial PET/CECT fusion image which demonstrated a volume of interest (VOI) at the left submandibular lymph node with 9.7 in SUVmax 
value. (d) Axial delayed PET image at almost the same level as in (a). (e) Axial delayed CT image at almost the same level as in (b). (f) Axial 
PET/CT fusion image showed higher SUVmax value; 11.2. The percentage difference between these two SUVmax values (%∆SUVmax) was 
about 16%.  
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Figure 4.15: Follow-up PET/CT images of patient 3 of Malaysian patients at almost the same level as in Fig. 4.14, show no more avid FDG 
activity at her left submandibular lymph node. (a) Axial PET image of early scan. (b) Axial Contrast-enhanced CT (CECT) image of early 
scan. (c) Axial PET/CECT fusion image. (d) Axial delayed PET image at almost the same level as in (a). (e) Axial delayed CT image at almost 
the same level as in (b). (f) Axial PET/CT fusion image at almost the same level as in (c). These findings have been classified as complete 
remission of the disease. Note that the bilateral symmetrical FDG avid areas are found to be caused by the physiological brown fats uptakes. 
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Figure 4.16: PET/CT images during the diagnosis process of patient 4 of Malaysian patients show an avid FDG activity at his right hip joint 
(blue arrows). (a) Axial PET image of early scan. (b) Axial Contrast-enhanced CT (CECT) image of early scan. (c) Axial PET/CECT fusion 
image which demonstrated a volume of interest (VOI) at the right hip joint with SUVmax value of 8.3. (d) Axial delayed PET image at almost 
the same level as in (a). (e) Axial delayed CT image at almost the same level as in (b). (f) Axial PET/CT fusion image showed higher SUVmax 
value; 8.9. The percentage difference between these two SUVmax values (%∆SUVmax) was about 7%.  
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Figure 4.17: Follow-up PET/CT images of patient 4 of Malaysian patients show less avidity of FDG uptake at his right hip joint (blue arrows), 
as compared with the previous images in Fig. 4.16.  (a) Axial PET image of early scan. (b) Axial Contrast-enhanced CT (CECT) image of early 
scan. (c) Axial PET/CECT fusion image with SUVmax value of 4.1 at the right hip joint. (d) Axial delayed PET image at almost the same level 
as in (a). (e) Axial delayed CT image at almost the same level as in (b). (f) Axial PET/CT fusion image showed higher SUVmax value; 4.7. The 
percentage difference between these two SUVmax values (%∆SUVmax) was about 15%, which corresponds to an active lesion. However, this 
less avidity of FDG uptake of the lesion is classified as a partial treatment response. 
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4.2. Discussion 
All the detected EPTB lesions of both Malaysian and Italian patients were found to have 
high accumulation of FDG. In addition, the application of iodine-based contrast media 
during the CT scan of FDG PET/CT imaging in the nine Malaysian EPTB patients 
demonstrated no significant changes in the SUVmax values of the lesions and the four 
normal organs. However, DTPI of FDG PE/CT scan seemed to be insufficient imaging 
technique for differentiating between EPTB and non-EPTB lesions. Reasons behind all 
of these findings are discussed in the following sections. 
 
4.2.1. FDG uptake in EPTB lesions 
In order to assess the feasibility of FDG PET/CT imaging in detecting EPTB lesions, it 
is essential to have a clear understanding of the mechanism that causes a high FDG 
uptake in this type of lesion. Pathophysiologically, EPTB emerges from the evolution 
process of primary TB infection [15]; in which the normal route for extrapulmonary 
spread of TB initially starts with the transportation of tubercle bacilli into the lymphatic 
system and followed by the dissemination of these bacilli into the blood circulation 
system [81]. Thus, the accumulating mechanism for FDG in EPTB lesions is strongly 
believed to be the same as in pulmonary TB (PTB) lesions.      
 Mycobacterium tuberculosis commonly enters the human body via the 
respiratory tract. As the first defence mechanism to stop the intrusion, the alveolar 
macrophages will phagocytose this pathogen [10]. This process explains the major role 
of macrophages in combating TB infection. Other inflammatory cells such as 
lymphocytes and neutrophils are also responsible for overcoming this infection [10]. 
Indeed, at an active stage, all these inflammatory cells will have high glucose metabolic 
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activity [6]. Therefore, the high accumulation of FDG at the sites of active tuberculous 
lesions is not a surprising finding, and it can be clearly seen in PET and/or PET/CT 
fusion images.  
 An earlier study by Ichiya et al. [138] found that positron emission tomography 
(PET) could be used in detecting infectious lesions such as PTB. However, there is still 
scarce data on the use of FDG PET/CT imaging during the diagnostic procedure of 
EPTB infectious disease. Only a few recent studies have found that EPTB lesion could 
have an FDG avid area in PET/CT images [7, 19, 62, 139, 140]. Similarly, in this study, 
all the detected EPTB lesions (from both populations; Malaysia and Italy) exhibit high 
SUVmax values; ranging from 2.8 to 20.8. Thus, based on the findings of this clinical 
imaging study, FDG PET/CT scan has been proven to offer valuable diagnostic 
information in depicting EPTB lesions.  
 On the other hand, when comparing the mean SUVmax1 values of EPTB and 
non-EPTB lesions among all sixteen Malaysian patients, it showed an insignificant 
statistical difference (7.0 ± 2.4 vs. 8.8 ± 4.6, P = 0.07), with a substantial overlapping in 
the SUVmax1 values of these two groups of lesions. Based on these results, it is 
strongly suggested that the SUVmax1 value alone cannot clearly differentiate between 
EPTB and other infectious lesions, although FDG PET/CT imaging can reliably depict 
EPTB lesions. Therefore, in the standard clinical practice, to establish the final/definite 
diagnosis of a disease, the semiquantitative analysis of PET/CT fusion images still 
needs to be augmented with other radiological and/or pathological findings. In addition, 
it has been recommended that extra caution and attention should be taken when 
interpreting FDG PET/CT images, especially if TB is considered as epidemic/endemic 
disease in a particular region or state [123, 132].  
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4.2.2. Effects of iodine contrast media on SUVmax values of PET/CT images 
The utilisation of iodine-based contrast media during CT scan of PET/CT imaging is 
still considered as a controversial issue [115]. Few studies recommend that unenhanced 
CT scan is sufficient to be used during the PET/CT imaging acquisitions [141, 142], 
whereas others advocate that the PET/contrast-enhanced CT (PET/CECT) imaging is 
the real “one-stop-shop” examination, which offers more accurate diagnosis of various 
diseases [25, 121, 143]. The advocates argue that PET/CECT scan could result in a 
change of patient’s clinical management, which may then avoid any unnecessary 
therapy [144, 145]. Besides, it has been reported that there is no pharmacologic 
interaction between iodine contrast media and FDG, as the injections are conducted 
with an hour interval between them [113]. Therefore, in this study, FDG PET/CECT 
scans were carried out during the initial whole body imaging of all Malaysian patients 
(except for patient 14 who was previously diagnosed with end-stage renal failure). 
The PET/CT image analysis using the standardised uptake values (SUVs) was 
reported to provide more reliable diagnostic information than that of the visual 
assessment [62]. However, there are several factors that could affect the reproducibility 
of these SUVs, which mostly depends on the scanning protocols like time of imaging 
(after FDG injection), type of reconstruction algorithms, type of attenuation maps, size 
of the region of interest, changes in uptake by organs other than the pathologic lesion, 
and methods of analysis (SUVmax and SUVmean) [146]. As a consequence, in standard 
clinical practice, the SUVs technique of PET/CT image analysis is compared and 
augmented with the findings of the other conventional imaging modalities in order to 
establish the imaging diagnosis of a disease.  
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 The application of iodine-based contrast media in CT component of PET/CT 
imaging could be problematic due to incorrect mapping of the PET attenuation 
correction factors that have been generated from the CECT image dataset [122]. During 
the calculation of the PET attenuation correction factors, the conversion algorithm may 
not be able to distinguish between the bony structures and the highly enhanced soft 
tissues, and this will lead to an overestimated value of the correction factors [115-117]. 
However, this effect has been found to be clinically insignificant because it does not 
change the diagnostic interpretation of a disease [113, 118, 119, 122]. 
 All the above data have been acquired from various types of cancer patients. To 
date, no study has attempted to address this issue in inflammations/infections, more 
specifically in EPTB infectious disease. Thus, in this study, the differences in SUVmax 
values of five different tissues (including the lesions) from the nine Malaysian EPTB 
patients were quantified. Interestingly, the results showed that none of the changes in 
any of these tissues were found to be statistically significant (all P values were higher 
than 0.05). Based on these findings, it is accepted that iodine-based contrast media can 
safely be applied in FDG PET/CT imaging of EPTB patients, without producing any 
significant effects on the SUVmax values regardless of either in the lesions or the 
normal organs. 
 
4.2.3. Dual time point imaging (DTPI) of FDG PET/CT scan in EPTB patients 
Currently, there is no consensus on the optimal scanning protocols of FDG PET/CT 
imaging that can be employed for accurately differentiating between 
inflammatory/infectious and malignant lesions [5]. An earlier animal model study by 
Yamada et al. [6] found that the FDG uptake of an inflammatory/infectious tissue 
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reached its peak in about 60 min after the time of injection, but then it gradually 
decreased with time. On the contrary, malignant lesions have been shown to keep 
increasing the FDG uptake for up to several hours after the injection time [98]. Based 
on this unique imaging characteristic of these two different pathologies, numerous 
studies have postulated that DTPI technique is a better and more reliable imaging 
method for differentiating multiple types of lesions on FDG PET/CT imaging [7, 21-23, 
62, 109].  
 The usefulness of DTPI technique in distinguishing between benign and 
malignant lesions in the thoracic region had been previously investigated in few studies 
[102, 104, 123, 132]. All these studies highlighted that the SUVmax value of active 
pulmonary tuberculosis (PTB) lesion could have an increment of up to 46% on the 
delayed PET/CT images, as compared with the initial images. Based on these findings, 
it shows that active PTB lesion has a similar imaging feature as in the malignant lesion. 
Therefore, DTPI technique of FDG PET/CT scan could not be effectively applied for 
differentiating benign from malignant lesions, particularly for the tuberculosis 
endemic/epidemic countries [123, 132].  
 On the other hand, a recent study has been conducted by Sathekge et al. [7] with 
the utilisation of DTPI technique during FDG PET/CT scans in a group of sixteen 
confirmed tuberculosis patients. As expected, their entire EPTB lesions show increasing 
pattern in the SUVmax values of the delayed FDG PET/CT images, with the highest 
mean percentage change of about 45% has been recorded in the SUVmax values of the 
bone involvement cases. These findings are in good agreement with the results of this 
clinical imaging study, where the SUVmax values of all detected EPTB lesions also 
increase during the delayed PET/CT imaging (exclude the two lesions of patient 8; a 
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relapsed EPTB patient, and one lesion of patient 6). However, when comparing the 
mean percentage change in the SUVmax values of our EPTB and non-EPTB lesions, it 
shows a statistically insignificant difference. This result indicates that DTPI technique is 
not a practical imaging method in distinguishing between EPTB and non-EPTB lesions 
on FDG PET/CT scan. Furthermore, it may conclude that the initial whole body 
PET/CT scan is a sufficient imaging procedure for differentiating EPTB from other 
infectious diseases. 
 The findings on the utilisation of DTPI technique during FDG PET/CT scans in 
the eleven of Malaysian patients have been documented and accepted for publication in 
Journal of Medical Imaging and Radiation Oncology; JMIRO.  
 
4.2.4. FDG PET/CT imaging in assessing therapeutic responses of EPTB 
patients 
Apart from detecting EPTB lesions, FDG PET/CT scan has been recently found to be a 
useful imaging tool for monitoring the therapeutic responses in EPTB patients [139]. 
Correspondingly, it is in accordance with the findings of this clinical imaging study. Out 
of the six Malaysian EPTB patients who underwent the follow-up FDG PET/CT scan 
(after completing the standard 6 months anti-TB treatment), complete remission signs 
with undetectable FDG uptake were clearly demonstrated in all EPTB lesions of the 
three patients. These imaging findings were classified as a positive treatment response, 
and for this reason, their anti-TB drugs treatment had been stopped.  
 In contrast, the other three patients were categorised as partially responded to 
anti-TB treatment, where a substantial decline in the SUVmax values was detected in all 
their EPTB lesions. But, these lesions had also exhibited increasing patterns on the 
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delayed PET/CT images, which could be classified as a sign of an active lesion with 
partial treatment response. Based on these results, it is highly recommended that FDG 
PET/CT imaging should be applied in evaluating and monitoring responses to anti-TB 
treatment in patients with EPTB. In addition, the %∆SUVmax value can potentially be 
used as a clinical imaging indicator for determining the activity status of EPTB lesion, 
in which this method may offer some benefits to the physician in choosing and deciding 
the correct treatment management for EPTB patients. However, this study warrants to 
be conducted in larger cohort of EPTB patients. 
 
4.2.5. Technical factors that can improve the quality of FDG PET/CT images 
As mentioned earlier, all FDG PET/CT image acquisitions of the sixteen Malaysian 
patients were conducted under the normal breathing phase (no information regarding 
this issue was obtained from the retrospective Italian data). Respiratory motion is 
known to be one of the most common causes for the misregistration artifact, which 
occurs mainly due to the inconsistency in position of the chest between both PET and 
CT acquisitions [42]. This kind of artifact has clearly been seen on the thoracic region 
of three patients (patients 8, 10 and 11; refer to Fig. 4.18). However, this misregistration 
artifact does not cause any problems in interpreting PET/CT fusion images, and in fact, 
this issue can be resolved effectively by reviewing the CT images for any sign of 
anatomical abnormalities [42]. Based on this observation, it has been believed that the 
normal breathing technique is acceptable to be used during PET/CT imaging. 
 In this clinical imaging study, all sixteen Malaysian patients placed both arms at 
above of the head (please refer to Fig. 4.7), but it was not the case for those twelve 
Italian patients (Fig. 4.19). Nevertheless, during the follow-up PET/CT scans, only one 
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of the six Malaysian patients (patient 2) was not capable of positioning both arms at 
above of his head; due to back pain, consequently the scanning was performed whilst 
his arms were placed by the side. Based on his body size, this patient was not 
categorised as a large patient, and therefore no truncation artifact was detected at the 
edge of CT Field of View (FOV) [68]. However, some fuzzy streaking lines were 
noticed at the area beyond his hands, which could have been caused by the humerus 
bones of the upper limbs, as shown in Fig. 4.20. From this finding, it is strongly 
suggested that whenever possible the whole body PET/CT imaging should be conducted 
with both arms placed over the head [146]. This method is optimal for preventing the 
occurrence of the truncation artifact, in addition to generating clearer PET/CT fusion 
images [42].        
 Metallic implants can cause streaking artifacts on PET/CT fusion images [63, 
147]. These artifacts were found in two of the Italian patients, who had metallic 
prosthetic implants at the lower lumbar region (patient 7) and right hip joint (patient 8). 
As recommended, the image should be interpreted using non-attenuated PET images 
[63, 64], however, in this study, the images of these two patients were analysed by 
applying the bone window setting CT images (window width: 2000, and window level: 
350), and then fused with PET images (Fig. 4.21). Based on our experience, this 
technique minimises the amount of streaking artifacts, making it helpful for better 
interpreting and analysing PET/CT fusion images. 
 The utilisation of an intravenous iodine-based contrast media during the CT scan 
of PET/CT imaging has been reported to cause an artifact on PET images [67]. 
However, as mentioned earlier, it was not the case in this clinical imaging study. No 
statistically and clinically significant effects were demonstrated on the SUVmax values 
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of either the lesion or the normal organs, even though an intravenous injection of 
iodine-based contrast media had been applied during the CT scan of FDG PET/CT 
imaging in a group of nine EPTB patients. 
 
 
 
Figure 4.18: PET/CECT fusion image of patient 8 of Malaysian patients shows the 
respiratory motion artefact, which can be seen as the fuzzy reddishness outline 
particularly at her anterior thoracic region. The green box represents a volume of interest 
(VOI) at the right subscapular soft tissue space with SUVmax value of 11.7.  
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Figure 4.19: Anterior Maximum Intensity Projection (MIP) image from one of Italian 
patients (patient 8) shows both hands position (by the sides) during her PET/CT imaging. 
Small blue box demonstrates an avid FDG activity at her right hip joint with SUVmax 
value of 4.9.   
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Figure 4.20: The axial PET (a & d), Contrast-enhanced CT (b & e) and fused PET/CECT (c & f) images from patient 2 of Malaysian patients. 
The upper row (a-c) images represent the PET/CT images during the initial diagnostic scan, whilst the lower row (d-f) images are during the 
follow-up scan. The white thin arrows demonstrate the fuzzy streaking lines, which occurs due to the humerus bones of the upper limbs. 
However, this patient is not large enough to produce truncation artifact at the rim region of CT Field of View (FOV).  
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Figure 4.21: Axial PET/CT fusion images from patient 8 of Italian patients show streaking artifact, which has been caused by metallic hip 
prosthetic implant at her right hip joint. (a) PET/CT fusion image at an abdomen window CT setting; width: 400 and level: 40, demonstrates a 
remarkable streaking artifact. (b) Less streaking artifact is seen when the PET image has been fused with bone window setting of CT image; 
width: 2000 and level: 350. The SUVmax values of both VOIs from these two images are same; 4.9.
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Overall, here are the findings of this clinical imaging study: 
1. All detected EPTB lesions from both Malaysian and Italian patients have shown 
high FDG uptakes, with the SUVmax values ranging from 2.8 to 20.8. These 
lesions can clearly be depicted on FDG PET/CT fusion images. Thus, it has been 
proven that FDG PET/CT scan is an important imaging procedure for detecting 
EPTB lesions. Furthermore, in the detection of EPTB lesions, FDG PET/CT 
imaging has demonstrated a relatively higher in its diagnostic performance as 
compared with the other conventional imaging modalities.  
2. The application of intravenous iodine-based contrast media does not cause any 
statistically and clinically significant differences in the SUVmax values of either 
in EPTB lesions or the normal organs. Therefore, an intravenous injection of 
iodine-based contrast media can safely be applied during the CT scanning of 
FDG PET/CT imaging of EPTB patients. 
3. Dual time point imaging (DTPI) technique of FDG PET/CT scan seems to be an 
impractical imaging method for differentiating between EPTB and non-EPTB 
lesions. As a result, the initial whole body FDG PET/CT imaging is a valuable 
scanning procedure in distinguishing EPTB from other infectious diseases. 
4. FDG PET/CT imaging provides more diagnostic information in terms of 
evaluating and monitoring the therapeutic responses of EPTB patients, which 
may help the physician for the treatment management of EPTB patient.  
5. To prevent the occurrence of truncation artifact on PET/CT fusion images, the 
scanning should be performed with both arms are placed at above of the head. In 
addition, the normal breathing is an adequate method for the image acquisitions 
of PET/CT imaging. 
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The results displayed in the previous chapter clearly indicate that the utilisation of an 
intravenous iodine contrast media during the CT scan of FDG PET/CT imaging will not 
significantly affect the SUVmax values of the five different tissues (heart, liver spleen, 
urinary bladder and lesion) in a group of nine confirmed EPTB patients. Thus, to further 
prove this clinical finding, an experimental phantom study was executed. This chapter 
briefly describes the issues regarding the application of iodine contrast media in FDG 
PET/CT scan. The experimental set up and results of the application of iodine contrast 
media during the CT scan of FDG PET/CT imaging and their effects on the SUVs 
(SUVmax and SUVmean) of PET/CT fusion images are then presented and discussed. 
 
5.1. Introduction 
In PET/CT imaging, the CT data is commonly used for two main purposes: 1) calculate 
the attenuation correction factors of the PET emission data, and 2) provide an accurate 
anatomical localisation of the lesions. As the PET attenuation correction factors can be 
derived from the CT data, hence, the PET transmission scan of using an external 
radiation source may no longer be necessary [43]. Routinely, the conversion of CT data 
(expressed in Hounsfield Units; HU) into the PET attenuation correction factors 
employs a simple bi-linear transform method [2, 4, 5], however this method is only well 
established for unenhanced CT scan [43, 49, 122]. Therefore, the CT scanning of 
PET/CT imaging is generally acquired without the utilisation of any contrast enhancing 
agents [121].  
  In contrast, when the CECT data is used for calculating the PET attenuation 
correction factors, it could cause the image artifacts on PET/CT fusion images (appear 
as FDG avid areas) [67, 148]. These artifacts occur due to an overlapping between the 
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HU values of the contrast enhanced soft tissues and the bones in CECT images, and 
accordingly, the standard conversion algorithm cannot distinguish these two structures 
[122]. This will lead to an overestimate on the PET attenuation correction factors [115-
117]; because the attenuation value of iodine falls off more rapidly with increasing 
energy (mostly caused by the photoelectric effect) as compared with the attenuation 
values of tissues having less density than iodine [118]. The fundamental explanation of 
these image artifacts is well addressed in the literature [49, 122, 149, 150].  
This study attempted to determine if any correction was required when iodine 
contrast media had been employed during FDG PET/CT imaging. The changes in the 
SUVs caused by the administration of iodine contrast media were measured, using a 
phantom designed to simulate as closely possible as in the actual patient scanning 
conditions. For this reason, an anthropomorphic phantom had been utilised in this study, 
and it was specifically designed to simulate a case of spinal tuberculosis at the lower 
abdomen region. The phantom allowed insertion of three dried human spinal vertebrae; 
to simulate the spine, and a tube of containing FDG solution could be positioned in the 
foramen; to simulate a spinal lesion. To the best of our knowledge, no phantom study 
has been previously reported to determine the effects caused by the application of non-
ionic iodine contrast media on the SUVs in this clinically important geometry. 
Therefore, the aim of this study was to address a gap in the literature by quantifying the 
differences on the SUVs of the PET/CT images under the conditions above. 
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5.2. Materials and methods 
5.2.1. PET/CT imaging acquisition 
All the imaging acquisitions of this study were performed on a Philips Gemini Dual 
PET/CT system at the Nuclear Medicine Department of The Alfred Hospital, 
Melbourne, Australia. This integrated imaging system consists of an Allegro 3-D PET 
scanner with gadolinium oxyorthosilicate (GSO) crystal detectors, and an Mx8000 EXP 
Dual-Slice CT scanner. The image acquisition commenced with a low-dose CT scout 
view (120 kVp), to set the scan lengths of the CT and PET scans, followed by a CT scan 
(140 kVp, 30 mAs, slice thickness of 5 mm, pitch factor of 1.0 and gantry rotation 
speed of 1.0 s), and finally the PET emission scan. The scanning parameters of the PET 
emission were: 3-D acquisition mode; slice image matrix of 144 x 144 pixels, axial 
Field of View (FOV) 18 cm, acquisition time 3 min per FOV, and slice thickness 4 mm 
with 5 mm reconstruction thickness to match the CT images.  
 
5.2.2. FDG PET/CT scans of the phantom 
All FDG PET/CT scans were conducted using an anthropomorphic phantom, 
comprising an ovoid plexiglass cylinder with such size and thickness as to replicate 
a standard man’s chest wall. These phantom scans are divided into four different phases: 
1. Phase 1: Simulation of an enhanced liver. 
2. Phase 2: PET/CT imaging of the simulated liver. 
3. Phase 3: PET/CT imaging of the simulated liver and bony lesion. 
4. Phase 4: PET/CT imaging of the simulated liver, bony lesion and blood vessels. 
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As stated above, across all the phases of this phantom study, liver has been chosen as 
the organ of interest. It is because of three main reasons:  
1. Liver is the second largest organ in human body.  
2. Liver shows an elevation in CT numbers (HU) on CECT images.  
3. Liver has a moderate physiological uptake of FDG on PET images. 
 
5.2.2.1. Phase 1: Simulation of an enhanced liver 
The uptake of iodine contrast media in the liver is dependent upon the delay from 
injection to scanning, but based on our clinical experience and the data published by 
Halls [151], the optimum HU for a normal liver due to iodine contrast media uptake in a 
CECT scan should be more than 100. In this study, a one litre normal saline bag was 
used to simulate a normal liver (labelled as saline bag 2). Prior to the PET/CT scanning 
procedure, iodine contrast media (Omnipaque 300 mgI/mL, GE Healthcare) was 
injected into saline bag 2 (at 5mL intervals). The CT scans were performed until saline 
bag 2 had an average maximum HU (HUmax) of greater than 100, to simulate the HU 
values of iodine contrast enhancement in a normal liver. For stabilisation purposes, four 
extra saline bags were inserted into the phantom along with saline bag 2, as depicted in 
Fig. 5.1. To eliminate the possibility of machine dependent artifacts influencing the 
results, the CT scans were conducted using the PET/CT system. These CT scans 
were also repeated three times to establish reproducibility of the results. 
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Figure 5.1: The set-up for the anthropomorphic phantom, which has been filled with 
saline bag 2 and four additional saline bags. The blue arrow shows saline bag 2 which has 
been injected with 15mL of iodine contrast media, so that the CT number of the bag is 
over 100 HU and it can be used to simulate iodine contrast enhancement in a normal liver. 
 
 
5.2.2.2. Phase 2: PET/CT imaging of the simulated liver  
Two saline bags (saline bag 1; without iodine contrast media, and saline bag 2; with 
iodine contrast media) were employed during this phase. The saline bags were injected 
with 9.3 MBq radioactivity of FDG each. For the first scan of this phase, saline bag 1 
and four extra saline bags were inserted into the phantom to simulate clinically 
appropriate scatter conditions for PET/CT imaging. PET/CT2a was then acquired with 
saline bag 1 in the phantom. For the second scan, saline bag 1 was replaced by saline 
bag 2. PET/CT2b was then acquired with saline bag 2 in the phantom. The set up of the 
phantom for imaging is shown in Fig. 5.2. 
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Figure 5.2: The set-up of the phase 2 phantom imaging study. The phantom is first imaged 
with saline bag 1 in place to obtain PET/CT2a (saline bag 1 contains radioactive FDG but 
no iodine contrast media). Then, the phantom is re-imaged with saline bag 2; replacing 
saline bag 1, to obtain PET/CT2b (saline bag 2 contains the same radioactivity of FDG as 
in saline bag 1, but also contains the typical clinically observed iodine contrast uptake for 
a normal liver).  
 
 
5.2.2.3. Phase 3: PET/CT imaging of the simulated liver and spinal lesion 
In this phase, a simulation of bony structures was introduced into the anthropomorphic 
phantom; therefore three dried human spinal vertebrae were used. One test tube 
(designated tube 1) of volume 10 mL and inner diameter 1 cm containing FDG (1.3 
MBq) was inserted into the vertebral foramen of the vertebrae (Fig. 5.3). Saline bags 1 
and 2 were re-used for this phase, but with two weeks interval from the phase 2 imaging 
(to assure that the radioactivity is totally decayed). For this phase both bags were 
injected with 9.5 MBq radioactivity of FDG. To minimise the impact of minor 
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variations in phantom geometry on the results, PET/CT imaging was repeated four 
times, with the following compositions (refer Table 5.1): (a) PET/CT3a imaging of 
saline bag 1 only, (b) PET/CT3b imaging of saline bag 2 only, (c) PET/CT3c imaging 
of saline bag 1 and tube 1, and (d) PET/CT3d imaging of saline bag 2 and tube 1. 
 
 
Figure 5.3: The blue arrow indicates tube 1, showing the positioning into which it has been 
placed within the vertebral foramen to simulate an FDG avid spinal lesion. This setting is 
only a gross approximation to spinal tuberculosis. Spinal TB typically grows within the 
vertebral body and not within the spinal cord [87]. 
 
 
Table 5.1: PET/CT scans of phase 3 phantom study. 
PET/CT scanning 
of phase 3 Simulated situation Inserted structures 
a) PET/CT3a liver with FDG uptake but without iodine contrast uptake saline bag 1 only 
b) PET/CT3b liver with FDG and iodine contrast uptake saline bag 2 only 
c) PET/CT3c 
liver with FDG uptake but without 
iodine contrast uptake, and spinal 
lesion FDG uptake 
saline bag 1 and tube 1 
d) PET/CT3d liver with FDG and iodine uptake, and spinal lesion FDG uptake saline bag 2 and tube 1 
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5.2.2.4. Phase 4: PET/CT imaging of the simulated liver, spinal lesion and 
    blood vessels 
In the lower abdomen region, the closest structures to the vertebral columns which are 
expected to show CECT enhancement are the abdominal aorta and inferior vena cava. 
To simulate this, another two test tubes were introduced (designated as tube 2 and 3), 
tube 3 having a higher concentration than tube 2 (19.0 mg/mL vs. 6.0 mg/mL). In this 
phase, again, two weeks interval from the previous phase was applied. The modular 
components of the plexiglass phantom for phase 4 were then: saline bag 1 with no 
iodine contrast and 9.3 MBq of FDG, saline bag 2 with sufficient iodine contrast to 
increase its CT number by 100 HU and also with 9.3 MBq of FDG, tube 1 with 1.7 
MBq of FDG, tube 2 stuck to the side of the vertebrae when deployed, and tube 3 also 
stuck to the side of vertebrae when deployed (tube 2 and 3 were not deployed at the 
same time, Fig. 5.4). Six separate PET/CT imaging sessions were conducted in phase 4, 
with the following phantom compositions (refer Table 5.2): (a) PET/CT4a imaging of 
the phantom with saline bag 1 and test tube 1, to simulate imaging spinal tuberculosis 
with liver FDG uptake in the absence of iodine; (b) PET/CT4b imaging of saline bag 2 
and tube 1, to simulate imaging spinal tuberculosis with a liver with iodine contrast and 
FDG uptake; (c) PET/CT4c imaging of saline bag 1, tube 1 and tube 2, to 
simulate imaging spinal tuberculosis in proximity to blood vessels with a low contrast 
uptake and a liver with FDG uptake but no contrast uptake; (d) PET/CT4d imaging of 
saline bag 2 and tube 1 and tube 2, to simulate imaging spinal tuberculosis in proximity 
to a blood vessel with a low contrast uptake and a liver with FDG uptake and contrast 
uptake; (e) PET/CT4e imaging of saline bag 1, tube 1 and tube 3, to simulate imaging 
spinal tuberculosis in proximity to a blood vessel with high contrast uptake and a liver 
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with FDG uptake and no contrast uptake; (f) PET/CT4f imaging of saline bag 2, tube 1 
and tube 3, to simulate imaging spinal tuberculosis in proximity to a blood vessel with 
high contrast uptake and a liver with FDG uptake and contrast uptake (Fig. 5.4). 
 
Table 5.2: PET/CT scans of phase 4 phantom study. 
PET/CT scanning 
of phase 4 Simulated situation Inserted structures 
a) PET/CT4a 
liver with FDG uptake but without iodine 
contrast uptake, and spine lesion FDG 
uptake 
saline bag 1 and tube 1 
b) PET/CT4b liver with FDG and iodine uptake, and spine lesion FDG uptake saline bag 2 and tube 1 
c) PET/CT4c 
liver with FDG uptake but without iodine 
contrast uptake, spinal lesion FDG uptake 
and low blood vessel enhancement 
saline bag 1, tubes 1 and 2 
d) PET/CT4d 
liver with FDG and iodine uptake, spinal 
lesion FDG uptake and low blood vessel 
enhancement 
saline bag 2, tubes 1 and 2 
e) PET/CT4e 
liver with FDG uptake but without iodine 
contrast uptake, spinal lesion FDG uptake 
and high blood vessel enhancement 
saline bag 1, tubes 1 and 3 
f) PET/CT4f 
liver with FDG and iodine uptake, spinal 
lesion FDG uptake and high blood vessel 
enhancement 
saline bag 2, tubes 1 and 3 
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Figure 5.4: The set-up for PET/CT imaging of the phase 4 case (f). The blue arrow shows 
the position of tube 1 in the vertebral foramen, containing 1.7 MBq of FDG to simulate 
spinal tuberculosis. The yellow arrow shows the position of tube 3 stuck to the side of 
dried vertebrae, containing a higher concentration of iodine contrast media (19.0 mg/mL) 
to simulate the effect of a blood vessel with high contrast uptake. Saline bag 2 (not 
discernable) is also present to simulate a liver with FDG and iodine contrast uptakes. 
 
 
5.2.3. Image analysis 
As a standard practice of the department, all PET emission images were reconstructed 
using the 3-D row-action maximum-likelihood algorithm (RAMLA) and the CT dataset 
was used to calculate the PET attenuation correction factors. All co-registered images 
were reviewed on the same imaging acquisition computer system in axial, coronal and 
sagittal planes along with the maximum intensity projection (MIP) images; a common 
3-D image used for visualising FDG distribution throughout the body [32]. The CT 
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images were reviewed in the soft tissue window setting (width: 350, level: 35) for 
general image interpretation. To measure HUmax for tube 2 and tube 3, the highest 
pixel values were determined by direct inspection by the operator of the axial images 
displayed on the CT console.  
 In order to obtain the SUVs as in a real patient, these values were relative to a 
nominal clinical injected dose of radioactivity for a 70 kg adult (370 MBq). For each of 
the structures (saline bags 1 and 2, and test tube 1), the SUVs were quantified by 
carefully drawing a 2-dimensional (2-D) region of interest (ROI) on the single slice of 
the attenuation corrected PET/CT fusion images; that gave the highest SUVmax and 
SUVmean values, using an automatic isocontour technique set at the 70% threshold line 
of the maximum pixel value (Fig. 5.5c). These ROIs were segmented by an experienced 
nuclear medicine technologist. The maximum (SUVmax) and mean (SUVmean) values 
were recorded.  
 Owing to a very small sample size, thus, the statistical analyses using the non-
parametric tests seemed to be more appropriate [152]. The Wilcoxon Signed Rank Test 
(alternative to the parametric paired samples t-test) was used to determine the difference 
in SUVs in phase 3 of the phantom study, while for phase 4, the analysis was performed 
using the non-parametric Friedman Test (alternative to the parametric one-way repeated 
measures ANOVA). P values of less than 0.05 were considered to be statistically 
significant. The absolute difference in SUVmax and SUVmean values (∆SUVmax and 
∆SUVmean) of each structure was also calculated. These statistical analyses were 
carried out using the SPSS program for Windows version 18.0. 
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Figure 5.5: An example of the image analysis on axial PET/CT fusion image. (a) PET image without attenuation correction shows the moderate 
activity of saline bag 2 (blue arrow). (b) CT image shows the contrast-enhancement of saline bag 2 with the average HUmax of 105 (yellow 
arrow). (c) Attenuation corrected PET/CT image shows the ROI of saline bag 2 with SUVmax and SUVmean values of 2.4 and 1.8, respectively 
(white arrow). 
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5.3. Results 
Overall, the range of SUVs for saline bags 1 and 2 generated in this study was 1.5 – 2.5. 
In phase 1 of the phantom study, the average HUmax values for saline bag 1 and 2 were 
about 15 and 105, respectively. Saline bag 2 yielded the average HUmax of 105 after 
the injection of 15mL of iodine contrast media (approximately 4.5 mg/mL in 
concentration). For phase 2, the highest absolute difference in SUVmax value 
(∆SUVmax) between saline bag 1 and 2 in the PET/CT images of phase 2 was +0.2 (the 
range for the SUVmax values of both saline bags was 2.1 – 2.3), whereas the highest 
∆SUVmean was equal to zero; the SUVmean value of 2.0 was detected in all imaging 
planes.  
The statistical analyses of the results for phase 3 are summarised in Table 5.3. 
The highest ∆SUVmax from saline bags 1 and 2, and tube 1 were -0.2, -0.2 and +0.9, 
respectively (the ranges were found to be 2.1 – 2.4 for both saline bags, and 9.1 – 12.5 
for tube 1). Furthermore, saline bag 2 and tube 1 demonstrated a lesser difference in the 
highest ∆SUVmean of about -0.4 and +0.6 (the SUVmean values were ranging from 1.5 
to 1.9 for saline bag 2, and from 2.4 to 4.5 for tube 1), while saline bag 1 showed a 
similar value to the ∆SUVmax (-0.2; range of 1.6 – 1.8). However, across all 
simulations, no statistically significant difference in SUVmax and SUVmean of any 
structure was observed (P > 0.05).  
The details analyses of the results for phase 4 are summarised in Table 5.4. With 
the separate insertion of other tubes (tubes 2 and 3), the highest ∆SUVmax for saline 
bags 1 and 2 were +0.2 and +0.1, respectively (the range for the SUVmax values of both 
saline bags was 2.0 – 2.3). These two structures exhibited an increase and unchanged in 
the ∆SUVmean: +0.1 for saline bag 1 (it showed the SUVmean value of 1.6) and zero 
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for saline bag 2 (the SUVmean value of 1.6 was detected in all imaging planes).  
However, the highest absolute difference in tube 1 remained at the same value (+1.5), 
for both SUVmax (range from 18.4 – 22.7) and SUVmean (range from 3.6 – 7.3). 
Again, all these changes were found to be statistically insignificant (P > 0.05).   
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Table 5.3: The results of the statistical analyses of phase 3 PET/CT imaging. 
Structure 
Mean ± SD 
SUVmaxa 
(SUVmeana) 
Mean ± SD 
SUVmaxb 
(SUVmeanb) 
Mean ± SD 
SUVmaxc 
(SUVmeanc) 
Mean ± SD 
SUVmaxd 
(SUVmeand) 
Highest 
∆SUVmax 
(∆SUVmean)
Wilcoxon test 
SUVmax 
(SUVmean) 
Saline bag 1 2.33 ± 0.06 (1.80 ± 0.00) - 
2.17 ± 0.06 
(1.63 ± 0.06) - 
-0.2 
(-0.2) 
NS 
(NS) 
Saline bag 2 - 2.37 ± 0.06 (1.83 ± 0.06) - 
2.37 ± 0.15 
(1.70 ± 0.17) 
-0.2 
(-0.4) 
NS 
(NS) 
Tube 1 - - 11.13 ± 1.78 (3.53 ± 1.00)
11.63 ± 1.42 
(3.80 ± 0.75) 
0.9 
(0.6) 
NS 
(NS) 
All data in parentheses are for the SUVmean. SD, standard deviation; a, PET/CT3a; b, PET/CT3b; c, PET/CT3c; 
d, PET/CT3d; SUVmax, Maximum Standardised Uptake Value; ∆SUVmax, the absolute difference in SUVmax 
value; SUVmean, Mean Standardised Uptake Value; ∆SUVmean, the absolute difference in SUVmean value; 
NS, not significant. 
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Table 5.4: The results of the statistical analyses of phase 4 PET/CT imaging. 
Structure 
Mean ± SD 
SUVmaxa 
(SUVmeana) 
Mean ± SD 
SUVmaxb 
(SUVmeanb) 
Mean ± SD 
SUVmaxc 
(SUVmeanc) 
Mean ± SD 
SUVmaxd 
(SUVmeand) 
Mean ± SD 
SUVmaxe 
(SUVmeane) 
Mean ± SD 
SUVmaxf 
(SUVmeanf) 
Highest 
∆SUVmax 
(∆SUVmean)
Friedman test 
SUVmax 
(SUVmean) 
Saline bag 1 2.20 ± 0.10 (1.53 ± 0.06) - 
2.10 ± 0.00 
(1.57 ± 0.06) - 
2.13 ± 0.15 
(1.53 ± 0.06) - 
0.2 
(0.1) 
NS 
(NS) 
Saline bag 2 - 2.17 ± 0.06 (1.60 ± 0.00) - 
2.07 ± 0.06 
(1.60 ± 0.00) - 
2.10 ± 0.00 
(1.60 ± 0.00)
0.1 
(0.0) 
NS 
(NS) 
Tube 1 22.43 ± 0.50 (5.73 ± 1.15) 
22.43 ± 0.64 
(5.70 ± 0.85)
22.20 ± 1.00 
(6.00 ± 1.47) 
20.33 ± 1.78 
(5.27 ± 1.61) 
21.10 ± 1.67 
(5.40 ± 1.15) 
20.97 ± 1.43 
(5.24 ± 1.52)
1.5 
(1.5) 
NS 
(NS) 
Tube 2 
(150 HU) N N Y Y N N   
Tube 3 
(475 HU) N N N N Y Y   
All data in parentheses are for the SUVmean. SD, standard deviation; a, PET/CT4a; b, PET/CT4b; c, PET/CT4c; d, PET/CT4d; e, PET/CT4e; f, 
PET/CT4f; SUVmax, Maximum Standardised Uptake Value; ∆SUVmax, the absolute difference in SUVmax value; SUVmean, Mean 
Standardised Uptake Value; ∆SUVmean, the absolute difference in SUVmean value; NS, not significant; N, not inserted; Y; inserted. 
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5.4. Discussion 
Across all phases of this phantom study, the range of SUVs in saline bags 1 and 2 were 
found to be within the clinically reported values for the normal liver; 1.49 – 4.89 [153]. 
The semiquantitative analysis of PET/CT images using the SUVs is reported to provide 
more reliable diagnosis than that of the visual assessment [62]. However, the 
reproducibility of the SUVs is dependent on the scanning protocols such dose uptake 
time, type of reconstruction algorithms, choice of attenuation maps, size of the region of 
interest, changes in uptake by organs other than the tumour, and methods of analysis 
(SUVmax and SUVmean) [146]. Therefore, in order to establish the final diagnosis of a 
disease, the PET/CT findings are still being compared along with the other radiological 
and/or pathological results.   
In the initial part of this phantom study (phase 2), the differences in the SUVs of 
the normal liver caused by the use of iodine contrast media during PET/CT image 
acquisition were investigated. The percentage difference in the SUVmax values of this 
study (approximately 10%) is very close to that reported in a previous clinical finding 
by Yau et al. [113]. In the latter part of this study (phases 3 and 4), the experimental 
works were mainly focused on the simulation of a spinal tuberculosis case. Spinal 
tuberculosis was considered as one of the most common forms of extrapulmonary 
tuberculosis (EPTB) in Malaysia [74]. Thus, the set-up of this phantom study is strongly 
believed to provide a clinical benefit particularly for detecting the lesion of EPTB 
infectious disease.  
This phantom study aimed to quantify the changes in SUVs (SUVmax and 
SUVmean) after the introduction of iodine contrast media during PET/CT imaging. 
Based on the results of this study, the highest percentage difference in SUVmax and 
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SUVmean values were about 10% and 26%, respectively. These values are in agreement 
with the previous phantom and patient based findings [113, 118, 119, 122, 154], which 
have concluded that the changes in both SUVmax and SUVmean values are not 
clinically significant although iodine contrast media has been utilised during the 
PET/CT imaging acquisitions. Indeed, two other clinical studies have demonstrated 
even greater percentage difference in SUVmax value of up to 27%, but this amount is 
still categorised as clinically insignificant [121, 149]. Furthermore, no pharmacologic 
interaction has been found between iodine contrast media and FDG, as both of them are 
usually administered with an interval of about an hour [113]. Therefore, based on the 
results of this phantom study and our recently published patients’ data [155], 
PET/CECT scan is suitable to be applied as a routine imaging procedure, which can 
offer an excellent imaging diagnosis for an infectious disease like EPTB.  
Even though the results of this anthropomorphic phantom study are sufficient to 
support the conclusion on clinical significance, there is still room for further 
optimisation of the measurement technique in future research. In this study, for 
example, dried human vertebrae with lower in density than encountered in vivo were 
used. Hence, by substituting these bones with other compact bones such as the mid-
shaft of the femur, the inevitable loss of bone density could be compensated, which then 
may result in better simulation of a spinal tuberculosis case.   
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5.5. Conclusion 
This phantom study has shown that the application of iodine-based contrast media 
during PET/CT imaging will not cause any statistically or clinically significant 
differences in the measurements of SUVmax and SUVmean values for an experimental 
set-up that mimics spinal tuberculosis at the lower abdomen region. Therefore, it has 
been recommended that iodine-based contrast media can safely be used during the CT 
scan of PET/CT imaging (excluding the patients with contraindications to iodine-based 
contrast media), without affecting the diagnostic accuracy of this integrated imaging 
modality. In addition, a complete intrinsic co-registration of diagnostic morphological 
and functional data can be obtained from this PET/CECT scanning procedure. 
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Based on the results of the clinical imaging study (as in Chapter 4), FDG PET/CT scan 
is proven to be a valuable imaging tool for detecting and localising EPTB lesions. This 
is the chief outcome of this research, which clearly demonstrates that FDG PET/CT 
imaging can be utilised during the diagnosis procedure of EPTB patients. By adding this 
ionising radiation based imaging modality, an obvious question which is related to the 
extra radiation dose received by a patient needs to be addressed. To fully solve this 
issue, a comprehensive dosimetric investigation and validation is required, in order to 
accurately measure the radiation dose delivered by both CT and PET scans. However, 
this thesis is mainly about introducing a new imaging modality in the diagnosis of 
EPTB infectious disease. Therefore, only a limited work was conducted for estimating 
the amount of radiation dose arising from FDG PET/CT scan.   
 
6.1.  A theoretical and historical overview of PET/CT dosimetry 
Theoretically, the absorbed radiation dose to a patient who undergoes PET/CT imaging 
consists of two different types of exposures; internal exposure from the PET scan and 
external irradiation from the CT scan [2, 156]. The absorbed radiation doses to the 
different body organs and tissues in CT and PET scans are not uniform throughout the 
body [36], and however, these very different patterns of the doses can be compared 
through the calculations of the effective dose [36, 157]. In fact, the International 
Commission on Radiological Protection (ICRP) has recommended that the effective 
dose can be used to calculate the whole body dose of the non-uniform irradiation [158]. 
In addition, it has been found that the effective dose is a valuable measurement for 
comparing and optimising between different techniques of the radiological 
examinations, such as in general radiography, CT and nuclear medicine [159, 160]. For 
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FDG PET/CT imaging, the effective dose is the sum of the effective doses arising from 
all the scanning components, in which the common scanning protocols consist of [156]:  
? a CT topogram (also known as scout view) for defining the area of scanning, 
? a low-dose CT scan, 
? a FDG PET emission scan and 
? a diagnostic CT scan. 
 
Effective dose is a single derived parameter, which aims to reflect the relative 
risk from the exposure to ionising radiation [161]. This quantity does not only account 
for the different organ doses, but also for the varying radiation susceptibilities of the 
organs and tissues within the body region that has been exposed to ionising radiation 
[156]. Effective dose (E) is calculated as the product of the dose equivalent calculated 
and its appropriate tissue weighting factor [162], as described in Equation 6.1: 
 
    TT HWE ⋅=         (6.1) 
 
where is WT the weighting factor for tissue (or organ) T, and is HT the calculated dose 
equivalent for tissue T (in milisieverts: mSv). The effective dose is expressed in SI unit 
of sieverts (Sv).  
 Tissue weighting factors (WT) represent the relative radiation sensitivity of each 
type of body tissue as determined from population averages over age and sex, and these 
values are derived from the atomic bomb survivors cohort [159, 160]. These weighting 
factors were initially defined by the ICRP in their publication no. 26 (ICRP 26), back in 
year 1977 [163], then were updated in ICRP 60 (1990) [164] and the most recent were 
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with ICRP 103 (2007) [165], as listed in Table 6.1. These revisions projected the 
advances in knowledge about radiation sensitivity of various organs and tissues [161]. 
The variations between the tissue weighting factors of these three reports are ranging 
from -83% to +140%, depends on the calculated tissue, and therefore, the calculation of 
effective doses may differ substantially depending on which ICRP publication is used 
[161]. 
 
Table 6.1: Tissue weighting factors (WT) from ICRP Publications 26, 60 and 103 [161]. 
Tissue or organ (WT) 
Publication  
ICRP 26 ICRP 60 ICRP 103 
Gonads 0.25 0.20 0.08 
Red bone marrow 0.12 0.12 0.12 
Lung  0.12 0.12 0.12 
Colon   0.12 0.12 
Stomach    0.12 0.12 
Breast  0.15 0.05 0.12 
Bladder   0.05 0.04 
Liver  0.05 0.04 
Esophagus   0.05 0.04 
Thyroid   0.03 0.05 0.04 
Skin    0.01 0.01 
Bone surface 0.03 0.01 0.01 
Brain    0.01 
Salivary glands   0.01 
Remainder organs  0.30 0.05 0.12 
Total; ∑ TW  1.00 1.00 1.00 
 
 
For each of the scanning components (PET and CT), the methods of estimating the 
absorbed radiation dose and/or the effective dose are different, and this will be 
explained further in the next few sections of this chapter.  
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6.1.1. PET radiation dose 
In nuclear medicine, the radiopharmaceutical that has been administered through either 
oral (absorption from the gastrointestinal tract) or intravenous injection, is non-
uniformly distributed within the body [36], and  its chemical structure will determine 
the organs in which the radiopharmaceutical is concentrated and excreted [36, 157]. 
Therefore, it is not an easy task to accurately measure the amount of radiation dose 
delivered by the radiopharmaceutical that has been distributed over a large area/volume. 
In fact, several factors could affect the calculation of the absorbed radiation dose from a 
nuclear medicine procedure such as the radiopharmaceutical used, the administered 
radioactivity, and the age and body weight of the patient [157]. In addition, for each 
organ/tissue, the absorbed radiation dose is determined by the administered radioactivity 
and the amount of radiopharmaceutical in the organ/tissue and nearby organs and/or 
tissues integrated over time [157].  
 
6.1.1.1. ICRP publications 
Since 1988, the Task Group of the ICRP had calculated the organ absorbed doses and 
effective doses of an adult, 15-, 10-, 5- and 1-year-old children, from a number of 
radioactive substances that were commonly used in nuclear medicine; ICRP 53 [166]. 
These data were then revised in ICRP 80 (1998) [167], and the most recent in ICRP 106 
(2008) [168]. Considering the fact that FDG is the most frequently used 
radiopharmaceutical in the clinical PET and/or PET/CT imaging, and all the scanning 
procedures of this research work have been conducted on adult patients, therefore the 
description of this section will only be focussing on the estimation of FDG PET dose for 
an adult patient.  
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 The dose coefficient values of various organs and the effective dose coefficient 
value for FDG (adult only) from three different ICRP publications (ICRP 53, ICRP 80 
and ICRP 106) are tabulated in Table 6.2. The absorbed radiation dose in organ or tissue 
T from FDG PET scan (DT); in miligrays (mGy), can be calculated according to 
Equation 6.2 [158, 169]:  
 
    
FDG
TT AD Γ⋅=       (6.2) 
 
where A is the administered radioactivity of FDG (in mega Becquerel: MBq) and FDGTΓ     
is the absorbed dose coefficient value for organ or tissue T (in mGy per MBq) that can 
be obtained from either one of the three ICRP publications; ICRP 53, ICRP 80 and 
ICRP 106. On the other hand, the effective dose (E); in mSv, resulting from an 
intravenous administration of the A radioactivity of FDG (in MBq) can be estimated 
using the following equation [169]: 
 
    T
T
T DWE ⋅=∑  
          
FDG
T
T
TWA Γ⋅⋅= ∑  
          
FDG
EA Γ⋅=        (6.3) 
 
  
where the total tissue weighting factors (∑WT) is equal to 1, as given in ICRP 26, 60 and 
103 (refer to Table 6.1), and FDGEΓ is the effective dose coefficient value for FDG which 
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has been expressed in mSv per MBq, and provided by ICRP 53 [166], 80 [167] and 106 
[168] (refer to Table 6.2).  
 
Table 6.2: The dose coefficient values of various organs and the effective dose coefficient 
value for FDG from ICRP Publications 53 [166], 80 [167] and 106  [168] (adult data only).  
Organ 
 
Absorbed dose per unit activity administered, FDGTΓ (mGy/MBq) 
ICRP 53 ICRP 80 ICRP 106 
Adrenals 0.0140 0.0120 0.0120 
Bladder 0.1700 0.1600 0.1300 
Bone surfaces 0.0100 0.0110 0.0110 
Brain 0.0260 0.0280 0.0380 
Breasts 0.0110 0.0086 0.0088 
Gallbladder  0.0120 0.0130 
Stomach 0.0120 0.0110 0.0110 
Small intestine 0.0130 0.0130 0.0120 
Colon  0.0130 0.0130 
Upper large intestine 0.0130 0.0120 0.0120 
Lower large intestine 0.0160 0.0150 0.0140 
Heart 0.0650 0.0620 0.0670 
Kidneys 0.0210 0.0210 0.0170 
Liver 0.0120 0.0110 0.0210 
Lungs 0.0110 0.0100 0.0200 
Muscles  0.0110 0.0100 
Esophagus  0.0110 0.0120 
Ovaries 0.0150 0.0150 0.0140 
Pancreas 0.0120 0.0120 0.0130 
Red marrow 0.0110 0.0110 0.0110 
Skin  0.0080 0.0078 
Spleen 0.0120 0.0110 0.0110 
Testes 0.0120 0.0120 0.0110 
Thymus  0.0110 0.0120 
Thyroid 0.0097 0.0100 0.0100 
Uterus 0.0200 0.0210 0.0180 
Remaining organs 0.0110 0.0110 0.0120 
Effective dose coefficient, 
FDG
EΓ  (mSv/MBq) 0.0270 0.0190 0.0190 
 
 
It is important to note that there are some variations in the organs absorbed dose 
coefficient values and the effective dose coefficient value of the three ICRP 
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publications. For instance, the absorbed dose coefficient values for gallbladder, colon, 
muscles, esophagus, skin and thymus were first listed as primary organs in ICRP 80. 
Furthermore, these coefficient values have changed over the time. As an example, the 
absorbed dose coefficient values of urinary bladder and lower large intestine decrease in 
each subsequent publication (ICRP 106), whereas for brain, the value is increased in all 
three ICRP publications. Besides, for breasts, heart, liver and lungs, the absorbed dose 
coefficient values have decreased in ICRP 80, but then increase in ICRP 106. However, 
only for red marrow, the absorbed dose coefficient value remains unchanged through all 
the publications. For the effective dose coefficient value, it is higher in ICRP 53 as 
compared to those of ICRP 80 and ICRP 106. As a consequence for all these changes, 
the estimation of the organ absorbed dose and the effective dose for the exact same PET 
scan can differ substantially depending on which ICRP publication is used.    
 
6.1.2. CT radiation dose 
Three different scanning protocols are commonly employed for the CT component of 
PET/CT imaging [36]: 
1. Diagnostic CT scan. 
2. CT scan for co-registration and localisation.  
3. CT for calculating the attenuation correction map. 
 
Each of these scanning protocols can differently affect the total effective dose of the 
PET/CT imaging [36].  
When PET/CT imaging is conducted with the whole body diagnostic CT 
protocol, the CT component will be the major contributor for the total absorbed 
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radiation dose [170]. The term ‘diagnostic’ means that the scan is usually carried out 
with the utilisation of intravenous and/or oral contrast media [27], also referred as 
contrast-enhanced CT (CECT) scan. In fact, this type of scanning technique requires 
higher tube current (mA) value in order to compensate for an increase in the tissue 
density, and therefore will result in the elevation of the absorbed radiation dose. 
However, when the CT is acquired on the basis of co-registration and localisation, the 
tube current can be reduced to about 35% from the tube current of diagnostic CT scan 
[36]. Furthermore, if the CT scan is only needed for measuring the attenuation 
correction map, the exposure factors (tube current and kVp) can be further decreased, 
which may then produce an effective dose as minimum as 3% of the effective dose from 
the diagnostic CT scan [36].  
 
6.1.2.1. Computed Tomography Dose Index (CTDI), Dose Length Product  
  (DLP) and the effective dose 
One of the most common and useful dosimetric quantities in CT scan is the computed 
tomography dose index (CTDI). This quantity is defined as the integral of the dose 
profile for a single-slice along a line parallel to the axis of rotation divided by the 
nominal slice thickness [171, 172], and it is measured from 14 contiguous sections 
[173]. 
   ∫−=
T
T
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                                (6.4) 
 
T represents the nominal slice thickness and D(z) is the dose distribution along a line 
parallel to the z-axis. This CTDI includes the radiation scattered into the neighbouring 
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volume of the slice [171]. To overcome the limitations of CTDI that related with the 
measurement from 14 contiguous sections, a more convenient radiation dose index was 
established by using a fixed integration interval of 100 mm for any thickness of T [171, 
173]. This newer radiation dose index was termed as CTDI100 (refer to Equation 6.5), 
and it can directly be measured using a pencil ionisation chamber with an active length 
of 100 mm [171, 173, 174].  
   ∫−=
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 In order to incorporate the absorption characteristics of a patient, CTDI is 
commonly measured on the acrylic cylindrical phantoms of having either 16 or 32 cm 
diameter to simulate the exposure of the head or body region [171, 173, 175]. These 
phantoms have holes (one at the centre and four at the peripheral) that allow for the 
insertion of the ionisation chamber with an active length of 100 mm [171, 174, 176]. 
With the assumption that dose in a CTDI phantom decreases in radial direction from 
surface to centre, the average CTDI in an irradiated slice from a single exposure can be 
calculated by using the weighted CTDI (CTDIw) [171, 174]; in mGy to air [174]:  
 
  pcw CTDICTDICTDI ,100,100 3
2
3
1 +=    (6.6) 
 
where CTDI100,c represents the measured CTDI at the central position and CTDI100, p is 
the average CTDI measured from four different periphery locations (east, west, south 
and north parts).  
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 With the advent technology in CT scanner, it has lead to the introduction of 
another CTDI, which is referred as volume CTDI (CTDIvol). This CTDIvol is an index 
that quantifies the intensity of radiation beam being produced by the CT scanner [177], 
and has been incident onto the patient [175]. This value represents the average absorbed 
radiation dose in the x, y, and z directions for a specific scanning protocol [178], and it 
is expressed in terms of air kerma, in mGy unit [177]. In helical/spiral CT, it can be 
defined as the weighted CTDI (CTDIw) divided by the pitch [178, 179], (Equation 6.7). 
 
   pitchCTDICTDI wvol =       (6.7) 
 
Pitch is equal to the table increment distance per x-ray tube rotation divided by the 
nominal beam width at the isocentre of the CT scanner [179].  
 On the other hand, to obtain a dose quantity that describes the radiation exposure 
for a full scan or a complete examination, another dose descriptor known as the dose 
length product (DLP) has been introduced [171]. DLP is defined as the product of the 
CTDIvol and the irradiated scan length (in cm) [161, 180], and expressed in mGy · cm 
unit (refer to Equation 6.8). It can be used to quantify the total amount of radiation 
received by a patient from a given CT examination [181]. 
 
   lengthscanCTDIDLP vol ⋅=     (6.8) 
 
 Both CTDI and DLP are the recommended dosimetric quantities that describe 
the CT dose and practice [171]. Indeed, these two values can directly be obtained from 
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the display screen of the operator console in the current commercial CT imaging system 
[156, 169, 182]. However, both of these values are actually meant to serve as an index 
of radiation dose due to the CT exposure only, and cannot be used as an accurate 
estimation of the radiation dose acquired by an individual patient [173]. Therefore, the 
radiation risk for a patient who has undergone CT examination can be estimated from 
the effective dose (E) [171].    
 For CT scan, the effective dose (E) can be calculated either by utilising the value 
of DLP or CTDIvol. According to the previous study by Christner et al. [161], and ICRP 
102 [178], the effective dose (E) is calculated based on the DLP value of a CT scan, as 
the following Equation 6.9: 
 
    DLPkE ⋅=        (6.9) 
 
where k coefficient is an empirical weighting factor, which is a function of the 
anatomical region scanned (expressed in mSv · mGy-1· cm-1 unit). This value can be 
obtained directly from ICRP 102 (2007) [178], as tabulated in table below.    
 
Table 6.3: The k coefficient values for adult and paediatric patients of various ages for 
various anatomical scanning regions [178]. 
Anatomical region k coefficient (mSv · mGy-1 · cm-1) 
0-year-old 1-year-old 5-year-old 10-year-old Adult 
Head 0.0110 0.0067 0.0040 0.0032 0.0021 
Neck 0.0170 0.0120 0.0110 0.0079 0.0059 
Head and neck 0.0130 0.0085 0.0057 0.0042 0.0031 
Chest 0.0390 0.0260 0.0180 0.0130 0.0140 
Abdomen and pelvis 0.0490 0.0300 0.0200 0.0150 0.0150 
Chest, abdomen and pelvis 
(trunk) 
0.0440 0.0280 0.0190 0.0140 0.0150 
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Although DLP of the CT scan can be used to estimate the effective dose (E), a 
recent study has found that this method could end with an underestimated dose value, as 
compared with the effective doses derived from the organs/tissues weighting factors of 
ICRP 60 and ICRP 103 (E60 and E103; the subscripts 60 and 103 represent the ICRP 
publication used) [161]. Based on this, it gives more constructive and academic reasons 
why in this study CTDIvol should be applied for estimating the effective dose (E), rather 
than using the DLP. In addition, a previous study by Brix, G. and his co-workers have 
established the dose coefficient value that relates CTDIvol with the CT effective dose 
( CTEΓ ), approximately 1.47 mSv/mGy [169]. This coefficient has been developed from 
the mean value of the measured absorbed doses from thirteen organs, which could 
represent the coefficient value of a whole body CT scan that extends from the thyroid to 
symphysis pubis [2, 156]. Therefore, the CT effective dose (E) can be estimated using 
the following [2, 156]:  
 
    vol
CT
E CTDIE ⋅Γ=    (6.10) 
 
 The absorbed radiation dose received by a patient from the CT examination is 
determined by various factors such as the inherent characteristics of the CT scanner, the 
size of the patient, the anatomical region scanned, and the scanning protocol and 
technique used [181]. To be more specific, for the last influence factor, it can be 
classified further into few scanning parameters like tube current-time product 
(miliampere-seconds: mAs), x-ray beam energy (peak kilovoltage: kVp), slice 
thickness, object thickness or attenuation, and pitch [173]. Among all these, mAs is the 
most important factor that corresponds to the number of x-ray photons in the defined 
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exposure time [181], and it has linear relation with the CT radiation dose [157, 181]. 
Therefore, for a given CT scanner, when all other scanning parameters are exclusively 
held constant, halving the mAs means halving the radiation dose [157, 181]. In addition, 
few recommendations have been documented in ICRP 87, for reducing the radiation 
dose to the patient during CT scan that can be applied by the user and the manufacturer 
[181], as listed in the Table 6.4. 
 
Table 6.4: The recommendations for patient dose reduction during CT scan [181]. 
Measures for the CT user Measures for the CT manufacturer 
? Checking the indication and limiting the 
scanned volume 
? Increasing the pre-filtration of the 
radiation spectrum 
? Adapting the scanning parameters to the 
patient cross-section  
? Attenuation-dependent tube current 
modulation 
? Pronounced reduction of mAs values for 
children 
? Low-dose scanning protocols for 
children and special indications 
? Use of spiral CT with pitch factors > 1 and 
calculation of overlapping images instead 
of acquiring overlapping single scans 
? Automatic exposure control (AEC) for 
conventional CT and spiral CT 
? Adequate selection of image reconstruction 
parameters 
? Noise-reducing image reconstruction 
procedures 
? Use of z-filtering with multi-slice CT 
systems 
? Further development of algorithm for z-
filtering and adaptive filtering 
 
 
6.2. FDG PET/CT dose estimation of Malaysian patients 
Of the Malaysian cohort, the dosimetric data of PET/CT scans were only acquired for 
twelve patients. This sample size was somewhat reduced due to the fact that our clinical 
imaging study was conducted by using the PET/CT facilities from the two private 
hospitals; Prince Court Medical Centre and Beacon International Specialist Centre, and 
later, all images were reviewed and evaluated on the workstation at our institution 
(Nuclear Imaging Centre, University Putra Malaysia). Although dual time point 
imaging (DTPI) technique had been successfully employed in thirteen Malaysian 
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patients, CTDIvol of the delayed CT scans were only obtained for eight patients. All 
these dosimetric data are tabulated in Table 6.5.  
 
Table 6.5: The dosimetric data and administered radioactivity of FDG for all sixteen 
Malaysian patients. 
Patient no. CTDIvol (mGy) FDG radioactivity (MBq) Unenhanced CT CECT Delayed CT 
1 3.05 10.18 3.14 592 
2 2.42 2.42 2.42 419 
3 2.08 6.40 2.20 277 
4 1.61 5.26 1.23 322 
5 5.40 5.40 n/a 337 
6 5.40 5.40 n/a 145 
7 n/a n/a – 382 
8 1.91 6.70 2.29 361 
9 n/a n/a n/a 383 
10 2.42 8.61 2.63 500 
11 1.99 6.70 1.65 368 
12 1.74 5.68 0.98 375 
13 n/a n/a n/a 346 
14 n/a − n/a 272 
15 1.65 5.68 − 354 
16 1.87 6.28 − 383 
CTDIvol, volume CT Dose Index; CECT, contrast-enhanced CT; n/a, not available; −, not 
done. 
 
 
 Owing to slight variations in the scanning parameters (patients 2, 5 and 6) and 
some missing data (patients 7, 9, 13 , 14, 15 and 16), the estimation of the effective dose 
from CT, PET and PET/CT scans could only be calculated for the other seven patients. 
In these dose estimations, the effective dose coefficient value for CT ( CTEΓ ) has been 
computed from the original data of the previous study by Brix et al. [169] together with 
slight modification on their data; by multiplying their organ-specific CT absorbed dose 
coefficient ( CTEΓ ) with the most recent tissue weighting factor published in the ICRP 
103 [165]. This goes the same for the effective dose coefficient value of FDG ( FDGEΓ ), 
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as it is acquired using the data from several studies [158, 169, 183], and again some 
modifications have been applied on these published data, through the utilisation of the 
tissue weighting factor from the ICRP 103 [165] and the organ absorbed dose 
coefficient of FDG from the ICRP 106  [168]. (All the modifications and calculations of 
the PET and CT effective doses are presented in Appendices 6 and 7). Based on this 
limited set of data, the statistical analyses were performed using the SPSS program for 
Windows version 18.0. All results were evaluated using a 5% error level and a 
difference was considered to be statistically significant when P < 0.05. 
 
6.2.1. Calculation results and analyses 
The means and standard deviations (SD) of all scans are presented in Table 6.6. In order 
to test for any differences among the four stand-alone imaging scans (unenhanced CT, 
CECT, delayed CT and PET), a one-way repeated measures ANOVA with the post-hoc 
Bonferroni test were performed on the mean effective doses of each scan. The 
multivariate approach to the analysis of within-subjects data was used. A significant 
difference was found among the four stand-alone imaging conditions (Wilks’ Lambda 
(Λ) = 0.024, F (3, 4) = 54.047, P = 0.001, η2 = 0.976). Post-hoc testing was carried out 
using pairwise comparisons of estimated marginal means with Bonferroni adjusted α 
levels. Significant differences at P < 0.05 were found for all six possible pairwise 
comparisons, except for the pair between unenhanced CT and delayed CT scans (refer 
to Fig. 6.1). There was no significant difference between the mean effective doses of the 
unenhanced CT and the delayed CT scans (P = 1.00).  
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Table 6.6: The effective doses of the stand-alone and the integrating PET/CT scans for the seven Malaysian patients. 
Patient no. 
Effective dose (mSv) 
Stand-alone scan Integrating PET/CT scan 
Unenhanced CT (A) CECT (B) Delayed CT (C) PET (D ) A + B + D A + B + C + D 
1 4.41 14.71 4.54 10.48 29.60 34.14 
3 3.01 9.25 3.18 4.90 17.16 20.34 
4 2.33 7.60 1.78 5.70 15.63 17.41 
8 2.76 9.68 3.31 6.39 18.83 22.14 
10 3.50 12.44 3.80 8.85 24.79 28.59 
11 2.88 9.68 2.38 6.51 19.07 21.46 
12 2.51 8.21 1.42 6.64 17.36 18.78 
Mean 3.06 10.22 2.92 7.07 20.35 23.27 
 ± SD 0.70 2.50 1.12 1.93 5.01 5.97 
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Figure 6.1: The mean differences in the effective doses of unenhanced CT, CECT, delayed 
CT and PET scans for the seven Malaysian patients. One-way repeated measures ANOVA 
results with a significant difference among the four stand-alone imaging conditions 
(Wilks’ Lambda (Λ) = 0.024, F (3, 4) = 54.047, P = 0.001, η2 = 0.976). In addition, post-host 
Bonferroni test has shown significant differences at P < 0.05 for all six possible pairwise 
comparisons, except for the pair between unenhanced CT and delayed CT scans (P = 
1.00). Error bars represent ± standard deviation.  
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 For the effective doses of the two integrated PET/CT scans (PET, unenhanced 
CT and CECT, and PET, unenhanced CT, CECT and delayed CT), a paired samples t-
test was used. There was a highly statistically significant difference between the means 
effective doses of both integrated scans (P < 0.001) (refer to Fig. 6.2). This result 
indicated that there was a significant increment on the effective dose when the delayed 
CT scan was conducted during the DTPI technique of FDG PET/CT scan. The mean 
additional effective dose that had been attributed from the delayed CT scan was 
approximately 2.91 ± 1.12 mSv.   
 In comparison, when PET is integrated with CECT scan only (B + D), the 
effective dose will be substantially reduced by more than one seventh of the total PET, 
unenhanced CT and CECT effective dose (17.29 ± 4.34 mSv vs. 20.35 ± 5.01 mSv). 
However, the combination of PET with unenhanced CT scans (A + D) may result in 
enormous dose reduction towards the total effective dose, which is approximately half 
of that from PET, unenhanced CT and CECT scans (10.12 ± 2.56 mSv vs. 20.35 ± 5.01 
mSv). Therefore, it has been strongly believed that both scanning methods 
(PET/unenhanced CT and PET/CECT) could potentially offer some benefits especially 
when radiation dose is the major concern.   
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Figure 6.2: The mean difference in the effective doses of the two integrated scanning 
acquisitions (PET + unenhanced CT + CECT and PET + unenhanced CT + CECT + 
delayed CT) for the seven Malaysian patients. A two-tailed paired samples t-test results 
with a high significant difference with P value of less than 0.001 (*). Error bars represent ± 
standard deviation.  
 
 
 
 
 
 
 
 
 
 180
6.2.2. Discussion 
Our results demonstrate that CT examinations are the major contributor towards the 
total effective dose of PET/CT imaging, which corresponds to approximately 65%. 
However, when a delayed CT scan is performed, the attributed percentage is then 
increased to as high as 76% of the total effective dose: PET + unenhanced CT + CECT 
+ delayed CT. This finding is in concordance with a recent retrospective study by 
Chawla, S. C. and her colleagues [184]. Furthermore, they have specifically mentioned 
that the diagnostic CT scan with the utilisation of intravenous contrast media is a 
standard of practice for the PET/CT imaging at their institution, which is the same as in 
the clinical trial of this research. Indeed, their PET/CT imaging system (Biograph 
PET/CT, Siemens Healthcare Solutions) and the CT scanning parameters (especially the 
mAs, kVp and scanning coverage area) are also similar to this study, and thus, the data 
are comparable. In another study, Huang et al. [158] reported a range of the whole body 
PET/CT effective dose was from 13.45 mSv to 32.18 mSv, depending on the CT 
protocol used and the gender of the patient. Correspondingly, up to 81% of the total 
PET/CT effective dose were attributable to the CT doses [158].  
 In this study, the injected amount of FDG radioactivity was derived from 
patient’s body weight. For all sixteen Malaysian patients, the injected radioactivity was 
about 6.11 MBq/kg (refer to Table 6.5). This amount is larger than the value used in a 
recent PET/CT dosimetric study by Khamwan et al. [183], although the physical 
characteristics (body weight and height) of these patients are generally about the same 
with the patients from its neighbouring country (Thailand). Therefore, it is expected that 
all PET scans of this study could result in the higher effective doses. However, when 
comparing the total PET/CT effective dose of each patient with those of Thai patients, it 
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has shown a very good agreement (exclude patient 1, as she has received the largest 
amount of injected radioactivity of FDG; 592 MBq, because of a high body weight, 
approximately 94 kg), even if two CT examinations (unenhanced CT and CECT) are 
performed during the image acquisitions. This is mainly due to the utilisation of lower 
mAs value (30 mAs for unenhanced CT and 100 mAs for CECT) during all the CT 
scans of this study; mAs is one of the main parameters that controls the CT radiation 
dose [181].  
 The mean PET/CT effective dose of this limited number of Malaysian patients is 
also in accordance with the findings of two previous studies [169, 184]. Although by 
performing the delayed CT scan has resulted with a significant increment in the total 
PET/CT effective dose, the mean effective dose of this special scanning protocol is still 
within their reported effective dose range; about 25 mSv. Indeed, it is relatively less 
than the mean effective dose from the protocol C of the Huang’s study [158]; 31.91 and 
32.18 mSv for female and male patients, respectively. Therefore, it has been believed 
that the addition radiation dose caused by the delayed CT scan is not a major issue, and 
this DTPI technique can perhaps be applied as a standard protocol, especially if it helps 
in enhancing the diagnostic accuracy of PET/CT imaging.    
 In order to better estimate the effective dose of PET scan, the calculation should 
be computed using a specialised software called OLINDA [185]. This software has been 
developed by a research group from the Vanderbilt University, Tennessee, and it is 
commonly used to estimate the internal radiation dose from the administration of 
radionuclide in nuclear medicine. In contrast, for the CT effective dose, several 
softwares are currently available in the market such as ImPACT, CT Dose, CT-Expo 
and ImpactDose. Owing to no access of such softwares, therefore, the PET/CT effective 
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dose of this study was only derived from the calculation methods by utilising the 
available dosimetric descriptors; CTDIvol and administered radioactivity of FDG.    
 
6.2.3. Conclusion 
The mean effective dose arising from FDG PET/CT scans in the seven Malaysian 
patients of this study is in accordance with the previously reported values (less than 25 
mSv), even though DTPI technique has been utilised during the imaging acquisitions. 
CT scans are found to be the major contributor for the total PET/CT effective dose, and 
therefore, if some modifications have been carried out on the CT scanning parameters, 
this approach may extensively reduce the total PET/CT effective dose.   
 
 
6.3. The dosimetric experiments to partially validate the clinical data 
As mentioned earlier, this dosimetric study also consists of multiple experimental 
attempts‡ for quantifying the amount of the radiation dose arising from FDG PET/CT 
scan. In order to clearly describe all steps and procedures used in conducting of these 
experiments, this section is divided into two different categories: 
1. FDG PET/CT irradiation 
2. Constructing and plotting the dose response curves  
 
 
 
                                                
‡ The term attempt is used to indicate that a full dosimetric study for an accurate measurement 
of the radiation dose delivered by FDG PET/CT to an organ or the whole body is not done in 
this thesis. To do that, a comprehensive dosimetric investigation and validation is required, 
which is beyond the aims of this thesis. 
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6.3.1. FDG PET/CT irradiation 
In this study, an anthropomorphic phantom (the same as in Chapter 5) was used. A 
small piece of XRCT and XRQA gafchromic films was sticked onto the outer surface of 
the phantom, for measuring the radiation dose delivered by the CT component of 
PET/CT imaging (refer to Fig. 6.3). These two types of films are the most sensitive 
radiochromic films that currently available in the market, which can detect the absorbed 
radiation dose as low as 0.1 mGy [186]. Furthermore, a syringe that contained an 
amount of FDG radioactivity (1 GBq) was tapped inside the phantom, and three 
dosimeters (XRCT and XRQA films, and PRESAGE§) were deployed as close as 
possible to the syringe. Then, a CT scan was performed by using the same exposure 
parameters as for the low-dose CT of FDG PET/CT imaging (140 kVp, 30 mAs, slice 
thickness of 5 mm, pitch factor of 1.0 and gantry rotation speed of 1.0 s) on Philips 
Gemini Dual PET/CT system. Immediately after completing the CT scan, those two 
outer films (XRCT and XRQA) were removed, but the remaining three dosimeters 
(inside the phantom) were kept the same for the next 24 hours. All these irradiations 
were conducted at the Nuclear Medicine Department of The Alfred Hospital, 
Melbourne, Australia. 
 
                                                
§ PRESAGE is a dosimeter made of polyurethane matrix, which is suitable for 3-D dosimetry. 
In this study, PRESAGE was bought from Heuris Pharma LLC, Skillman, New Jersey, USA. 
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Figure 6.3: The set-up for FDG PET/CT irradiation of the anthropomorphic phantom, 
where three dosimetry methods (Gafchromic XRCT and XRQA films, and PRESAGE) 
have been utilised.  
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6.3.2. The dose response curves 
PET/CT imaging system consists of two dedicated scanners that operate with two 
different types of energies; polychromatic x-ray at mean photon energy of 70 keV and 
monochromatic gamma radiation with 511 keV energy level [3, 187]. Thus, the dose 
response curve for each of these electromagnetic waves (x-ray and gamma radiation) 
needs to be constructed and plotted separately. The description on the methods used for 
constructing and plotting the dose response curves of x-ray will be first presented and 
then followed by those for gamma radiation.  
 
6.3.2.1. The x-ray dose response curves 
With the aim of covering a wide range of energy, this section can be divided into two, 
according to the method of irradiations:  
1. Irradiations with CT machine at an energy range of 80 – 140 kVp. 
2. Irradiations with a superficial x-ray radiotherapy (SXRT) machine at 150 kVp 
energy level. 
 
6.3.2.1.1. CT irradiations 
Both gafchromic XRQA and XRCT films are suitable to be used for CT dose 
assessment, as stated in the literature [186, 188-190]. Because of this reason, these two 
films were selected in this study. In order to obtain a free-in-air condition, the films 
were tapped at the end of PET/CT table, in which the table was then raised to its 
isocentric level. The long axis of both films was placed perpendicular to the CT x-ray 
beam (refer to Fig. 6.4). A total of sixteen irradiations with different exposure factors 
(as listed in Table 6.7) were carried out by using only the CT component of the same 
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PET/CT imaging system (Philips Gemini Dual). Then, CTDIvol of each irradiation was 
recorded accordingly.   
 
 
Figure 6.4: The set-up for CT irradiation of gafchromic XRCT and XRQA films with the 
CT scanner of PET/CT imaging system.  
 
Table 6.7: The exposure factors (kVp and mAs) of all sixteen CT irradiations that have 
been carried out for constructing and plotting the dose response curves of gafchromic 
XRCT and XRQA films at various CT energies (80 kVp – 140 kVp).  
Irradiation 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
kVp 80 80 80 80 100 100 100 100 120 120 120 120 140 140 140 140
mAs 170 340 600 760 170 340 600 760 170 340 600 760 170 340 600 760
 
 
6.3.2.1.2. SXRT irradiations 
This dosimetric experiment was performed after completing the analyses of all films 
from CT irradiations. Based on the results obtained (which will be described later), only 
gafchromic XRCT film was used. The irradiations of XRCT films using SXRT machine 
(Therapax 3 Series, Pantak Inc., Branford, CT, U.S.A.) were carried out at William 
Buckland Radiotherapy Centre (The Alfred Hospital, Melbourne, Australia). This 
SXRT machine has a dose rate of about 1.00 Gy/min. In this study, all XRCT film 
pieces were irradiated to the various low radiation doses (0.5, 1.0, 5.0 and 20.0 mGy) 
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with 150 kVp (1.0 mm Cu HVL) x-ray energy using a 15 cm diameter collimator at 87 
cm distance between the x-ray tube and the films (refer to Fig. 6.5). These dose values 
were believed to produce an adequate degree of film blackening for the tested x-ray 
beam energy, and in fact, the highest dose of 20.0 mGy was within the range for the 
mean calculated whole body FDG PET/CT effective dose of the seven Malaysian 
patients (refer to Table 6.6); there is no difference between the absorbed dose and the 
effective dose for gamma and x rays (1 mGy ≈ 1 mSv) [191].  
 
 
Figure 6.5: The set-up for gafchromic XRCT films irradiations with the SXRT machine, 
where the source to film distance is kept at approximately 87 cm. All irradiations are 
performed at 150 kVp x-ray energy with a 15 cm diameter collimator.   
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6.3.2.2.  The gamma radiation dose response curves 
In developing the dose response curves of gamma radiation, again, only XRCT type of 
film was utilised. The films were exposed to two different sources of gamma radiation:  
1. Technetium-99m (Tc-99m).  
2. Flourine-18 (F-18).  
 
6.3.2.2.1. Technetium-99m irradiations 
For the irradiations with Tc-99m radioisotope (gamma ray energy of about 140.5 keV), 
a cylinder container with peripheral rods was used (refer to Fig. 6.6). A syringe which 
contained 15 GBq radioactivity of Tc-99m was inserted and placed at the centre of the 
container. Then, three pieces of XRCT films were stuck onto the three peripheral rods, 
where the distance of the films to the radiation source was about 5 cm. The amount of 
absorbed radiation dose was measured by using a compact ionisation chamber (CC13, 
Wellhöfer) that had been connected to a multichannel dosimeter. The distance between 
this ionisation chamber and the radiation source was also kept at approximately 5 cm. 
The films were irradiated for 30, 60 and 90 min, and the count charge of each irradiation 
was recorded. In addition, to accurately quantify the absorbed radiation dose, the level 
of background radiation was measured for all three irradiated time. By this, the net 
absorbed dose of all irradiations could be calculated. 
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Figure 6.6: The set-up for gafchromic XRCT films irradiations with Technetium-99m; Tc-
99m (gamma energy of 140.5 keV). The irradiations have been performed for 30, 60 and 
90 min.  
 
 
6.3.2.2.2. Flourine-18 irradiations 
By utilising the same methods as in Tc-99m irradiations, XRCT films had also been 
exposed to a higher gamma energy of 511 keV produced by F-18. However, for this 
experiment, only 1.9 GBq radioactivity of F-18 was used (refer to Fig. 6.7). The 
variation between the measured radioactivity of the two isotopes used was due to a 
couple of different factors, most importantly the very large difference in their half-lives. 
The F-18 which was produced off-site and delivered very early in the morning has a 
half life of 109 minutes. The Tc-99m on the other hand was milked from a generator on-
site just prior to being used and has a much longer half -life of 6 hours. In addition, all 
the experiments were performed after the completion of the daily clinical works, by 
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which the initial activity of the delivered F-18 had decayed significantly. Both of these 
are acknowledged to be the limiting factors of this dosimetric study.  
 
For radiation protection and safety reasons, both Tc-99m and F-18 irradiations were 
conducted in the brachytherapy room at William Buckland Radiotherapy Centre, The 
Alfred Hospital, Australia.  
 
 
Figure 6.7: The set-up for gafchromic XRCT films irradiations with Flourine-18; F-18, 
solution (gamma energy of 511 keV). The irradiations have been performed for 30, 60 and 
90 min.  
 
 
6.3.3. The dosimetric results and analyses 
All gafchromic XRCT and XRQA films were scanned using an Epson Perfection V700 
photo flatbed scanner (Seiko Epson Corporation, Nagano, Japan) at least 24 hours after 
the irradiations; to minimise the effects from post irradiation colouration [192, 193], 
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with 24-bit colour red, green, blue (RGB) mode in reflective format without any filters 
and image enhancement options. The images of 600 dpi resolution were saved as 
uncompressed tagged image file (tif) format, which then were analysed using ImageJ 
software (version 1.37) with RGB split and red colour 33.3% technique. The red 
channel values were selected for the image analyses of this study because the main 
absorption peak of these films (after the irradiation) had been found to be at 636 nm, 
which was the same as in the red region of the visible light spectrum [189, 194]. By 
subtracting the mean gray value of an unirradiated film with those of the irradiated 
films, the net gray values for all the exposed films were obtained. From these data, the 
dose response curve of the gafchromic films from each irradiation was then plotted.  
 
6.3.3.1. FDG PET/CT irradiation 
In quantifying the amount of radiation dose delivered by the CT component of PET/CT 
imaging, both gafchromic XRCT and XRQA films had demonstrated slight colour 
changes with the mean net gray values of 12.04 and 8.16, respectively (refer to Fig. 
6.8). On the other hand, with 24 hours irradiation to 1 GBq radioactivity of F-18, an 
obvious colour change was detected on these two XRCT and XRQA films, in which the 
mean net gray values were approximately 156 and 155 (refer to Fig. 6.9). These results 
clearly indicate that both XRCT and XRQA films are suitable to be applied for dose 
measurement in CT and FDG PET/CT scans. 
 In contrast, no radiochromic colour change was observed on PRESAGE. This 
finding was not unexpected because PRESAGE was commonly used in measuring a 
high radiation dose (of the order of 1 Gy or more), particularly for radiotherapy [195-
197].  
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Figure 6.8: Gafchromic XRQA and XRCT films at 24 hours after irradiation to the CT 
component of PET/CT imaging. The mean net gray values of both films are 8.16 and 
12.04, respectively. The blue boxes represent the area of determining the gray value from the 
irradiated CT slices. For an accurate measurement of the absorbed dose on XRCT film, the 
position of all boxes is kept away from the black metric scale, as it could affect the gray value 
reading.   
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Figure 6.9: Gafchromic XRQA and XRCT films at 24 hours after irradiation to 1 GBq 
radioactivity of FDG and the CT component of PET/CT imaging. The mean net gray 
values of both films are 155.18 and 159.93, respectively. The blue boxes represent the area 
of determining the gray value from the irradiated films. For an accurate measurement of the 
absorbed dose on XRCT film, the position of all boxes is kept away from the black metric 
scale, as it could affect the gray value reading.   
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6.3.3.2. The dose response curves 
6.3.3.2.1. The x-ray dose response curves 
All the exposed gafchromic XRCT and XRQA films of the sixteen CT irradiations are 
shown in Figures 6.10 and 6.11. In addition, the CTDIvol of all CT irradiations are listed 
in Table 6.8. Based on these data, the dose response curves for both XRCT and XRQA 
films were plotted against the recorded CTDIvol of each energy level. Interestingly, 
across all the tested energy levels (80 – 140 kVp), gafchromic XRCT film had 
demonstrated a slightly higher in the sensitivity for detecting the absorbed radiation 
dose than those of XRQA film (refer to Fig. 6.12). Therefore, for the subsequent 
irradiations (SXRT, Tc-99m and F-18), only XRCT film was used.   
 
 
Figure 6.10: Gafchromic XRCT films at 24 hours after CT irradiations with various 
exposure factors (kVp and mAs). The blue boxes represent the area of determining the gray 
value from the irradiated CT slices. 
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Figure 6.11: Gafchromic XRQA films at 24 hours after CT irradiations with various 
exposure factors (kVp and mAs). The blue boxes represent the area of determining the gray 
value from the irradiated CT slices. 
 
 
Table 6.8: The CTDIvol of all sixteen CT irradiations. 
Irradiation CTDIvol (mGy)
1 6.68 
2 13.36 
3 23.57 
4 33.19 
5 12.60 
6 25.21 
7 49.44 
8 62.62 
9 20.51 
10 41.02
11 80.44 
12 101.89 
13 29.21 
14 58.42 
15 114.56 
16 145.11
 
 
 
 196
 
Figure 6.12: Dose response curves of gafchromic XRCT and XRQA films at 100 kVp CT 
energy. Both curves fit with second order polynomial trend lines. This result shows that 
XRCT film has a slightly higher sensitivity in detecting the absorbed radiation dose than 
XRQA film. Error bars represent ± standard deviation.  
 
 
For the irradiations with SXRT machine, a noticeable colour change can be seen 
after the films were exposed to 20.0 mGy dose (Fig. 6.13). The dose response curve of 
this dosimetric experiment was again well fitted with second order polynomial trend 
line (Fig. 6.14). 
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Figure 6.13: Gafchromic XRCT films at 24 hours after the irradiations with SXRT 
machine at 150 kVp energy level. A noticeable colour change can be seen at 20.0 mGy 
dose. The blue boxes represent the area of determining the gray value from the irradiated 
films. 
 
 
 
 
 
 198
 
Figure 6.14: The dose response curve of XRCT film with the irradiations of SXRT 
machine at 150 kVp energy level. The curve fits with second order polynomial trend line. 
Error bars represent ± standard deviation.  
 
 
6.3.3.2.2. The gamma radiation dose response curves 
XRCT film was changed in its colour at 60 min irradiation time to 15 GBq radioactivity 
of Tc-99m (Fig. 6.15). On the contrary, none of these films displayed visible colour 
changes after the exposures to 1.9 GBq radioactivity of F-18, even with 90 min 
irradiation time (Fig. 6.16). This was due to a vast variation in the radioactivity of both 
isotopes. However, the dose response curves of the two different irradiations (Tc-99m 
and F-18) were well fitted with second order polynomial trend lines (Fig. 6.17 and 
6.18). These results may indicate that gafchromic XRCT is an appropriate type of 
radiochromic film for being utilised in estimating the radiation doses arising from 
different gamma energy levels, but, the dose response curve of each energy needs to be 
obtained [190].     
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Figure 6.15: Gafchromic XRCT films at 24 hours after the irradiations with 15 GBq 
radioactivity of Tc-99m (140.5 keV). A noticeable colour change can be seen at 60 min 
irradiation time. The blue boxes represent the area of determining the gray value from the 
irradiated films. 
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Figure 6.16: Gafchromic XRCT films at 24 hours after the irradiations with 1.9 GBq 
radioactivity of FDG (511 keV). Of these three different irradiation times, none of the 
films are found to have a visible colour change. The blue boxes represent the area of 
determining the gray value from the irradiated films. 
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Figure 6.17: The dose response curve of XRCT film at Tc-99m gamma energy level (140.5 
keV). The curve fits with second order polynomial trend line. Error bars represent ± 
standard deviation.  
 
 
 
 
Figure 6.18: The dose response curve of XRCT film at F-18 gamma energy the level (511 
keV). The curve fits with second order polynomial trend line. Error bars represent ± 
standard deviation.  
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6.3.4. Discussion 
Gafchromic XRCT and XRQA films are commonly and routinely utilised in the dose 
assessments of CT scan and diagnostic radiology [186, 194]. Indeed, both of these films 
consist of the same active and radiation-sensitive materials [194]. However, the results 
from CT irradiations of this dosimetric study showed, across the tested energy range (80 
– 140 kVp), XRCT film was slightly more sensitive in recording and detecting the 
absorbed radiation dose as compared with XRQA film. Thus, in constructing the dose 
response curves of the later irradiations (SXRT and gamma radiation), only XRCT film 
was used.   
 In the irradiations with SXRT machine, the absorbed radiation doses were 
ranging from 0.5 mGy to 20.0 mGy. Although these values seem to be quite minimal, 
the manufacturer has stated that gafchromic XRCT film can be used to measure the 
absorbed dose as low as 0.1 mGy [186]. Thus, XRCT film is capable to detect the lower 
absorbed radiation doses of these dosimetric experiments. On the other hand, when 
comparing the dose response curves of Tc-99m with F-18 (both radiopharmaceuticals 
emit gamma radiation), at the higher energy levels, more doses were required to 
produce an equivalent degree of film blackening. This finding is in accordance with the 
previous study by Butson et al. [186], even though all their XRCT films have been 
irradiated with an x-ray beam. Therefore, it is clear that gafchromic XRCT film is 
sensitive and suitable to be applied for quantifying the low absorbed radiation dose that 
has been delivered either by x or gamma ray.  
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6.3.5. Conclusion 
Although accurate dose quantification for the whole body FDG PET/CT imaging has 
not been achieved throughout these experimental attempts, the results show that 
gafchromic XRCT film could potentially be used for measuring the absorbed radiation 
dose of FDG PET/CT scan. Therefore, the findings of this preliminary study have 
opened a new window for two-dimensional (2-D) dose measurement in FDG PET/CT 
imaging, particularly by using the radiologic type of gafchromic film. 
 
 
6.4. Recommendations for reducing the FDG PET/CT radiation dose 
Several studies have recommended few techniques or strategies in managing the 
PET/CT radiation dose to the patient [36, 156, 157, 183, 184, 187]. These techniques 
are classified according to the scanning component; FDG PET and CT scans.  
 
6.4.1. FDG PET scan 
Radiation dose to patients, whom have been intravenously administered with FDG, is 
directly proportional to the injected radioactivity [156, 187]. Thus, by reducing the 
amount of injected radioactivity of FDG, the radiation dose can effectively be reduced. 
In addition, some studies have proposed a lower FDG administered radioactivity of 5.2 
MBq/kg, particularly when performing PET/CT imaging to a pediatric patient [36, 198-
200]. In this case, if a lower FDG administered radioactivity (5.2 MBq/kg) is used 
during the clinical trial of this research, the PET effective dose of each patient could be 
further reduced up to 15%.   
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 On the other hand, to compensate with the lower administered radioactivity of 
FDG and obtain a good quality PET emission image (with adequate count density), the 
imaging time per bed position may need to be increased [36, 156, 187]. 
Correspondingly, Gelfrand, M. J. [36] has reported that imaging time of 5 min per bed 
position is sufficient to be applied during PET/CT scan. However, when the per bed 
position imaging time is increased, it means that a longer total scanning time is required 
to perform a complete whole body PET/CT scan [156, 187]. This can result in patient 
discomfort, which then may cause a motion-induced misregistration artifact in the 
corresponding PET and/or CT images [156, 187]. Therefore, there should be a balance 
between the amount of administered radioactivity of FDG and the selected imaging time 
per bed position.  
 Another technique that can be employed for reducing the radiation dose from 
PET scan is by conducting the PET image acquisition in three-dimensional (3-D) mode 
[36, 157]. This 3-D acquisition mode enhances the sensitivity of the PET scanner as 
compared with 2-D mode [36, 157]. For this reason, PET emission scans of all patients 
from both populations (Malaysia and Italy) were carried out using 3-D acquisition 
mode, as described in the Chapter 3.  
 Apart from all of the above techniques, frequent voiding during uptake phase 
and after the scan is also a very effective measure to reduce the radiation dose in PET 
imaging [156, 187]. It can be achieved either by a good oral hydration or the 
administration of a diuretic drug like furosemide [146] (this method has been applied in 
all sixteen Malaysian patients during their preparation time, as mentioned in the Chapter 
3). The rational for this approach is mainly based on fact that FDG is finally 
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accumulated in the urinary bladder, and this can be a major source of internal exposure 
to the bladder itself as well as to its neighbouring organs [169].    
 
6.4.2. CT scan 
As highlighted in section 6.3 of this chapter, there are three different scanning protocols 
that are commonly conducted during the CT scan of PET/CT imaging: diagnostic 
contrast-enhanced CT, co-registration and anatomical localisation CT, and CT for the 
attenuation correction mapping only. Each of these protocols results with a significant 
variation in the total PET/CT effective dose [36]. Thus, by properly knowing the main 
purpose of the CT scan before commencing PET/CT imaging, it could be very 
beneficial to the patient in terms of reducing the radiation dose. This fact augments the 
need for fully trained radiation technologist, which could facilitate him/her to choose 
the best approach to be employed during the scanning [178, 181].  
 Tube current modulation (generally known as Automatic Exposure Control; 
AEC) technique is one of the most effective methods for managing the radiation dose of 
the CT scan [201, 202]. This technique can considerably reduce the radiation dose to the 
patient in multi detector CT (MDCT) scan, without affecting the image quality [202]. 
However, it should be noted that the tube current modulation technique was not applied 
in the entire CT examinations of PET/CT imaging for both Malaysian and Italian 
patients (as mentioned in Chapter 3). Furthermore, the CT scanning parameters like 
mA, time per rotation, mAs, kVp, pitch value and slice thickness can significantly affect 
the CT effective dose [157]. The relationship between each of these parameters with the 
CT effective dose has been concisely addressed in the previous study by Gelfand, M. J. 
and Lemen, L. C. [157]. Nevertheless, out of all the parameters, mA and mAs are the 
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key elements [181], in which it is widely accepted that by decreasing these two values 
the CT radiation dose can be substantially reduced [184], as both of them have linear 
relation to the CT absorbed radiation dose [157].   
 The mAs reduction technique was exclusively applied during the CT scans of 
the three Malaysian patients; patients 2, 5 and 6 (as highlighted in section 6.4.1). For 
patient 2, the mAs value of 30 had been used during both of his CT scans (unenhanced 
CT and CECT), while 50 mAs was employed for patients 5 and 6. Based on the CT 
images of these three patients, 50 mAs was found to be sufficient for CECT scan; this 
lower mAs value produces the same diagnostic image quality with good organ 
enhancement as in 100 mAs (as shown in Fig. 6.19d). By halving the mAs value, the 
CT radiation dose has also been reduced by half, which is highly beneficial for the 
patient especially in regards to pediatric patients. However, if the mAs value was further 
reduced to 30 (as in patient 2), the image quality of the CECT images had been 
degradated significantly, due to the greater noise content [157] (Fig. 6.19f). Therefore, 
based on these findings, it could be suggested that 30 mAs is suitable to be used during 
the low dose CT protocol or unenhanced CT scan (as in the case of CT for anatomical 
localisation and co-registration images). In addition, if CT scan is performed for the 
diagnostic purposes (CECT), the selection of 50 mAs is seemed to be a better approach 
rather than using the higher mAs value. 
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                       Unenhanced CT                                           CECT 
                                    
Note: The numbers in parentheses represent the mAs values that have been used during the 
unenhanced CT and CECT scans, respectively.  
 
Figure 6.19: Example of the unenhanced CT (a, c & e) and CECT (b, d & f) images from 
patients 1, 5 and 2 of the Malaysian patients. The mAs value of 30 seems more appropriate 
to be used during unenhanced CT, as compared to 50 mAs (a & e vs. c). In CECT scans, 
although the mAs has been reduced by half (from 100 to 50 mAs), there is no different in 
the image quality of both images (b & d), where the later image can still demonstrate a 
good organs enhancement (d). However, if the mAs is further reduced to 30, the image 
quality has been extensively decreased; by less evident of organs enhancement and greater 
noise content (f).  
 
 
 Patient 1 
    (30, 100) 
Patient 5 
    (50, 50) 
Patient 2 
    (30, 30) 
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CHAPTER 7 
 
CONCLUSIONS  
AND  
FUTURE DIRECTIONS  
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This research has encompassed three distinct studies; starting with the clinical trial, 
followed by a phantom study and the dosimetric study. Based on all findings of this 
research work, the following conclusions have been reached. These in turn have also 
given rise to possible future research directions.  
 
7.1. Conclusions 
 
‘FDG PET/CT imaging can clearly detect EPTB lesion’ 
 
This research thesis comprises novel and original work based on innovative scanning 
techniques of using an integrated PET/CT imaging system in detecting EPTB lesions. 
The major findings of this thesis are: 
 
? All the detected EPTB lesions from both populations of the patients (Malaysia 
and Italy) in this study can clearly be depicted on the FDG PET/CT fusion 
images, with the high SUVmax1 values; ranging from 2.8 to 20.8. However, the 
utilisation of SUVmax1 value (from initial whole body FDG PET/CT scan) 
alone seems to be an impractical for the image analysis method in differentiating 
between EPTB and non-EPTB lesions. Thus, in standard clinical practice, the 
FDG PET/CT imaging finding still needs to be compared with the results of the 
other radiological examinations. 
 
? Iodine-based contrast media can safely be applied during FDG PET/CT imaging 
of EPTB patient, in which it will not significantly and clinically affect the 
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SUVmax values of the fused images. This patients’ finding has also been 
augmented with the results of the anthropomorphic phantom study, where no 
statistical differences are found on the SUVmax and SUVmean values of the 
simulated tissues (liver, blood vessels and spinal lesion).   
 
? DTPI technique of FDG PET/CT scan may not be an effective scanning 
procedure for distinguishing EPTB from other infectious lesions. However, 
based on the results of follow-up FDG PET/CT scan in the six Malaysian EPTB 
patients, this technique could help the physician for determining the activity 
status of EPTB lesion. This interesting imaging finding warrants further 
investigation in larger cohort of patients who have completed the six months 
anti-TB treatment.   
 
? The mean effective dose arising from FDG PET/CT scans of this study is in 
accordance with the previously reported values (< 25 mSv), even though DTPI 
technique has been performed during the imaging acquisitions. In addition, 50 
mAs value could be an optimal tube current-time product for FDG PET/CT 
imaging when contrast-enhanced CT (CECT) scan is required. By using this 
mAs value, the amount of CT radiation dose can be reduced by half as compared 
with the higher value (100 mAs), and at the same time maintains the same 
diagnostic CT image quality.  
 
? From dose assessment perspective, gafchromic XRCT film has a potential to be 
applied for quantifying the absorbed radiation dose arising from FDG PET/CT 
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imaging in two-dimensional (2-D). However, more comprehensive experiments 
need to be conducted in order to solve the uncertainties of utilising a 2-D dose 
measurement for estimating the whole body radiation dose. This issue is opened 
for future studies in the radiation dose measurement of FDG PET/CT imaging.     
 
 In conclusion, this research has shown that a comprehensive assessment of 
EPTB infectious disease might be obtained by supplementing the anatomical 
manifestations of the lesions seen on CT images with the functional characteristics 
provided by the PET images, which results in a multi-dimensional multi-modality 
evaluation. The findings of this thesis could offer a significant change in the diagnostic 
algorithm of EPTB infection, in which it appears that, the improvement in detecting and 
determining the extension of EPTB lesions has been achieved. These observations, 
taken together, provide the beginnings of a suitable body of evidence upon which a 
physician can make a clinical decision on whether the use of FDG PET/CT imaging is 
indicated for the detection of EPTB lesions. 
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7.2. Future directions 
Two studies that could possibly be performed in order to complement and verify the 
results of this research include:  
 
1. A prospective study of using a dynamic scanning protocol during FDG PET/CT 
imaging of EPTB patients. The result of this study would give a detailed 
assessment and better understanding on the FDG accumulating process of EPTB 
lesion.  
 
2. The application of other radiopharmaceutical, such as FDG-labelled white blood 
cells (FDG-WBC) for detecting EPTB lesions. FDG-WBC has been previously 
reported to have a high sensitivity and specificity in the detection of infectious 
lesion. Thus, by conducting this study, it could enhance the capability and 
feasibility of using PET/CT imaging in identifying and localising EPTB lesions. 
This study may also provide an alternative radiotracer for the imaging diagnosis 
of EPTB infectious disease.  
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Subject Information Sheet 
 
You are being selected to participate in this research project on ‘18F FDG PET CT 
evaluation in mycobacterium tuberculosis extra pulmonary infection’ 
 
Purpose 
The purpose of this research project is to   document all findings of 
EXTRAPULMONARY Mycobacterium Tuberculosis infection, using 18F-FDG PET- 
CT modality. 
 
Procedures involve 
Within these research activities, you will be subjected to PET CT examination with 18F 
FDG injection. There will be two occasions where this examination takes part. The first 
examination takes place during ‘early check point’ for the purpose of diagnosis. This will 
be followed by a prolonged period of treatment using Direct Observation Treatment 
Scheme DOTS for over an interval of 6 months. After completion of treatment with 
antituberculous drugs, you will have to undergo another round of PET CT examination to 
observe the treatment responsiveness and to observe any residual changes. 
 
Your responsibilities 
Your responsibility is to cooperate with our team of doctors. 
 
You are required to be fasting for at least 6 hours prior to all above mentioned 
procedures. 
 
During the imaging procedure, we require your full cooperation to ensure good optimum 
quality of images to be produced. 
 
The experiment 
 
The experimental part of this research activity is to look at the pattern of activity of 18F 
FDG uptake in the tuberculous infective lesion that you have on PET CT imaging 
modality. 
 
a.What is Positron Emission Tomography? 
 
Positron emission tomography, also called PET imaging or a PET scan, is a diagnostic 
examination that involves the acquisition of physiologic images based on the detection of 
radiation from the emission of positrons. Positrons are tiny particles emitted from a 
radioactive substance administered to the patient. The subsequent images of the human 
body developed with this technique are used to evaluate a variety of diseases. 
 
 
 
 
 
  
b.How should I prepare for the procedure? 
 
PET is usually done on an outpatient basis. Your doctor will give you detailed 
instructions on how to prepare for your examination. You should wear comfortable, 
loose-fitting clothes. You should not eat for four hours before the scan. You will be 
encouraged to drink water. Your doctor will instruct you regarding the use of medications 
before the test.  
 
How does the procedure work? 
 
Before the examination begins, a radioactive substance is produced in a machine called a 
cyclotron and attached, or tagged, to a natural body compound, most commonly glucose, 
but sometimes water or ammonia. Once this substance is administered to the patient, the 
radioactivity localizes in the appropriate areas of the body and is detected by the PET 
scanner. 
 
Different colors or degrees of brightness on a PET image represent different levels of 
tissue or organ function. For example, because healthy tissue uses glucose for energy, it 
accumulates some of the tagged glucose, which will show up on the PET images. 
However, cancerous tissue, which uses more glucose than normal tissue, will accumulate 
more of the substance and appear brighter than normal tissue on the PET images. 
 
To begin the procedure,   your permission will be asked to draw 5 mls of blood to look at 
your glucose level to ensure you are at ‘true fasting’ state. Your physical statistics and 
body weight will be measured to derive your lean body mass in order to calculate the 
dosage of 18F -FDG which will be in the form of normal saline.  A small amount of 
radioactive glucose is then injected into your bloodstream.  
 
There is no danger to you from this injection. Glucose (also known as sugar) is a 
common substance every cell in your body needs in order to function. Radioactive 
glucose must pass multiple quality control measures before it is used for any patient 
injection.  
 
The radiation exposure associated with PET is similar to that associated with a 
conventional CT scan.  
 
After the injection, you will wait approximately an hour, while the injection material is 
distributed throughout your body.  
 
Then, you will be asked to lie on a table that passes slowly through the scanner. The 
scanner resembles a CT scanner, but has a much larger opening. Some people fall asleep 
during the scan. Before the imaging procedure, you will be asking to empty your bladder. 
During imaging procedures, you are required to lie still on the table couch and breathe 
quietly. The whole procedure will last about 40 to 50 minutes. 
Upon completion of the image acquisition, you will be informed by the radiographer in-
charge. 
 
When a disease strikes, the biochemistry of your tissues and cells are changed. In cancer, 
for example, cells begin to grow at a much faster rate, feeding on sugars like glucose. 
PET works by using a small amount of a tracer drug chemically attached to glucose or 
other compounds. You are injected with the tracer. It travels through your body emitting 
signals and eventually collects in the organs targeted for examination. If an area in an 
organ is cancerous or infected, the signals will be stronger than in the surrounding tissue. 
A scanner records these signals and transforms them into pictures of chemistry and 
function.  
 
How will I feel afterwards? 
 
You should feel fine. There are no side-effects from the injected tracer.  
 
Is PET Safe? 
 
The risks associated with a PET scan are minimal. Most studies are conducted with an 
injection made up of radioactive glucose (sugar). The radiation exposure associated with 
PET is similar to a conventional whole-body diagnostic CT scan.  
In terms of comparison the risk of radiation exposure is 400 times chest radiograph which 
is equal to 8 mSv with a lifetime cancer mortality risk estimation of 4.0 x 10-4.  
However, the information gathered from this study will be invaluably beneficial to you 
and others. Therefore the advantages in carrying out this examination definitely outweigh 
the risk.    
 
 
What are the benefits vs. risks? 
Because PET allows study of body function, it can help physicians detect alterations in 
biochemical processes that suggest disease before changes in anatomy are apparent with 
other imaging tests, such as CT or MRI.  
 
The expected benefits from PET CT imaging as compared to other routine conventional 
method of imaging in your illness will be higher detection rate of infective foci. 
Therefore follow up can be done more accurately following anti tuberculous drug 
treatment by prolonging the course of the treatment. This will make the treatment more 
effective and precise in terms of duration. 
 
Current practice using conventional method of imaging often failed in holding up the 
course of infection effectively as the organism involved managed to ‘hide’ in the ‘normal 
looking tissues’ during follow up study. 
Thus, it will make treatment to this illness ineffective. This may result in further 
complication and complicates further by disability. 
 
PET CT imaging procedure has been performed world wide and has been recently 
established in Malaysia even though the technology has been around for the past 5-8 
years in the modern western and far eastern countries. So far, there has been no reported 
trial related injury during the procedure. 
 
Because the radioactivity is very short-lived, your radiation exposure is low. The 
substance amount is so small that it does not affect the normal processes of the body.  
 
The radioactive substance may expose radiation to the fetus in patients who are pregnant 
or the infants of women who are breast-feeding. The risk to the fetus or infant should be 
considered in relation to the potential information gain from the result of the PET 
examination. If you are pregnant, you should inform the PET imaging staff before the 
examination is performed. 
 
What happens after my scan? 
 
After your scan, you will get up from the scanner bed and check out with the receptionist. 
You will be notified when your results will be available.  
 
a.Are there potential side effects to a PET scan?  
 
No, there are no side effects to having a PET scan performed. The only pain involved is 
the needle prick when you receive the radiopharmaceutical injection and it doesn't differ 
from any other type of injection you might receive in its "pain quotient."  
 
b.When will I get my results?  
 
You will ordinarily receive your results within 24 hours of your PET scan.  
 
Are there alternatives to PET? 
 
Yes and no. There are examinations that you can have performed. CT and MRI, for 
example, both examine the anatomical (physical) structure. Therefore, they can be useful 
in determining the size and location of a tumor; however, neither of them can determine 
the tumor's viability, whereas PET can determine whether a tumor is still active.  
 
Why is PET not well known? Why have I never heard of PET before? 
 
While PET has been around for years, it has only been in the last few years that PET has 
moved from the research realm to the diagnostic/clinical sphere. In Malaysia this is the 
latest modern advanced technology available in aiding the clinician to diagnosed disease.  
 
 
 
 
 
How many PET studies are performed per year? 
 
In the Western community (Europe and US), approximately 350,000 PET scans will be 
performed in 2002. The numbers of scans are increasing dramatically, now that PET is no 
longer only for research purposes. It is estimated that within the next five years in excess 
of 2,000,000 PET scans will be performed per year.  
 
Do I have to pay? 
 
You are very fortunate to have this opportunity to be examined using a very sophisticated 
equipment from the latest invention in diagnostic imaging in medicine. Unfortunately, 
this examination is very expensive. The cost of the examination is RM 7 000 per patient 
but the sponsor will bear the expenses.    
 
Though non obligatory, we would be grateful if you are kind enough to contribute at any 
amount voluntarily to reduce the cost of this examination. The money will be ‘recycled’ 
in recruiting other potential subjects for similar investigation. 
 
Your return trip with appropriate transport to the PET CT Centre in Wijaya International 
Medical Centre / Subang Jaya Medical Centre or Putrajaya Hospital will be provided.     
 
Do I have to take part? 
Your involvement in this research activity is on a voluntary basis. If you decide to 
withdraw, be kind enough to inform us in due consideration. You will not be panelized 
for your decision. 
 
Confidentiality 
The authority from Faculty of Medicine UPM and the Ministry of Health Malaysia 
will be granted direct access to your original medical records for verification of 
these research activities. However, your confidentiality will not be violated. Your 
records will be kept safe and will never be available for the public. Your identity 
will be hidden in all published data including oral and poster presentation or during 
scientific writing. 
 
 
 
 
 
 
 
 
 
 
 
 
Whom to contact? 
The following consultants are available if you need further clarification in relation to this 
study: 
 
1. Professor Madya Dr Abdul Jalil Nordin   
    Radionuclide Imaging Unit  
    Faculty Medicine, UPM  
   Tel: 012 3042842  
 
2. Dr Noraini Abdul Rahim  
    Consultant Radiologist  
    Diagnostic Imaging Department  
    Serdang Hospital 
    Tel: 012 2801847  
 
 
Alternative Centres for PET CT examination  
Under the following circumstances, this research activity may be withhold or postponed: 
 
1. Inavailability of 18F FDG in case of cyclotron or its component breaks down 
2. Break down of PET CT machine  
3. Shut down of the Centre  
 
The activity may also take place at other centres with PET CT facilities like Subang Jaya 
Medical Centre and Putrajaya Hospital or Prince Court Hospital depending on the 
availability of substance for injection and the machine.  
 
Upon resuming our research activity we will inform you in due time. 
 
Duration of research activities  
 
You are expected to be involved in this research activity for at least 6-8 months from the 
date of confirming your diagnosis till completion of antibiotic treatment for 6 months or 
12 months. 
Along this period, you are expected to undergo PET CT examination twice i.e. at the 
beginning of infection and upon completion of your treatment. We anticipate 
approximately not less than 27 patients to be participating in this activity. 
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Brown fat uptake of 18F-FDG on dual 
time point PET/CT imaging
Hairil Rashmizal A R, Noraini A R, Rossetti C, Abdul Jalil N
ABSTRACT
The aim of this report was to assess the changes 
in the 18F-fluorodeoxyglucose (18F-FDG) uptake 
of brown fats on integrated positron emission 
tomography/computed tomography (PET/
CT) imaging. The patient presented with an 
enlargement of the neck lymph nodes, and was 
suspicious for tuberculous lymphadenitis. A 
whole body PET/CT imaging was performed, 
followed by a delayed imaging of the neck and 
thoracic regions. A visually increased 18F-FDG 
uptake was taken as a positive finding. A semi-
quantitative evaluation was performed using a 
maximum standardised uptake value (SUVmax) 
with a cut-off value above 2.5. There were a 
number of 18F-FDG avid activity areas seen at the 
supraclavicular, mediastinal, paravertebral and 
perirenal regions. These are in keeping with the 
physiological 18F-FDG uptake in brown fat. The 
differences in SUVmax between the two scans 
ranged from −20 percent to +20 percent. Based 
on our observation, dual time point imaging may 
not be a reliable method for assessing the 18F-
FDG uptake of brown fat.
Keywords: brown fat, dual time point imaging, 
18F-FDG, PET/CT 
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INTRODUCTION
In the last two decades, it was believed that the uptake 
of 18F-fluorodeoxyglucose (18F-FDG) in the neck and 
shoulder regions was caused by muscle uptake. However, 
this issue was resolved after the introduction of fusion 
physiological and morphological imaging modalities, 
namely positron emission tomography/computed 
tomography (PET/CT), which clearly showed that the 
uptake was of brown fat.(1-4)
 Human adipose tissue can be divided into two types, 
white fat and brown fat. White fat mainly serves to 
protect the body parts, while the main function of brown 
fat is heat generation. Brown fat has a high density of 
mitochondria in the fat cells and is rich in vascularisation. 
These features are responsible for the brownish colour 
of brown fat. Brown fat can be named according to its 
location: supraclavicular, mediastinal, paravertebral and 
perirenal. Supraclavicular fat can extend from the neck 
inferiorly to the shoulders, and sometimes, to the axillae. 
Mediastinal fat exists in small pockets that are linked 
with all the structures of the mediastinum. Paravertebral 
brown fat runs parallel to the thoracic vertebrae on either 
side of the spinal column and extends into the intercostal 
spaces. Perirenal fat tends to be concentrated on the top 
of the kidneys at the location of the adrenal glands. 
 The biological mechanism for the accumulation 
of 18F-FDG uptake in brown fat is well established.(1,5) 
Previous studies have mainly focused on supraclavicular 
brown fat,(1,2,6,7) whereas the other areas of brown fat 
have been under-reported. It is important for physicians 
to recognise these normal variants of 18F-FDG uptake 
Fig. 1 (a) Multi-imaging planar (MIP) image shows the initial 
whole body PET/CT imaging. (b) MIP of the second PET/
CT imaging (limited from the base of the skull to the upper 
abdominal region and covering the whole liver) shows the 
distribution of high 18F-FDG uptake of brown fats.
1a
1b
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in brown fat, so that they are not misinterpreted as a 
significant pathologic state. To the authors’ knowledge, 
dual time point imaging (DTPI) using 18F-FDG PET/CT 
on brown fat, especially for the mediastinal and perirenal 
areas, has not been previously described.
CASE REPORT 
A 25-year-old Malay woman presented with a history of 
left lateral neck swelling for several weeks. There were 
no general symptoms of tuberculosis (TB) infection such 
as cough, low grade fever, night sweat or loss of weight. 
The patient had a family history of TB infection, and her 
sister had been diagnosed with pulmonary tuberculosis 
(PTB) infection seven months ago. The patient was 
screened for TB infection through blood investigation, 
sputum test and acid fast bacilli, but the results were 
negative. The aspiration of the swollen neck lymph 
node suggested a reactive node. The patient underwent a 
whole body PET/CT examination to assess the extension 
of the lesion. 
 A DTPI approach was applied during the scanning 
session. All imaging studies were performed on a dual-
modality PET/CT system (Biograph 6, Siemens Medical 
Solutions Inc, Hoffman Estates, IL, USA). PET/CT 
imaging was started 46 minutes after an intravenous 
injection of 368.3 MBq of 18F-FDG. The total 
acquisition time for the initial whole body PET/CT was 
about 25 minutes. Using the same parameters, a delayed 
PET/CT imaging was obtained about 121 minutes after 
the 18F-FDG injection (time interval between the first 
and second imaging was about 75 minutes), and it was 
limited to the neck, thorax and upper abdomen regions, 
covering the whole liver (Fig. 1). 
 In this case, a semi-quantitative evaluation 
method using the maximum standardised uptake 
value (SUVmax) was applied to evaluate the imaging 
findings. Inconsistencies in measurement were observed 
in the SUVmax values of the brown fat at different 
locations between the initial and delayed images. The 
initial SUVmax1 measured along the right and left 
supraclavicular, mediastinal, right and left paravertebral 
as well as the right and left perirenal were 17.6, 18.9, 
7.0, 13.9, 7.4, 10.4 and 20.8, respectively. In the 
delayed imaging, the SUVmax2 of the mediastinal, right 
paravertebral and left perirenal declined to 5.6, 11.7 and 
18.5, respectively, whereas the rest showed an increment 
(Fig. 2). The differences in SUVmax between the two 
readings, expressed as Δ%SUVmax, ranged from 
approximately −20% to +20% (Table I).
DISCUSSION
Brown fat can lead to false positive interpretations for 
PET imaging. The aim of this report is to demonstrate the 
imaging characteristics of brown fat on 18F-FDG PET/
CT, as described by several other studies.(1-4,6,8) It is well 
known that brown fat mainly functions in non-shivering 
Fig. 2 Image acquisitions of 18F-FDG PET/CT show (a & b) an increase in the SUVmax values of the right supraclavicular brown fat 
from 17.6 on the initial scan to 20.1 on the delayed scan and (c & d) a decrease in the SUVmax values of the right paravertebral 
brown fat from 13.9 to 11.7. 
2a 2b
2c 2d
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Table I. The SUVmax and Δ%SUVmax values of the different areas of brown fat.
Area of brown fat SUVmax 1a SUVmax 2b Δ%SUVmaxc
Right supraclavicular 17.60 20.10 14.20
Left supraclavicular 18.90 22.70 20.11
Mediastinal 7.00 5.60 −20.00
Right paravertebral 13.90 11.70 −15.83
Left paravertebral 7.40 7.80 5.41
Right perirenal 10.40 11.20 7.69
Left perirenal 20.80 18.50 −11.06
SUVmax: maximum standardised uptake value
a Maximum SUV derived from first PET/CT imaging acquisition.
b Maximum SUV derived from second PET/CT imaging acquisition.
c The percentage differences in maximum SUV.
thermogenesis by stimulating the sympathetic nerve 
system, which can cause a significant increase of glucose 
uptake in brown fat.(9) The amount of glucose uptake in 
brown fat has been shown to be closely correlated with 
gender,(9,10) age,(9) cold exposure(2) and medications.(10,11)
 The 18F-FDG SUVs in our patient were in the range 
of those reported by Yeung et al(3) and Hadi et al.(8) 
The four main areas of brown fat appearance on the 
18F-FDG PET/CT were highlighted and the SUVmax 
changes during DTPI protocol were observed. In our 
case, there were remarkable reductions in the SUVmax 
values between the two time points (Δ%SUVmax), 
which can be seen clearly in the brown fat located at 
the mediastinal, paravertebral and perirenal areas, while 
the rests of the values showed a 5%–20% increment. No 
specific pattern was observed in the changes from either 
side of the body. 
 The inconsistent uptake of 18F-FDG on DTPI 
protocol in our patient is similar to that in previous 
reports,(7,12) except that in our patient, premedications, 
such as muscle relaxants, were not prescribed prior to the 
examination, unlike in the other studies.(7,10) The patient’s 
comfort was ensured by providing a warm blanket and 
maintaining a pleasant room temperature. In view of the 
heavy patient workflow in the department, we selected a 
two-hour interval for our second time point of imaging, 
as recommended in previous studies.(13,14)  
 In conclusion, based on our limited observation and 
in view of the inconsistent SUV changes in brown fat 
glucose uptake with time, DTPI protocol may not be a 
useful method for improving the diagnostic value of 18F-
FDG PET/CT examination at this point. In order to have 
a constructive understanding of the 18F-FDG uptake of 
brown fat in DTPI imaging, further investigations with a 
larger group of patients are warranted. 
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APPENDIX 6 
Estimating the PET effective dose of the seven Malaysian patients 
This appendix describes the calculations that have been performed in order to figure out 
the whole body effective dose coefficient of FDG ( FDGEΓ ) for the PET component of 
PET/CT imaging. For this, some modifications on the data of the several studies [158, 
169, 183] are carried out by utilising the tissue weighting factor (WT) of the ICRP 60 
[164] and 103 [165], and the organ absorbed dose coefficient of FDG ( FDGTΓ ) of the 
ICRP 80 [167] and 106 [168]. In total, there are four modifications, in which three are 
based on the data from Brix et al. [169] and one from the data of Huang et al. [158].  
 In the study conducted by Brix, G. and his co-workers, they calculated their 
whole body effective dose coefficient for FDG ( FDGEΓ ) from the data of the 13 organs or 
tissues [169]. The weighting factors for these organs were taken from the ICRP 60 
[164], and these values were then multiplied by the organ absorbed dose coefficient for 
FDG of the ICRP 80 [167]. For modification 1, the tissue weighting factors remained 
the same as in Brix’s study, but the organ absorbed dose coefficient of FDG ( FDGTΓ ) was 
taken from the ICRP 106 [168]. In modifications 2 and 3, the tissue weighting factors of 
the ICRP 103 [165] were used, however the organs absorbed dose coefficient ( FDGTΓ ) 
was based on the data of the ICRP 80 [167]; modification 2, and the ICRP 106 [168] for 
modification 3.  
 The whole body effective dose coefficient of FDG ( FDGEΓ ) in the Huang’s study 
was developed based on the data of the 23 organs, with the utilisation of the tissue 
weighting factors (WT) from the ICRP 103 [165] and the organs absorbed dose 
coefficient of FDG ( FDGTΓ ) values from the ICRP 80 [167]. However, in modification 4 
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of this study, the organ absorbed dose coefficient of FDG ( FDGTΓ ) have been changed 
with those from the ICRP 106 [168]. In addition, a recent study on Thai cancer patients 
has proposed the whole body effective dose coefficient for FDG ( FDGEΓ ) of about 14.08 
µSv/MBq [183], which is the lowest in value as compared to others (please refer to 
Table A6.1). Therefore, in this research, by including the effective dose coefficient 
value for FDG ( FDGEΓ ) from the ICRP 106 [168], a total of 8 coefficient values have 
been generated. All these values are then multiplied with the injected amount of FDG 
radioactivity for the seven Malaysian patients. Based on these results, the mean 
effective dose of each patient is calculated, as listed in Table A6.2. 
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Table A6.1: The list of seven whole body effective dose coefficient values for FDG ( FDGEΓ ) that have been used in the calculations of this study. 
Organ 
 
Organ or tissue effective dose coefficient for FDG, WT · 
FDG
TΓ  ( µSv/MBq) 
Brix et al. [169]  Modification 1 Modification 2 Modification 3 Huang et al. [158] Modification 4 Khamwan et al. [183] 
Gonads 2.70 2.50 1.08 1.00 1.08 1.00 0.92 
Lungs 1.20 2.40 1.20 2.40 1.20 2.40 0.56 
Stomach 1.32 1.32 1.32 1.32 1.32 1.32 1.39 
Colon 1.56 1.56 1.56 1.56 1.56 1.56 1.26 
Red bone marrow 1.32 1.32 1.32 1.32 1.32 1.32 2.17 
Esophagus 0.55 0.60 0.44 0.48 0.44 0.48 − 
Thyroid 0.50 0.50 0.40 0.40 0.40 0.40 0.42 
Liver 0.55 1.05 0.44 0.84 0.44 0.84 1.19 
Bladder 8.00 6.50 6.40 5.20 6.40 5.20 2.55 
Breasts 0.34 0.44 1.03 1.06 1.03 1.06 0.88 
Bone surfaces 0.11 0.11 0.11 0.11 0.11 0.11 0.21 
Skin 0.08 0.08 0.08 0.08 0.08 0.08 0.01 
Brain − − − − 0.28 0.38 − 
Thymus − − − − 0.14 0.16 − 
Spleen − − − − 0.14 0.14 0.89 
Adrenal glands − − − − 0.16 0.16 − 
Pancreas − − − − 0.16 0.17 − 
Kidneys − − − − 0.27 0.22 1.64 
Large intestine − − − − 0.18 0.17 − 
Small intestine − − − − 0.17 0.16 − 
Uterus − − − − 0.27 0.23 − 
Muscles − − − − 0.14 0.13 − 
Heart − − − − 0.81 0.87 − 
Remaining organs 0.55 0.60 1.32 1.44 − − − 
Whole body effective dose 
coefficient, FDGEΓ (µSv/MBq) 
19.00 19.00 16.70 17.20 18.10 18.55 14.08 
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Table A6.2: The calculations for the mean value of the whole body PET effective dose of our patients. 
 
Effective dose coefficient for FDG, FDGEΓ  (mSv/MBq) 
 ГE1 ГE2 ГE3 ГE4 ГE5 ГE6 ГE7 ГE8  
0.01900 0.01900 0.01900 0.01670 0.01720 0.01810 0.01855 0.01408 
 
Patient no. Injected radioactivity of FDG, A (MBq) 
Effective dose (mSv) Mean A · ГE1 A · ГE 2 A · ГE 3 A · ГE 4 A · ГE 5 A · ГE 6 A · ГE 7 A · ГE 8 
1 592 11.25 11.25 11.25 9.89 10.18 10.72 10.98 8.34 10.48 
3 277 5.26 5.26 5.26 4.63 4.76 5.01 5.14 3.90 4.90 
4 322 6.12 6.12 6.12 5.38 5.54 5.83 5.97 4.53 5.70 
8 361 6.86 6.86 6.86 6.03 6.21 6.53 6.70 5.08 6.39 
10 500 9.50 9.50 9.50 8.35 8.60 9.05 9.28 7.04 8.85 
11 368 6.99 6.99 6.99 6.15 6.33 6.66 6.83 5.18 6.51 
12 375 7.13 7.13 7.13 6.26 6.45 6.79 6.96 5.28 6.64 
ГE1, effective dose coefficient from ICRP 106 [168]; [168]; ГE 2, effective dose coefficient from Brix et al. [169]; ГE3, effective dose coefficient from 
our modification 1; ГE4, effective dose coefficient from our modification 2; ГE5, effective dose coefficient from our modification 3; ГE6, effective dose 
coefficient from Huang et al. [158]; ГE7, effective dose coefficient from our modification 4; ГE8, effective dose coefficient from Khamwan et al. [183]. 
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APPENDIX 7 
Estimating the CT effective dose of the seven Malaysian patients 
This appendix describes the calculations for the organ or tissue effective dose 
coefficient of the whole body CT scan ( CTEΓ ). For this research, the data are adapted 
from the previous study by Brix, et al. [169], with a slight modification of using the 
most recent tissue weighting factor (WT) from the ICRP 103 [165]. 
 In Brix’s study, the whole body CT effective dose coefficient that related with 
CTDIvol ( CTEΓ ) was derived by multiplying the measured absorbed dose from the 13 
organs with their weighting factors (WT) of the ICRP 60 [164]. However, for the 
modification of this study, the tissue weighting factors (WT) from the ICRP 103 [165] 
were utilised. Therefore, a total of two different whole body CT effective dose 
coefficient values ( CTEΓ ) (refer to Table A7.1) have been generated for this research. To 
estimate the whole body CT effective dose of the seven Malaysian patients, these two 
coefficient values are multiplied with the CTDIvol of each scanning protocols. Based on 
this, the mean CT effective dose of each patient is calculated, as listed in Table A7.2.         
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Table A7.1: The two whole body CT effective dose coefficient values (ГE  ) that have 
been used in the calculations of this study. 
Organ 
Organ or tissue CT effective dose coefficient,  
WT · CTTΓ ( mSv/mGy) 
Brix, et al [169] Modification 1 
Gonads 0.28 0.113 
Lungs 0.174 0.174 
Stomach 0.174 0.174 
Colon 0.184 0.184 
Red bone marrow 0.153 0.154 
Esophagus 0.072 0.057 
Thyroid 0.123 0.096 
Liver 0.079 0.063 
Bladder 0.069 0.055 
Breasts 0.072 0.173 
Bone surfaces 0.009 0.009 
Skin 0.007 0.007 
Remaining organs  0.069 0.164 
Whole body CT effective 
dose coefficient, CTEΓ  
(mSv/mGy) 
1.47 1.42 
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Table A7.2: The calculations for the mean value of the CT effective dose of all the 
scanning protocols in our patients. 
 Effective dose coefficient for whole 
body CT, CTEΓ (mSv/mGy) 
 
 ГE1 ГE2  
1.47 1.42 
 
Patient no. Scan CTDIvol (mGy) 
Effective dose (mSv) Mean CTDIvol · ГE1 CTDIvol · ГE2 
1 Unenhanced CT 3.05 4.48 4.33 4.41 
 CECT 10.18 14.96 14.46 14.71 
 Delayed CT 3.14 4.62 4.46 4.54 
3 Unenhanced CT 2.08 3.06 2.95 3.01 
 CECT 6.40 9.41 9.09 9.25 
 Delayed CT 2.20 3.23 3.12 3.18 
4 Unenhanced CT 1.61 2.37 2.29 2.33 
 CECT 5.26 7.73 7.47 7.60 
 Delayed CT 1.23 1.81 1.75 1.78 
8 Unenhanced CT 1.91 2.81 2.71 2.76 
 CECT 6.70 9.85 9.51 9.68 
 Delayed CT 2.29 3.37 3.25 3.31 
10 Unenhanced CT 2.42 3.56 3.44 3.50 
 CECT 8.61 12.66 12.23 12.44 
 Delayed CT 2.63 3.87 3.73 3.80 
11 Unenhanced CT 1.99 2.93 2.83 2.88 
 CECT 6.70 9.85 9.51 9.68 
 Delayed CT 1.65 2.43 2.34 2.38 
12 Unenhanced CT 1.74 2.56 2.47 2.51 
 CECT 5.68 8.35 8.07 8.21 
 Delayed CT 0.98 1.44 1.39 1.42 
ГE1, CT effective coefficient from Brix et al. [169]; ГE2, CT effective dose coefficient from our 
modification 1.  
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